SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_____________________

FORM 10-Q

[Mark One]

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended ~~September~~March 3031, ~~2018~~2019

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from _______ to _______

Commission File Number: 0-25203

OmniComm Systems, Inc.
(Exact name of registrant as specified in its Charter)

Delaware	11-3349762
(State or other jurisdiction of Incorporation or organization)	(IRS Employer Identification Number)

2101 W. Commercial Blvd. Suite 3500, Fort Lauderdale, FL	33309
Address of principal executive offices	Zip Code

954.473.1254
(Registrant’s Telephone Number including area code)

No Changes

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [√] No [ ]

Indicate by check mark whether the registrant has submitted electronically ~~and posted on its corporate website, if any,~~ every Interactive Data File required to be submitted ~~and posted~~ pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit ~~and post~~ such files). Yes [√] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer [ ] Accelerated filer [ ] Non-accelerated filer ~~(Do not check if smaller reporting company)~~ [ ] Smaller reporting company [√] Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [√]

The number of shares outstanding of each of the issuer’s classes of common equity as of ~~November 12~~May 14, ~~2018~~2019: ~~152~~159,~~343~~128,~~647~~341 common stock $0.001 par value.

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value	OMCM	OTCQX Market

Table of Contents

Table of Contents to the Quarterly Report on Form 10-Q for the ~~nine~~three month ~~period ended September 30, 2018~~

~~PART~~period I.ended ~~FINANCIAL~~MArch ~~INFORMATION~~31, 3 ITEM 1. FINANCIAL STATEMENTS 3 ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 34 ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 50 ITEM 4. CONTROLS AND PROCEDURES 50 PART II. OTHER INFORMATION 50 ITEM 1. LEGAL PROCEEDINGS 50 ITEM 1A. RISK FACTORS 50 ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 51 ITEM 3. DEFAULTS UPON SENIOR SECURITIES 51 ITEM 4. MINE SAFETY DISCLOSURES 51 ITEM 5. OTHER INFORMATION 51 ITEM 6. EXHIBITS 51 SIGNATURES 522019

PART I. FINANCIAL INFORMATION	3
ITEM 1. FINANCIAL STATEMENTS	3
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	33
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	42
ITEM 4. CONTROLS AND PROCEDURES	43
PART II. OTHER INFORMATION	43
ITEM 1. LEGAL PROCEEDINGS	43
ITEM 1A. RISK FACTORS	43
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	43
ITEM 3. DEFAULTS UPON SENIOR SECURITIES	43
ITEM 4. MINE SAFETY DISCLOSURES	44
ITEM 5. OTHER INFORMATION	44
ITEM 6. EXHIBITS	44
SIGNATURES	45

Table of Contents

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

OMNICOMM SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

	September 30, 2018			December 31, 2017
	March 31, 2019			December 31, 2018
	(unaudited)
ASSETS
CURRENT ASSETS
Cash	$	1,~~371~~351,~~962~~916		$	1,~~176~~440,~~551~~524
Accounts receivable, net of allowance for doubtful accounts of $197,911 and $149,980, respectively		5,124,404			7,492,597
Accounts receivable, net of allowance for doubtful accounts of $152,867 and $176,220, respectively		3,989,881			6,175,277
Prepaid expenses		~~390~~261,~~565~~741			~~297~~384,~~131~~212
Other current assets		111,~~917~~633			115,~~463~~204
Total current assets		65,~~898~~605,~~848~~171			8,~~977~~005,~~742~~217
Property and equipment, net		1,~~330~~500,~~744~~338			~~552~~1,~~538~~360,315
Other assets
Intangible assets, net		~~819~~643,~~750~~135			97730,~~925~~835
Other assets		129,018			46,714
Operating lease right-of-use assets		1,569,465			-0-
TOTAL ASSETS	$	9,178,360		$	9,674,919
Other assets		89,088			131,847
TOTAL ASSETS	$	9,407,197		$	10,228,214
LIABILITIES AND SHAREHOLDERS' (DEFICIT)
CURRENT LIABILITIES
Accounts payable and accrued expenses	$	1,~~686~~230,~~536~~092		$	2,~~586~~070,~~045~~158
Notes payable, related parties, current portion, net of discount of $46,946 and $-0-, respectively		353,054			-0-
Deferred revenue, current portion		5,302,370			6,457,319
Convertible notes payable, current portion		-0-			50,000
Finance lease liability, current portion		116,728			115,761
Deferred revenue, current portion		6,209,198			7,564,587
Conversion feature liability, related parties		862,083			670,634
Capital lease liability, current portion		114,594			-0-
Conversion feature liability		45,415			35,705
Patent settlement liability, current portion		-0-			112,500
Warrant liability, related parties		750,625			601,781
Conversion feature liability, related parties		1,744,002			1,604,723
Warrant liability		853,991			687,118
Conversion feature liability		96,510			81,224
Operating lease liability, current portion		598,108			-0-
Warrant liability, related parties		2,754,207			2,196,570
Total current liabilities		9,759,412			10,638,476
Warrant liability		1,682,000			1,244,229
Total current liabilities		14,640,101			15,439,878
LONG TERM LIABILITIES
Line of credit, long term		32,~~200~~500,000			2,~~650~~900,000
Notes payable, related parties, long term, net of current portion, net of discount of $-0- and $117,365, respectively		-0-			282,635
Notes payable, long term, net of current portion, net of discount of $98,548 and $123,184, respectively		458,952			434,316
Notes payable, long term, net of current portion, net of discount of $186,268 and $279,402, respectively		516,232			423,098
Convertible notes payable, related parties, long term, net of current portion		5,770,000			5,770,000
Convertible notes payable, long term, net of current portion		200,000			~~350~~200,000
Deferred revenue, long term, net of current portion		1,~~658~~912,~~064~~260			1,~~952~~794,~~366~~237
Capital lease liability, long term, net of current portion		206,010			-0-
Finance lease liability, long term, net of current portion		143,757			175,089
TOTAL LIABILITIES		26,190,407			26,867,977
Operating lease liability, long term, net of current portion		971,357			-0-
COMMITMENTS AND CONTINGENCIES (See Note 10)
TOTAL LIABILITIES		21,715,738			21,912,118
COMMITMENTS AND CONTINGENCIES (See Note 11)
SHAREHOLDERS' (DEFICIT)
Preferred stock, $0.001 par value, 10,000,000 shares authorized, 3,772,500 shares undesignated
Series A convertible preferred stock, 5,000,000 shares authorized, -0- and -0- issued and outstanding, respectively, at $0.001 par value; liquidation preference $-0- and $-0-, respectively		-0-			-0-
Series B convertible preferred stock, 230,000 shares authorized, -0- and -0- issued and outstanding, respectively, at $0.001 par value; liquidation preference $-0- and $-0-, respectively		-0-			-0-
Series C convertible preferred stock, 747,500 shares authorized, -0- and -0- issued and outstanding, respectively, at $0.001 par value; liquidation preference $-0- and $-0-, respectively		-0-			-0-
Series D preferred stock, 250,000 shares authorized, 250,000 and 250,000 issued and outstanding, respectively, at $0.001 par value		250			250
Common stock, 500,000,000 shares authorized, 152,309,472 and 148,542,805 issued and outstanding, respectively, at $0.001 par value		152,311			148,544
Common stock, 500,000,000 shares authorized, 158,278,341 and 155,368,647 issued and outstanding, respectively, at $0.001 par value		158,280			155,370
Additional paid in capital - preferred		999,750			999,750
Additional paid in capital - common		5556,~~130~~877,~~550~~493			5456,~~379~~233,~~454~~085
Accumulated other comprehensive (loss)		(~~431~~441,~~661~~935	)		(~~397~~436,~~237~~505	)
Accumulated (deficit)		(7269,~~863~~902,~~247~~379	)		(7268,~~323~~635,~~819~~854	)
TOTAL SHAREHOLDERS' (DEFICIT)		(1712,~~012~~308,~~047~~541	)		(1711,~~193~~683,~~058~~904	)
TOTAL LIABILITIES AND SHAREHOLDERS' (DEFICIT)	$	9,~~178~~407,~~360~~197		$	910,~~674~~228,~~919~~214

See accompanying summary of accounting policies and notes to unaudited condensed consolidated financial statements

Table of Contents

OMNICOMM SYSTEMS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)

	For the nine months ended						For the three months ended
	For the three months ended
	September 30,						September 30,
	March 31,
	2018			2017			2018			2017
	2019			2018
Revenues	$	195,~~557~~534,~~161~~298		$	197,~~420~~040,~~456~~369		$	~~6,379,641~~		$	~~6,490,147~~
Reimbursable revenues		~~775~~181,~~788~~521			~~755~~150,~~344~~103			~~463,183~~			~~225,766~~
Total revenues		205,~~332~~715,~~949~~819			207,~~175~~190,~~800~~472			~~6,842,824~~			~~6,715,913~~
Cost of goods sold		31,~~240~~054,~~449~~681			31,~~320~~153,~~190~~625			~~1,044,020~~			~~1,133,480~~
Reimbursable expenses-cost of goods sold		~~368~~69,~~542~~219			~~802~~57,~~975~~876			~~253,793~~			~~181,965~~
Total cost of goods sold		31,~~608~~123,~~991~~900			41,~~123~~211,~~165~~501			~~1,297,813~~			~~1,315,445~~
Gross margin		164,~~723~~591,~~958~~919			165,~~052~~978,~~635~~971			~~5,545,011~~			~~5,400,468~~
Operating expenses
Salaries, benefits and related taxes		103,~~695~~662,~~132~~432			93,~~906~~659,~~293~~340			~~3,483,627~~			~~3,393,915~~
Rent and occupancy expenses		~~930~~311,~~972~~799			~~841~~289,~~718~~334			~~337,824~~			~~292,669~~
Consulting services		~~219~~50,~~856~~827			~~185~~125,~~222~~536			~~55,736~~			~~64,488~~
Legal and professional fees		~~381~~131,~~648~~763			~~367~~221,~~403~~252			~~72,776~~			~~126,959~~
Travel		~~588~~148,~~247~~562			~~679~~200,~~766~~396			~~190,785~~			~~188,406~~
Telephone and internet		~~114~~50,~~696~~634			~~115~~29,~~660~~683			~~43,682~~			~~39,786~~
Selling, general and administrative		1440,~~297,008~~533			~~937~~409,~~313~~756			~~383,958~~			~~277,047~~
Bad debt expense		47(23,~~931~~353	)		40(3,~~369~~387	)		~~21,679~~			~~87,366~~
Intangible asset impairment		79,634			-0-			-0-			-0-
Depreciation expense		128,800			77,776
Depreciation expense		279,532			249,801			115,687			87,382
Amortization expense		87,700			64,149
Amortization expense		248,790			16,455			91,343			5,580
Total operating expenses		4,989,697			5,073,835
Total operating expenses		14,883,446			13,340,000			4,797,097			4,563,598
Operating income/(loss)		(397,778	)		905,136
Operating income/(loss)		1,840,512			2,712,635			747,914			836,870
Other income/(expense)
Other income/(expense)
Interest expense, related parties		(190,109	)		(225,418	)
Interest expense, related parties		(682,986	)		(717,782	)		(229,906	)		(252,585	)
Interest expense		(79,270	)		(90,943	)
Interest expense		(283,407	)		(342,240	)		(95,622	)		(127,488	)
Interest income		4			5
Interest income		16			589			7			3
Change in derivative liabilities		(583,657	)		28,416
Change in derivative liabilities		(1,160,473	)		723,532			(2,918,886	)		(812,535	)
Transaction gain/(loss)		(15,726	)		(22,678	)
Transaction gain/(loss)		(97,984	)		19,006			(12,128	)		(3,104	)
Income/(loss) before income taxes		(1,266,536	)		594,518
Income/(loss) before income taxes		(384,322	)		2,395,740			(2,508,621	)		(358,839	)
Income tax (expense)		11			(1,035	)
Income tax (expense)		(155,106	)		(1,194	)		(154,071	)		-0-
Net income/(loss) attributable to common stockholders	$	(1,266,525	)	$	593,483
Net income/(loss) attributable to common stockholders	$	(539,428	)	$	2,394,546		$	(2,662,692	)	$	(358,839	)
Net income/(loss) per share
Net income/(loss) per share
Basic	$	(0.01	)	$	0.00
Basic	$	(0.00	)	$	0.02		$	(0.02	)	$	(0.00	)
Diluted	$	(0.01	)	$	0.00
Diluted	$	(0.00	)	$	0.02		$	(0.02	)	$	(0.00	)
Weighted average number of shares outstanding
Weighted average number of shares outstanding
Basic		157,341,946			149,653,916
Basic		150,282,732			147,805,410			150,905,124			147,858,566
Diluted		157,341,946			152,693,666
Diluted		150,282,732			147,850,886			150,905,124			147,858,566

See accompanying summary of accounting policies and notes to unaudited condensed consolidated financial statements

Table of Contents

OMNICOMM SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/(LOSS)

(unaudited)

	For the nine months ended					For the three months ended
	For the three months ended
	September 30,					September 30,
	March 31,
	2018			2017		2018			2017
	2019			2018
Net income/(loss) attributable to common stockholders	$	(~~539~~1,~~428~~266,525	)	$	2593,~~394,546~~483	$	~~(2,662,692~~	)	$	~~(358,839~~	)
Other comprehensive income/(loss)
Change in foreign currency translation adjustment		(345,~~424~~430	)		131,~~386~~287		~~(13,256~~	)		~~1,310~~
Other comprehensive income/(loss)		(345,~~424~~430	)		131,~~386~~287		~~(13,256~~	)		~~1,310~~
Comprehensive income/(loss)	$	(~~573~~1,~~852~~271,955	)	$	2594,~~407,932~~770	$	~~(2,675,948~~	)	$	~~(357,529~~	)

See accompanying summary of accounting policies and notes to unaudited condensed consolidated financial statements

Table of Contents

OMNICOMM SYSTEMS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' (DEFICIT) FOR THE ~~YEAR~~THREE MONTH PERIODS ENDED ~~DECEMBER~~MARCH 31, ~~2017~~2019 AND ~~THE~~MARCH ~~NINE MONTHS ENDED SEPTEMBER 30~~31, 2018 ~~(unaudited)~~

	Preferred Stock					Common Stock
	Series D Preferred			Additional								Additional						Accumulated other			Total
	Number	$0.001		paid in capital		Number			$0.001			paid in capital			Accumulated			comprehensive			shareholders'
	of shares	Par value		preferred		of shares			Par value			common			(deficit)			(loss)			(deficit)
Balances at December 31, 2016	250,000	$	250	$	999,750		147,786,917		$	147,788		$	53,425,956		$	(75,291,037	)	$	(410,505	)	$	(21,127,798	)
Employee stock option expense													364,271									364,271
Foreign currency translation adjustment																			13,268			13,268
Restricted stock issuance/(forfeiture)							(16,668	)		(17	)		(2,817	)								(2,834	)
Cashless issuance of common stock, stock option exercise							22,556			23			(23	)								-0-
Issuance of common stock, stock option exercise							250,000			250			35,000									35,250
Issuance of common stock, warrant exercise							500,000			500			154,500									155,000
Reclassification of conversion feature liability associated with convertible debt													402,567									402,567
Net income/(loss) for the year ended December 31, 2017	-0-		-0-		-0-		-0-			-0-			-0-			2,967,218			-0-			2,967,218
Balances at December 31, 2017	250,000		250		999,750		148,542,805			148,544			54,379,454			(72,323,819	)		(397,237	)		(17,193,058	)
Employee stock option expense													157,628									157,628
Foreign currency translation adjustment																			(34,424	)		(34,424	)
Restricted Stock Issuance/Forfeiture							1,900,000			1,900			39,835									41,735
Issuance of common stock, purchase of Acuity software							1,666,667			1,667			498,333									500,000
Issuance of common stock, stock option exercise							200,000			200			44,800									45,000
Reclassification of conversion feature liability associated with convertible debt													10,500									10,500
Net income/(loss) for the period ended September 30, 2018	-0-		-0-		-0-		-0-			-0-			-0-			(539,428	)		-0-			(539,428	)
Balances at September 30, 2018 (unaudited)	250,000	$	250	$	999,750		152,309,472		$	152,311		$	55,130,550		$	(72,863,247	)	$	(431,661	)	$	(17,012,047	)

FOR THE THREE MONTH PERIOD ENDED MARCH 31, 2019



	Preferred Stock						Common Stock
	Series D Preferred				Additional						Additional					Accumulated other			Total
	Number		$0.001		paid in capital		Number		$0.001		paid in capital		Accumulated			comprehensive			shareholders'
	of shares		Par value		preferred		of shares		Par value		common		(deficit)			(loss)			(deficit)

Balances at December 31, 2018		250,000	$	250	$	999,750		155,368,647	$	155,370	$	56,233,085	$	(68,635,854	)	$	(436,505	)	$	(11,683,904	)

Employee stock option expense												52,927								52,927

Foreign currency translation adjustment																	(5,430	)		(5,430	)

Restricted stock issuance/forfeiture								900,000		900		76,710								77,610

Issuance of common stock, stock option exercise								1,800,000		1,800		448,200								450,000

Cashless issuance of common stock, warrant exercise								209,694		210		66,571								66,781

Net income/(loss) for the period ended March 31, 2019		-0-		-0-		-0-		-0-		-0-		-0-		(1,266,525	)		-0-			(1,266,525	)

Balances at March 31, 2019 (unaudited)		250,000	$	250	$	999,750		158,278,341	$	158,280	$	56,877,493	$	(69,902,379	)	$	(441,935	)	$	(12,308,541	)

FOR THE THREE MONTH PERIOD ENDED MARCH 31, 2018



	Preferred Stock						Common Stock
	Series D Preferred				Additional						Additional					Accumulated other			Total
	Number		$0.001		paid in capital		Number		$0.001		paid in capital		Accumulated			comprehensive			shareholders'
	of shares		Par value		preferred		of shares		Par value		common		(deficit)			(loss)			(deficit)

Balances at December 31, 2017		250,000	$	250	$	999,750		148,542,805	$	148,544	$	54,379,454	$	(72,323,819	)	$	(397,237	)	$	(17,193,058	)

Employee stock option expense												56,526								56,526

Foreign currency translation adjustment																	1,287			1,287

Issuance of common stock, purchase of Acuity								1,666,667		1,667		498,333								500,000

Net income/(loss) for the period ended March 31, 2018		-0-		-0-		-0-		-0-		-0-		-0-		593,483			-0-			593,483

Balances at March 31, 2018 (unaudited)		250,000	$	250	$	999,750		150,209,472	$	150,211	$	54,934,313	$	(71,730,336	)	$	(395,950	)	$	(16,041,762	)

See accompanying summary of accounting policies and notes to unaudited condensed consolidated financial statements

Table of Contents

OMNICOMM SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

	For the nine months ended
	For the three months ended
	September 30,
	March 31,
	2018			2017
	2019			2018
CASH FLOWS FROM OPERATING ACTIVITIES
Net income/(loss)	$	(~~539~~1,~~428~~266,525	)	$	2593,~~394,546~~483
Adjustment to reconcile net income/(loss) to net cash provided by/(used in) operating activities
Change in derivative liabilities		1583,~~160,473~~657			(~~723~~28,~~532~~416	)
Intangible asset impairment		79,634			-0-
Interest expense from derivative instruments		24,637			54,518
Interest expense from derivative instruments		163,553			241,664
Employee stock compensation		130,537			56,526
Employee stock compensation		199,363			467,930
Provision for doubtful accounts		(23,353	)		(3,387	)
Provision for doubtful accounts		47,931			40,369
Depreciation and amortization		216,500			141,925
Depreciation and amortization		528,322			266,256
Operating lease right-of-use assets		160,165			-0-
Changes in operating assets and liabilities
Accounts receivable		2,~~320~~208,~~262~~749			~~(889~~1,502,206	)
Prepaid expenses		~~(93~~122,~~434~~471	)		~~(47~~29,~~519~~547	)
Other current assets		~~(454~~3,571	)		2(9,~~915~~271	)
Other assets		~~(82~~42,~~304~~759	)		4(20,~~843~~977	)
Accounts payable and accrued expenses		(~~899~~840,~~509~~066	)		(~~510~~1,~~316~~024,533	)
Patent settlement liability		(112,500	)		(449,479	)
Operating lease liability		(160,165	)		-0-
Deferred revenue		(1,649,691	)		(406,867	)
Patent settlement liability		-0-			(112,500	)
Net cash provided by/(used in) operating activities		1,122,218			1,279,921
Deferred revenue		(1,036,926	)		(2,282,127	)
Net cash provided by/(used in) operating activities		166,011			(1,103,006	)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment		(~~700~~270,~~028~~711	)		(~~212~~92,~~173~~794	)
Purchase of Acuity software		~~(552,403~~-0-	)		~~-0-~~(552,403	)
Net cash provided by/(used in) investing activities		(1,252,431	)		(212,173	)
Net cash (used in) investing activities		(270,711	)		(645,197	)
CASH FLOWS FROM FINANCING ACTIVITIES
Repayments of notes payable		(200,000	)		(1,020,000	)
Proceeds/(repayments) from revolving line of credit		(400,000	)		1,750,000
Proceeds/(repayments) from revolving line of credit		550,000			(200,000	)
Proceeds from exercise of warrants		450,000			-0-
Proceeds from exercise of stock options		45,000			35,250
Principal repayment of finance lease obligation		(30,365	)		-0-
Principal repayment of capital lease obligation		(38,064	)		-0-
Net cash provided by/(used in) financing activities		19,635			1,750,000
Net cash provided by/(used in) financing activities		356,936			(1,184,750	)
Effect of exchange rate changes on fixed and intangible assets		1,887			(3,898	)
Effect of exchange rate changes on fixed and intangible assets		3,112			(18,125	)
Effect of exchange rate changes on cash and cash equivalents		(5,430	)		1,287
Effect of exchange rate changes on cash and cash equivalents		(34,424	)		13,386
Net increase/(decrease) in cash and cash equivalents		(88,608	)		(814	)
Net increase/(decrease) in cash and cash equivalents		195,411			(121,741	)
Cash and cash equivalents at beginning of period		1,440,524			1,176,551
Cash and cash equivalents at beginning of period		1,176,551			1,439,332
Cash and cash equivalents at end of period	$	1,351,916		$	1,175,737
Cash and cash equivalents at end of period	$	1,371,962		$	1,317,591
Supplemental disclosures of cash flow information:
Cash paid during the period for:
Income taxes	$	175,~~035~~041		$	1,~~194~~035
Interest	$	~~889~~245,~~984~~256		$	~~802~~254,~~327~~092
Non-cash transactions:
Notes payable issued in exchange for existing notes payable	$	-0-		$	350,000
Restricted stock issuance/(forfeiture)	$	77,610		$	-0-
Restricted stock issuance/(forfeiture)	$	41,735		$	(2,834	)
Common stock issued for the purchase of Acuity software	$	-0-		$	500,000
Common stock issued for the purchase of Acuity software	$	500,000		$	-0-
Reclassification of warrant feature liability associated with warrant exercise	$	66,781		$	-0-
Capital expenditures funded by capital lease borrowing	$	359,603		$	-0-
Operating lease right of use assets and operating lease liability upon adoption of ASU 2016-02, Leases (Topic 842)	$	1,729,630		$	-0-
Reclassification of conversion feature liability associated with convertible debt	$	10,500		$	402,567

See accompanying summary of accounting policies and notes to unaudited condensed consolidated financial statements

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~SEPTEMBER~~MARCH 3031, ~~2018~~2019 AND ~~SEPTEMBER~~MARCH 3031, ~~2017~~2018

(unaudited)

NOTE 1:

ORGANIZATION AND NATURE OF OPERATIONS

OmniComm Systems, Inc. (“OmniComm” or the “Company”) is a healthcare technology company that provides web-based electronic data capture (“EDC”) and eClinical solutions and related value-added services to pharmaceutical and biotech companies, contract research organizations (“CROs”) and other clinical trial sponsors principally located in the United States, Europe and East Asia. Our proprietary EDC and eClinical software applications: TrialMaster®, TrialOne®, eClinical Suite, Promasys®, IRTMaster, AutoEncoder and Acuity ~~Analytics~~ (the “EDC Software”) allow clinical trial sponsors and investigative sites to securely collect, validate, transmit and analyze clinical trial data.

Our ability to compete within the EDC and eClinical industry is predicated on our ability to continue enhancing and broadening the scope of solutions offered through our EDC ~~Software~~and eClinical software and services. Our research and product development efforts are focused on developing new and complementary software solutions, as well as enhancing our existing software solutions through the addition of increased functionality. While our main product development efforts are conducted in our Fort Lauderdale, Florida office, we also conduct product development in other parts of the U.S. as well as in Southampton, England and Bengaluru, India. During the ~~nine~~three month periods ended ~~September~~March 3031, ~~2018~~2019 and ~~September~~March 3031, ~~2017~~2018 we spent $21,~~469~~089,~~280~~081, which represents 19% of revenue, and $2922,~~230~~304,~~565~~ which represents 13% of revenue, respectively, on research and product development activities, which are primarily comprised of salaries to our developers and other research and product development personnel and related costs associated with the development of our software products.

NOTE 2:

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION

The Company’s accounts include those of all its wholly-owned subsidiaries, which are more fully described in the Company’s ~~2017~~ 2018 Annual Report filed on Form 10-K with the Securities and Exchange Commission, and have been prepared in conformity with (i) accounting principles generally accepted in the United States of America; and (ii) the rules and regulations of the United States Securities and Exchange Commission. All significant intercompany accounts and transactions between the Company and its subsidiaries have been eliminated in consolidation.

UNAUDITED FINANCIAL STATEMENTS

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information, pursuant to the rules and regulations of the Securities and Exchange Commission. Pursuant to such rules and regulations, certain financial information and footnote disclosures normally included in the consolidated financial statements have been condensed or omitted. The results for the ~~nine~~three month periods ended ~~September~~March 3031, ~~2018~~2019 and ~~September~~March 3031, ~~2017~~2018 are unaudited, but reflect all adjustments (consisting only of normally recurring adjustments) which management considers necessary for a fair presentation of operating results.

The operating results for the ~~nine~~three month period ended ~~September~~March 3031, ~~2018~~2019 are not necessarily indicative of the results that may be expected for the year-ended December 31, ~~2018~~2019. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year-ended December 31, ~~2017~~2018.

ESTIMATES IN FINANCIAL STATEMENTS

The preparation of the unaudited condensed consolidated financial statements in conformity with generally accepted accounting principles ("GAAP") requires management to make estimates and assumptions that affect the amounts reported in the financial statements and footnotes thereto. Significant estimates incorporated in our financial statements include the recorded allowance for doubtful accounts, the estimate of the appropriate amortization period of our intangible assets, the evaluation of whether our intangible assets have suffered any impairment, the allocation of revenues under multiple-element customer contracts, ~~royalty-based~~the ~~patent~~determination of lease term and lease assets and liabilities, the value of derivatives associated with debt issued by the Company and the valuation of any corresponding discount to the issuance of our debt. Actual results may differ from those estimates.

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~SEPTEMBER~~MARCH 3031, ~~2018~~2019 AND ~~SEPTEMBER~~MARCH 3031, ~~2017~~2018

(unaudited)

Reclassifications

Certain reclassifications have been made in the ~~2017~~ 2018 financial statements to conform to the ~~2018~~ 2019 presentation. These reclassifications did not have any effect on our net income/(loss) or shareholders’ deficit.

foreign currency translation

The financial statements of the Company’s foreign subsidiaries are translated in accordance with Accounting Standards Codification (“ASC”) 830-30, Foreign Currency Matters—Translation of Financial Statements ("ASC 830-30"). The reporting currency for the Company is the U.S. dollar. The functional currency of the Company’s subsidiaries, OmniComm Europe GmbH in Germany, OmniComm Spain S.L. in Spain and OmniComm Systems B.V. in the Netherlands is the Euro. The functional currency of the Company’s subsidiary, OmniComm Ltd. in the United Kingdom, is the British Pound Sterling. The functional currency of the Company’s subsidiary, OmniComm eClinical Solutions Pvt. Ltd. in India, is the Indian Rupee. Accordingly, the assets and liabilities of the Company’s foreign subsidiaries are translated into U.S. dollars using the exchange rate in effect at each balance sheet date. Revenue and expense accounts of the Company’s foreign subsidiaries are translated using an average rate of exchange during the period. Foreign currency translation adjustments are accumulated as a component of other comprehensive income/(loss) as a separate component of stockholders’ equity. Gains and losses arising from transactions denominated in foreign currencies are primarily related to intercompany accounts that have been determined to be temporary in nature and accordingly, are recorded directly to the statement of operations. We record translation gains and losses in accumulated other comprehensive income as a component of stockholders’ equity. We recorded a translation loss of $345,~~424~~430 and a translation gain of $131,~~386~~287 for the ~~nine~~three month periods ended ~~September~~March 3031, ~~2018~~2019 and ~~September~~March 3031, ~~2017~~2018, respectively.

REVENUE RECOGNITION POLICY

The Company derives revenues from software licenses and services of its EDC and eClinical products and services which can be purchased on a stand-alone basis. License revenues are derived principally from the sale of term licenses for the following software products offered by the Company: TrialMaster, TrialOne, eClinical Suite and Promasys. Service revenues are derived principally from the Company's delivery of the hosted solutions of its TrialMaster software product, and consulting services and customer support, including training, for all of the Company's products.

For revenue from product sales, the Company recognizes revenue in accordance with Financial Accounting Standards Board ("FASB") ~~Accounting Standards Codification ("~~ASC") 606 (“ASC 606"). A five-step analysis must be met as outlined in ASC 606: (i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) performance obligations are satisfied. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. The Company defers any revenue for which the product has not been delivered or is subject to refund until such time that the Company and the customer jointly determine that the product has been delivered or no refund will be required.

The Company operates in one reportable segment which is the delivery of EDC and eClinical Software and services to clinical trial sponsors. The Company segregates its revenues based on the activity cycle used to generate its revenues. Accordingly, revenues are currently generated through four main activities, including hosted applications, licensing, professional services and maintenance-related services.

Hosted Application Revenues

The Company offers its TrialMaster and TrialOne software products as hosted application solutions delivered through a standard web browser, with customer support and training services. The Company's TrialOne and Promasys solutions are primarily deployed on a technology transfer or off-the-shelf basis. To date, hosted applications revenues have been primarily related to TrialMaster. OnOmniComm ~~April~~announced ~~30,~~that ~~2019,~~it ~~OmniComm will~~ would decommission its eClinical Suite hosting platform effective April 30, 2019 as many of the eClinical Suite clients utilizing these hosting services have transitioned to TrialMaster, the eClinical Suite studies have been completed or the studies have transitioned to another hosting platform. Currently there is one remaining client utilizing the hosting platform and we are finalizing the transition plan with the client.

Revenues resulting from TrialMaster application hosting services consist of three components of services for each clinical trial. The first component is comprised of application set-up, including design of electronic case report forms and edit checks, installation and server configuration of the system. The second component involves application hosting and related support services as well as billable change orders which consist of amounts billed to customers for functionality changes made. The third component involves services required to close out, or lock, the database for the clinical trial.

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~SEPTEMBER~~MARCH 3031, ~~2018~~2019 AND ~~SEPTEMBER~~MARCH 3031, ~~2017~~2018

(unaudited)

Fees charged for the trial system design, set-up and implementation are amortized and recognized ratably over the estimated hosting period. Work performed outside the original scope of work is contracted for separately as an additional fee and is generally recognized ratably over the remaining term of the hosting period. Fees for the first and third stages of the service are typically billed based upon milestones. Revenues earned upon completion of a contractual milestone are deferred and recognized over the estimated remaining hosting period. Fees for application hosting and related services in the second stage are generally billed monthly or quarterly in advance.

Licensing Revenues

The Company's software license revenues are earned from the sale of off-the-shelf software. From time to time a client might require significant modification or customization subsequent to delivery to the customer. The Company generally enters into software term licenses for its EDC and eClinical Software products with its customers for three to five year periods, although customers have entered into both longer and shorter term license agreements. These arrangements typically include multiple elements: software license, consulting services and customer support. The Company bills its customers in accordance with the terms of the underlying contract. Generally, the Company bills license fees in advance for each billing cycle of the license term, which typically is either on a quarterly or annual basis. Payment terms are generally net 30 to net 45 days.

The Company has sold perpetual licenses for EDC and eClinical Software products in certain situations to existing customers with the option to purchase customer support, and may, in the future, do so for new customers based on customer requirements or market conditions. The Company has established vendor specific objective evidence of fair value for the customer support. Accordingly, license revenues are recognized upon delivery of the software and when all other revenue recognition criteria are met. Customer support revenues are recognized ratably over the term of the underlying support arrangement. The Company generates customer support and maintenance revenues from its perpetual license customer base.

Professional Services

The Company may also enter into arrangements to provide consulting services separate from a license arrangement. In these situations, revenue is recognized on a time-and-materials basis. or upon completion of milestones. Professional services can be deemed to be as essential to the functionality of the software at inception and typically are for initial trial configuration, implementation planning, loading of software, building simple interfaces, running test data and documentation of procedures. Subsequent additions or extensions to license terms do not generally include additional professional services.

Maintenance Revenues

Maintenance includes telephone-based help desk support and software maintenance, including updates to the software through new software version releases. The Company generally bundles customer support with the software license for the entire term of the arrangement. As a result, the Company generally recognizes revenues for both maintenance and software licenses ratably over the term of the software license and support arrangement. The Company allocates the revenues recognized for these arrangements to the different elements based on management's estimate of the relative fair value of each element. The Company generally invoices each of the elements based on separately quoted amounts and thus has a fairly accurate estimate of the relative fair values of each of the invoiced revenue elements.

Pass-through Revenue and Expense

The Company accounts for pass-through revenue and expense (reimbursable revenue and reimbursable expense) in accordance with Accounting Standards Update ("ASU") 2016-08, Principal versus Agent Considerations (Reporting Revenue Gross versus Net), (“ASU 2016-08”). In accordance with ASU 2016-08 these amounts are recorded as revenue in the statement of operations with a corresponding expense recorded in cost of goods sold. Pass-through revenues and expenses include amounts associated with third-party services provided to our customers by our service and product partners. These third-party services are primarily comprised of Interactive Voice and Web Response software services (IVR and IWR), travel and shipping that are incurred on our clients’ behalf.

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~SEPTEMBER~~MARCH 3031, ~~2018~~2019 AND ~~SEPTEMBER~~MARCH 3031, ~~2017~~2018

(unaudited)

The fees associated with each business activity for the ~~nine~~three month periods ended ~~September~~March 3031, ~~2018~~2019 and ~~September~~March 3031, ~~2017~~2018, respectively, are:

	For the nine months ended
	For the three months ended
Revenue activity	~~September~~March 3031, ~~2018~~2019		~~September~~March 3031, ~~2017~~2018
Set-up fees	$	2811,~~683,182~~354	$	31,~~948~~208,~~687~~554
Change orders		1218,~~090,333~~622		1420,~~054,288~~080
Maintenance		41,~~163~~413,~~138~~243		31,~~749~~370,~~897~~091
Software licenses		82,~~423~~300,~~355~~130		73,~~951~~269,~~228~~400
Professional services		2603,~~617,149~~731		2431,~~526,379~~083
Hosting		1368,~~355,792~~739		~~945~~491,~~321~~264
Total	$	205,~~332~~715,~~949~~819	$	207,~~175~~190,~~800~~472

COST OF GOODS SOLD

Cost of goods sold primarily consists of costs related to hosting, maintaining and supporting the Company’s application suite and delivering professional services and support. These costs include salaries, benefits and bonuses for the Company’s professional services staff. Cost of goods sold also includes outside service provider costs. Cost of goods sold is expensed as incurred.

CASH AND CASH EQUIVALENTS

Cash equivalents consist of highly liquid, short-term investments with maturities of 90 days or less. The carrying amount reported in the accompanying consolidated balance sheets approximates fair value.

ACCOUNTS RECEIVABLE

Accounts receivable are judged as to collectability by management and an allowance for bad debts is established as necessary. The allowance is based on an evaluation of the collectability of accounts receivable and prior bad debt experience. The Company had recorded an allowance for uncollectible accounts receivable of $~~197~~152,~~911~~867 as of ~~September~~March 3031, ~~2018~~2019 and $~~149~~176,~~980~~ 220 as of December 31, ~~2017~~2018.

The following table summarizes activity in the Company's allowance for doubtful accounts for the ~~nine~~three month period ended ~~September~~March 3031, ~~2018~~2019 and the year ended December 31, ~~2017~~2018.

	September 30, 2018			December 31, 2017
	March 31, 2019			December 31, 2018
Beginning of period	$	~~149~~176,~~980~~220		$	~~179~~149,~~813~~980
Bad debt expense		47(23,~~931~~353	)		~~130~~41,~~346~~782
Write-offs		-0-			(~~160~~15,~~179~~542	)
End of period	$	~~197~~152,~~911~~867		$	~~149~~176,~~980~~220

Concentration of Credit Risk

Cash and cash equivalents and restricted cash are deposited with major financial institutions and, at times, such balances with any one financial institution may be in excess of FDIC-insured limits. As of March 31, 2019, $932,167 was deposited in excess of FDIC-insured limits. Management believes the risk in these situations to be minimal.

Except as follows, the Company has no significant off-balance-sheet risk or credit risk concentrations. Financial instruments that subject the Company to potential credit risks are principally cash equivalents and accounts receivable. Concentrated credit risk with respect to accounts receivable is limited to creditworthy customers. The Company's customers are principally located in the United States, Europe and East Asia. The Company is directly affected by the overall financial condition of the pharmaceutical, biotechnology and medical device industries and management believes that credit risk exists and that any credit risk the Company faces has been adequately reserved for as of March 31, 2019. The Company maintains an allowance for doubtful accounts based on accounts past due according to contractual terms and historical collection experience. Actual losses, when incurred, are charged to the allowance. The Company's losses related to collection of accounts receivable have consistently been within management's expectations. As of March 31, 2019, the Company believes no additional credit risk exists beyond the amounts provided for in our allowance for uncollectible accounts. The Company evaluates its allowance for uncollectable accounts on a quarterly basis based on a specific review of receivable aging and the period that any receivables are beyond the standard payment terms. The Company does not require collateral from its customers in order to mitigate credit risk.

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~SEPTEMBER~~MARCH 3031, ~~2018~~2019 AND ~~SEPTEMBER~~MARCH 3031, ~~2017~~2018

(unaudited)

~~Concentration~~One customer accounted for 7% of ~~Credit~~our ~~Risk~~revenues during the three month period ended March 31, 2019 or approximately $417,000. One customer accounted for 11% of our revenues during the three month period ended March 31, 2018 or approximately $770,000. The following table summarizes the number of customers who individually comprise greater than 10% of total revenue and/or total accounts receivable and their aggregate percentage of the Company's total revenue and gross accounts receivable for the three month periods ended March 31, 2019 and March 31, 2018 and the year ended December 31, 2018.

Cash and cash equivalents and restricted cash are deposited with major financial institutions and, at times, such balances with any one financial institution may be in excess of FDIC-insured limits. As of September 30, 2018, $1,404,402 was deposited in excess of FDIC-insured limits. Management believes the risk in these situations to be minimal.

	Revenues				Accounts receivable
For the period ended	Number of customers		Percentage of total revenues		Number of customers		Percentage of accounts receivable
March 31, 2019		-0-		0%		1		10%
December 31, 2018		1		13%		1		20%
March 31,2018		1		11%		2		20%

~~Except~~The astable ~~follows,~~below ~~the~~provides ~~Company~~revenues ~~has~~from noEuropean significant off-balance-sheet risk or credit risk concentrations. Financial instruments that subject the Company to potential credit risks are principally cash equivalents and accounts receivable. Concentrated credit risk with respect to accounts receivable is limited to creditworthy customers. ~~The~~for ~~Company's customers are principally located in~~ the ~~United~~three ~~States,~~month ~~Europe~~periods ~~and~~ended ~~East~~March ~~Asia. The Company is directly affected by the overall financial condition of the pharmaceutical~~31, ~~biotechnology~~2019 and ~~medical~~March ~~device industries and management believes that credit risk exists and that any credit risk the Company faces has been adequately reserved for as of September 30~~31, 2018. The Company maintains an allowance for doubtful accounts based on accounts past due according to contractual terms and historical collection experience. Actual losses, when incurred, are charged to the allowance. The Company's losses related to collection of accounts receivable have consistently been within management's expectations. As of September 30, 2018, the Company believes no additional credit risk exists beyond the amounts provided for in our allowance for uncollectible accounts. The Company evaluates its allowance for uncollectable accounts on a quarterly basis based on a specific review of receivable aging and the period that any receivables are beyond the standard payment terms. The Company does not require collateral from its customers in order to mitigate credit risk.

One customer accounted for 12% of our revenues during the nine month period ended September 30, 2018 or approximately $2,339,000. One customer accounted for 10% of our revenues during the nine month period ended September 30, 2017 or approximately $2,021,000. The following table summarizes the number of customers who individually comprise greater than 10% of total revenue and/or total accounts receivable and their aggregate percentage of the Company's total revenue and gross accounts receivable for the nine month periods ended September 30, 2018 and September 30, 2017 and the year ended December 31, 2017.

European revenues
For the three months ended
March 31, 2019				March 31, 2018
European revenues		% of Total revenues		European revenues		% of Total revenues
$	1,167,460		20%	$	1,068,475		15%

	Revenues		Accounts receivable
For the period ended	Number of customers	Percentage of total revenues	Number of customers	Percentage of accounts receivable
September 30, 2018	1	12%	1	13%
December 31, 2017	1	10%	1	24%
September 30, 2017	1	10%	2	38%

The Company serves its hosting customers from third-party web hosting facilities located in the United States and Europe. The Company does not control the operation of these facilities and they are vulnerable to damage or interruption. The Company maintains redundant systems that can be used to provide service in the event the third-party web hosting facilities become unavailable, although in such circumstances, the Company's service may be interrupted during the transition.

The table below provides revenues from European customers for the nine month periods ended September 30, 2018 and September 30, 2017.

European revenues
For the nine months ended
September 30, 2018		September 30, 2017
European revenues	% of Total revenues	European revenues	% of Total revenues
$3,513,571	17%	$2,514,601	12%

The Company serves its hosting customers from third-party web hosting facilities located in the United States and Germany. The Company does not control the operation of these facilities and they are vulnerable to damage or interruption. The Company maintains redundant systems that can be used to provide service in the event the third-party web hosting facilities become unavailable, although in such circumstances, the Company's service may be interrupted during the transition.

PROPERTY AND EQUIPMENT

Property and equipment are recorded at cost. Additions and betterments are capitalized; maintenance and repairs are expensed as incurred. Depreciation is calculated using the straight-line method over the asset’s estimated useful life, which is 5 years for leasehold improvements, computers, equipment and furniture and 3 years for software. Gains or losses on disposal are charged to operations.

LEASES

The Company accounts for leases in accordance with ASU No. 2016-02, “Leases (Topic 842)”, (“ASU 2016-02”). We determine if an arrangement is a lease at inception. As part of the lease determination process, we assess several factors, including, but not limited to, assessing our right to control and direct the use of the asset, as well as, assessing if the other party has a substantive substitution right. If we enter into leases that contain multiple components, we identify separate lease components based on whether or not the right to use the underlying assets is distinct and either highly dependent or highly interrelated with other rights in the contract. We also evaluate whether there are any non-lease components in the arrangement. If separate lease and non-lease components are identified, we allocate the consideration in the contract to the lease and non-lease components at the lease inception. Operating lease assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating leases are included in operating lease assets and operating lease liabilities on our balance sheet at March 31, 2019. Operating lease assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date to determine the present value of future payments. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. The lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.

With the adoption of Topic 842 on January 1, 2019, the Company recognized operating lease assets and operating lease liabilities of $1,729,630. There was no impact to the opening accumulated deficit balance as of January 1, 2019. Prior period amounts continue to be reported in accordance with our historic accounting under previous lease guidance, Topic 840.

ASSET IMPAIRMENT

Acquisitions and Intangible Assets

We account for acquisitions in accordance with ASC 805, Business Combinations (“ASC 805”) and ASC 350, Intangibles- Goodwill and Other (“ASC 350”). The acquisition method of accounting requires that assets acquired and liabilities assumed be recorded at their fair values on the date of a business acquisition. Our consolidated financial statements and results of operations reflect an acquired business from the completion date of an acquisition.

The judgments that we make in determining the estimated fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact net income in periods following an asset acquisition. We generally use either the income, cost or market approach to aid in our conclusions of such fair values and asset lives. The income approach presumes that the value of an asset can be estimated by the net economic benefit to be received over the life of the asset, discounted to present value. The cost approach presumes that an investor would pay no more for an asset than its replacement or reproduction cost. The market approach estimates value based on what other participants in the market have paid for reasonably similar assets. Although each valuation approach is considered in valuing the assets acquired, the approach ultimately selected is based on the characteristics of the asset and the availability of information.

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~SEPTEMBER~~MARCH 3031, ~~2018~~2019 AND ~~SEPTEMBER~~MARCH 3031, ~~2017~~2018

(unaudited)

Long-lived Assets

We review long-lived assets for impairment whenever events or changes in circumstances indicate that the related carrying amounts may not be recoverable. Determining whether an impairment has occurred typically requires various estimates and assumptions, including determining which cash flows are directly related to the potentially impaired asset, the useful life over which cash flows will occur, their amount and the asset’s residual value, if any. In turn, measurement of an impairment loss requires a determination of fair value, which is based on the best information available. We use quoted market prices when available and independent appraisals and management estimates of future operating cash flows, as appropriate, to determine fair value.

FAIR VALUE MEASUREMENT

OmniComm’s capital structure includes the use of warrants and convertible debt features that are classified as derivative financial instruments. Derivative financial instruments are recognized as either assets or liabilities and are measured at fair value under ASC 815, Derivatives and Hedging (“ASC 815”). ASC 815 requires that changes in the fair value of derivative financial instruments with no hedging designation be recognized as gains/(losses) in the earnings statement. The fair value measurement is determined in accordance with ASC 820, Fair Value Measurements and Disclosures (“ASC 820”).

DEFERRED REVENUE

Deferred revenue represents cash advances and amounts in accounts receivable as of the balance sheet date received in excess of revenue earned on on-going contracts. Payment terms vary with each contract but may include an initial payment at the time the contract is executed, with future payments dependent upon the completion of certain contract phases or targeted milestones. In the event of contract cancellation, the Company is generally entitled to payment for all work performed through the point of cancellation. As of ~~September~~March 3031, ~~2018~~2019, the Company had $7,~~867~~214,~~262~~630 in deferred revenues relating to contracts for services to be performed over periods ranging from one month to 7 6.25 years. The Company had $65,~~209~~302,~~198~~370 in deferred revenues that are expected to be recognized in the next twelve fiscal months.

ADVERTISING

Advertising costs are expensed as incurred. Advertising costs were $~~671~~185,~~030~~ 181 and $~~528~~209,~~777~~ 790 for the ~~nine~~three month periods ended ~~September~~March 3031, ~~2018~~2019 and ~~September~~March 3031, ~~2017~~2018, respectively, and are included under selling, general and administrative expenses in our unaudited condensed consolidated financial statements.

RESEARCH AND PRODUCT DEVELOPMENT EXPENSES

Software development costs are expensed as incurred. ASC 985-20, Software Industry Costs of Software to Be Sold, Leased or Marketed (“ASC 985-20”), requires the capitalization of certain development costs of software to be sold once technological feasibility is established, which the Company defines as completion to the point of marketability. The capitalized cost is then amortized on a straight-line basis over the estimated product life. To date, the period between achieving technological feasibility and the general availability of such software has been short and software development costs qualifying for capitalization have been immaterial. Accordingly, the Company has not capitalized any software development costs under ASC 985-20. During the ~~nine~~three month periods ended ~~September~~March 3031, ~~2018~~2019 and ~~September~~March 3031, ~~2017~~2018 we spent $21,~~469~~089,~~280~~081, which represents 19% of revenue, and $2922,~~230~~304,~~565,~~ which represents 13% of revenue, respectively, on research and product development activities, which include costs associated with the development of our software products and services for our clients’ projects and which are primarily comprised of salaries and related expenses for our software developers and consulting fees paid to third-party consultants. Research and product development costs are primarily included under Salaries, benefits and related taxes in our Statement of Operations.

EQUITY INCENTIVE PLANS

The OmniComm Systems, Inc. 2016 Equity Incentive Plan (the “2016 Plan”) was approved at our Annual Meeting of Stockholders on June 16, 2016. The 2016 Plan initially provides for the issuance of up to 10,000,000 shares of our common stock. In addition, the number of shares of common stock available for issuance under the 2016 Plan automatically increases on January 1st of each year for a period of nine (9) years commencing on January 1, 2017 and ending on (and including) January 1, 2025, in an amount equal to five percent (5%) of the total number of shares authorized under the 2016 Plan. As of March 31, 2019 11,576,250 shares of our common stock were authorized for issuance under the 2016 Plan.

The predecessor plan, the OmniComm Systems, Inc. 2009 Equity Incentive Plan (the “2009 Plan”) was approved at our Annual Meeting of Stockholders on July 10, 2009 and terminated on June 16, 2016 upon the approval of the 2016 Plan. The 2009 Plan provided for the issuance of up to 7,500,000 shares to employees, directors and key consultants. The 2016 and 2009 Plans are more fully described in “Note 14, Equity Incentive Plans”.

The Company accounts for its employee equity incentive plans under ASC 718, Compensation – Stock Compensation, (“ASC 718”) which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment transactions. ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company’s consolidated statements of operations. The Company currently uses the Black Scholes option pricing model to determine grant date fair value.

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~SEPTEMBER~~MARCH 3031, ~~2018~~2019 AND ~~SEPTEMBER~~MARCH 3031, ~~2017~~2018

(unaudited)

EQUITY INCENTIVE PLANS

The OmniComm Systems, Inc. 2016 Equity Incentive Plan (the “2016 Plan”) was approved at our Annual Meeting of Stockholders on June 16, 2016. The 2016 Plan initially provides for the issuance of up to 10,000,000 shares of our common stock. In addition, the number of shares of common stock available for issuance under the 2016 Plan automatically increases on January 1st of each year for a period of nine (9) years commencing on January 1, 2017 and ending on (and including) January 1, 2025, in an amount equal to five percent (5%) of the total number of shares authorized under the 2016 Plan. As of September 30, 2018 11,025,000 shares of our common stock were authorized for issuance under the 2016 Plan.

The Company accounts for its employee equity incentive plans under ASC 718, Compensation – Stock Compensation, (“ASC 718”) which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment transactions. ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company’s consolidated statements of operations. The Company currently uses the Black Scholes option pricing model to determine grant date fair value.

EARNINGS PER SHARE

The Company accounts for Earnings per Share using ASC 260, Earnings per Share, (“ASC 260”). Unlike diluted earnings per share basic earnings per share excludes any dilutive effects of options, warrants and convertible securities.

INCOME TAXES

The Company accounts for income taxes in accordance with ASC 740, Income Taxes (“ASC 740”). ASC 740 has as its basic objective the recognition of current and deferred income tax assets and liabilities based upon all events that have been recognized in the financial statements as measured by the provisions of the enacted tax laws.

Valuation allowances are established, when necessary, to reduce deferred tax assets to the estimated amount to be realized. Income tax expense represents the tax payable for the current period and the change during the period in the deferred tax assets and liabilities.

IMPACT OF NEW ACCOUNTING STANDARDS

~~During~~In February 2016, the ~~first~~FASB issued ~~nine~~ASU No. ~~months~~2016-02, “Leases (Topic 842)”, (“ASU 2016-02”). ASU 2016-02 requires that an entity should recognize assets and liabilities for leases with a maximum possible term of ~~2018~~more than 12 months. On January 1, 2019, we adopted ASU 2016-02, as amended, which supersedes the ~~following~~lease accounting guidance under Topic 840, and generally requires lessees to recognize operating and financing lease liabilities and corresponding right-of-use (ROU) assets on the balance sheet and to provide enhanced disclosures surrounding the amount, timing and uncertainty of cash flows arising from leasing arrangements. We adopted the new guidance using the modified retrospective transition approach by applying the new standard to all leases existing at the date of initial application and not restating comparative periods. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases, while our accounting ~~pronouncements:~~for finance leases remained substantially unchanged.

In ~~February~~August ~~2016~~2018, the FASB issued ~~Accounting~~ASU ~~Standard Update No. 2016~~2018-0215, ~~“Leases~~Intangibles ~~(Topic~~- ~~842)”,~~Goodwill ~~(“ASU~~and ~~2016~~other -~~02”).~~ ~~ASU 2016~~Internal-02Use ~~requires~~Software ~~that~~(Topic an350-40): ~~entity~~Customer’s ~~should~~Accounting ~~recognize~~for ~~assets~~Implementation ~~and~~Costs ~~liabilities~~Incurred ~~for~~in ~~leases with~~ a ~~maximum~~Cloud ~~possible~~Computing ~~term~~Arrangement ofthat ~~more~~is ~~than~~a 12Service ~~months~~Contract. AThis ~~lessee~~standard ~~would~~requires ~~recognize~~ a customer ~~liability~~in toa ~~make~~cloud ~~lease payments~~computing ~~(the~~arrangement ~~lease~~that ~~liability)~~is ~~and~~ a ~~right-of-use~~service ~~asset~~contract ~~representing its right~~ to ~~use~~follow the ~~leased~~internal-use ~~asset~~software ~~(the~~guidance ~~underlying~~in ~~asset)~~Topic ~~for~~350-40 ~~the lease term. This guidance also~~to ~~provides~~determine ~~accounting~~which ~~updates~~implementation ~~with~~costs ~~respect~~ to ~~lessor~~capitalize ~~accounting~~as ~~under a lease arrangement~~assets. ~~This~~The ~~new~~standard ~~lease guidance~~ is effective for ~~fiscal~~public ~~years~~companies ~~beginning~~for ~~after December~~fiscal 15years, ~~2018.~~and interim ~~Entities~~periods ~~have~~within ~~the~~those ~~option~~fiscal ofyears, ~~using~~beginning ~~either~~after aDecember ~~full~~15, ~~retrospective or a modified approach (cumulative effect adjustment in period of adoption) to adopt the new guidance~~2019. Early adoption is permitted ~~for all entities~~. WeThe ~~are~~Company is currently evaluating the ~~impact~~effect ofthat ~~the~~implementation ~~adoption~~ of this ~~guidance~~standard will have on ~~our~~the Company’s consolidated financial statements.

In April 2016, the FASB issued Accounting Standards Update 2016–10 “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing.” The amendments in this Update do not change the core principle of the guidance in Topic 606. Rather, the amendments in this Update clarify the following two aspects of Topic 606: identifying performance obligations and the licensing implementation guidance, while retaining the related principles for those areas. Topic 606 includes implementation guidance on (a) contracts with customers to transfer goods and services in exchange for consideration and (b) determining whether an entity’s promise to grant a license provides a customer with either a right to use the entity’s intellectual property (which is satisfied at a point in time) or a right to access the entity’s intellectual property (which is satisfied over time). The amendments in this Update are intended to render more detailed implementation guidance with the expectation to reduce the degree of judgement necessary to comply with Topic 606. The Company adopted the new standard effective January 1, 2018 using the modified retrospective method. Therefore, the comparative financial information has not been restated and continues to be reported under the accounting standards in effect for those periods. The adoption of the new standard did not have a material impact on the Company’s consolidated financial statements.

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2018 AND SEPTEMBER 30, 2017

(unaudited)

Accounting standards-setting organizations frequently issue new or revised accounting rules. We regularly review all new pronouncements to determine their impact, if any, on our financial statements.

NOTE 3:

EARNINGS/(LOSS) PER SHARE

Basic earnings/(loss) per share were calculated using the weighted average number of shares outstanding of ~~150~~157,~~282~~341,~~732~~ 946 and ~~147~~149,~~805~~653,~~410~~ 916 for the ~~nine~~three month periods ended ~~September~~March 3031, ~~2018~~2019 and ~~September~~March 3031, ~~2017~~2018, respectively.

The outstanding share balance as of ~~September~~March 3031, ~~2018~~2019 and ~~September~~March 3031, ~~2017~~2018, respectively, includes 1,~~900~~825,000 and -0- restricted shares that have been issued but are still at risk of forfeiture as the restrictions have not lapsed.

Antidilutive shares of 4033,~~741~~495,~~945~~677 have been omitted from the calculation of dilutive earnings/(loss) per share for the ~~nine~~three month period ended ~~September~~March 3031, ~~2018~~2019 and 3126,~~924~~343,~~411~~ 224 for the ~~nine~~three month period ended ~~September~~March 3031, ~~2017~~2018, as the shares were antidilutive. Provided below is the reconciliation between numerators and denominators of the basic and diluted earnings per share. The table below provides a reconciliation of anti-dilutive securities outstanding as of ~~September~~March 3031, ~~2018~~2019 and ~~September~~March 3031, ~~2017~~2018, respectively.

Anti-dilutive security	~~September~~March 3031, ~~2018~~2019		~~September~~March 3031, ~~2017~~2018
Employee stock options		2,~~670~~420,000		41,~~050~~295,000
Warrants		2619,020,000		2712,~~020~~950,000
Convertible notes		11,940,000		~~740~~11,980,000
Shares issuable for accrued interest		~~111~~115,~~945~~677		~~114~~118,~~411~~224
Total		4033,~~741~~495,~~945~~677		3126,~~924~~343,~~411~~224

The employee stock options are exercisable at prices ranging from $0.17 to $0.34 per share. The exercise prices on the warrants range from $0.25 to $0.60 per share. Shares issuable upon conversion of convertible debentures or accrued interest have a conversion price of $0.50 per share.

~~Some of the Company’s convertible debt has an anti-dilutive effect on net income/(loss) per share and was not included in the computation of diluted earnings per share.~~14

	For the nine months ended
	September 30, 2018								September 30, 2017
	Income/(loss)			Shares		Per-share			Income/(loss)		Shares		Per-share
	numerator			denominator		amount			numerator		denominator		amount
Basic EPS	$	(539,428	)		150,282,732	$	(0.00	)	$	2,394,546		147,805,410	$	0.02
Effect of dilutive securities		-0-			-0-		-0-			-0-		45,476		-0-
Diluted EPS	$	(539,428	)		150,282,732	$	(0.00	)	$	2,394,546		147,850,886	$	0.02

	For the three months ended
	September 30, 2018								September 30, 2017
	Income/(loss)			Shares		Per-share			Income/(loss)			Shares		Per-share
	numerator			denominator		amount			numerator			denominator		amount
Basic EPS	$	(2,662,692	)		150,905,124	$	(0.02	)	$	(358,839	)		147,858,566	$	(0.00	)
Effect of dilutive securities		-0-			-0-		-0-			-0-			-0-		-0-
Diluted EPS	$	(2,662,692	)		150,905,124	$	(0.02	)	$	(358,839	)		147,858,566	$	(0.00	)

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~SEPTEMBER~~MARCH 3031, ~~2018~~2019 AND ~~SEPTEMBER~~MARCH 3031, ~~2017~~2018

(unaudited)

Some of the Company’s convertible debt has an anti-dilutive effect on net earnings/(loss) per share and was not included in the computation of diluted earnings per share.

	For the three months ended
	March 31, 2019								March 31, 2018
	Income/(loss)			Shares		Per-share			Income/(loss)		Shares		Per-share
	numerator			denominator		amount			numerator		denominator		amount
Basic EPS	$	(1,266,525	)		157,341,946	$	(0.01	)	$	593,483		149,653,916	$	0.00

Effect of dilutive securities		-0-			-0-		-0-			139		3,039,750		-0-

Diluted EPS	$	(1,266,525	)		157,341,946	$	(0.01	)	$	593,622		152,693,666	$	0.00

NOTE 4:

PROPERTY AND EQUIPMENT, NET

Property and equipment consists of the following:

September 30, 2018

December 31, 2017

March 31, 2019

December 31, 2018

Description

Cost

Accumulated depreciation

Net book value

Cost

Accumulated depreciation

Net book value

Estimated useful life (years)

Computer & office equipment

3,~~046~~105,~~561~~515

2,~~129~~264,~~785~~773

~~916~~840,~~776~~742

23,~~322~~067,~~833~~069

12,~~949~~202,~~982~~166

~~372~~864,~~851~~903

Leasehold improvements

~~137~~138,~~054~~383

~~104~~108,~~335~~926

3229,~~719~~457

~~118~~136,~~380~~648

98106,~~901~~362

1930,~~479~~286

Computer software

2,~~305~~653,~~155~~982

12,~~957~~051,~~405~~411

~~347~~602,~~750~~571

2,~~010~~426,~~999~~339

1,~~886~~991,~~342~~842

~~124~~434,~~657~~497

Office furniture

~~169~~168,~~122~~839

~~135~~141,~~623~~271

3327,~~499~~568

~~162~~169,~~799~~120

~~127~~138,~~248~~491

3530,~~551~~629

Total

56,~~657~~066,~~892~~719

4,~~327~~566,~~148~~381

1,~~330~~500,~~744~~338

45,~~615~~799,~~011~~176

4,~~062~~438,~~473~~861

~~552~~1,~~538~~360,315

Depreciation expense for the ~~nine~~three month period ended ~~September~~March 3031, ~~2018~~2019 was $~~279~~128,~~532~~800 and $~~249~~77,~~801~~ 776 for the ~~nine~~three month period ended ~~September~~March 3031, ~~2017~~2018.

NOTE 5:

INTANGIBLE ASSETS, NET

Intangible assets consist of the following:

	September 30, 2018						December 31, 2017
	March 31, 2019						December 31, 2018
Asset	Cost		Accumulated amortization		Net book value		Cost		Accumulated amortization		Net book value		Estimated useful life (years)
eClinical Suite customer lists	$	1,392,701	$	1,392,701	$	-0-	$	1,392,701	$	1,392,701	$	-0-	3	3
Promasys B.V. customer lists		~~114~~111,~~877~~057		~~114~~111,~~877~~057		-0-		~~118~~113,~~780~~220		32113,~~994~~220		~~85,786~~-0-	15	15
Promasys B.V. software code		72,837		7172,~~623~~837		~~1,214~~-0-		72,837		6072,~~698~~837		~~12,139~~-0-	5	5
Promasys B.V. URLs/website		5856,~~019~~090		5856,~~019~~090		-0-		5957,~~990~~182		5957,~~990~~182		-0-	3	3
Acuity software code		1,052,403		~~233~~409,~~867~~268		~~818~~643,~~536~~135		~~-0-~~1,052,403		~~-0-~~321,568		~~-0-~~730,835	3	3
Total	$	2,~~690~~685,~~837~~088	$	12,~~871~~041,~~087~~953	$	~~819~~643,~~750~~135	$	12,~~644~~688,~~308~~343	$	1,~~546~~957,~~383~~508	$	97730,~~925~~835

During the second quarter of 2018 we recognized an impairment loss of $79,634 on the Promasys B.V. customer list after performing a fair value analysis on the asset utilizing a discounted cash flow model. The impairment charge is separately presented on the Statement of Operations.

Amortization expense for the ~~nine~~three month period ended ~~September~~March 3031, ~~2018~~2019 was $~~248~~87,~~790~~700 and $1664,~~455~~ 149 for the ~~nine~~three month period ended ~~September~~March 3031, ~~2017~~2018.

Remaining amortization expense for the Company’s intangible assets is as follows:

Year	Amortization
2018	$	88,914
2019	$	263,101
2019		350,801
2020		350,801
2021		29,~~234~~233
Total	$	~~819~~643,~~750~~135

1615

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~SEPTEMBER~~MARCH 3031, ~~2018~~2019 AND ~~SEPTEMBER~~MARCH 3031, ~~2017~~2018

(unaudited)

NOTE 6:

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses consist of the following:

Account	~~September~~March 3031, ~~2018~~2019		December 31, ~~2017~~2018
Accounts payable	$	~~760~~473,~~557~~266	$	1895,~~303,073~~145
Accrued payroll and related costs		~~681~~541,~~354~~369		~~925~~851,~~890~~530
Other accrued expenses		~~168~~142,~~675~~544		~~184~~250,~~131~~570
Accrued interest		7572,~~950~~913		~~172~~72,~~951~~913
Total accounts payable and accrued expenses	$	1,~~686~~230,~~536~~092	$	2,~~586~~070,~~045~~158

NOTE 7:

LINE OF CREDIT, NOTES PAYABLE AND LIQUIDITY

On March 18, 2013, the Company entered into a $2,000,000 revolving Line of Credit (“Line of Credit”) with The Northern Trust Company guaranteed by our then Chief Executive Officer and Director, Cornelis F. Wit (“Mr. Wit”). Mr. Wit receives 2.0% interest (approximately $9,500 per month) from the Company on the assets pledged for the Line of Credit. On December 18, 2013 the Company renewed the Line of Credit and increased the available balance to $4,000,000. On February 3, 2015 the Company renewed the Line of Credit and increased the available balance to $5,000,000. On April 7, 2017 the Company renewed the Line of Credit. The Line of Credit currently matures on April 7, 2020 and carries a variable interest rate based on the prime rate. At ~~September~~March 3031, ~~2018~~2019, $32,~~200~~500,000 was outstanding on the Line of Credit at an interest rate of 4.2550%.

Our primary sources of working capital are funds from operations and borrowings under our revolving Line of Credit. In the event that the Line of Credit is called for any reason, Mr. Wit has pledged to replace the borrowing capacity under the Line of Credit with a promissory note that utilizes the same maturity date and interest rate as the Line of Credit.

To satisfy our capital requirements, we may seek additional financing. There can be no assurance that any such funding will be available to us on favorable terms or at all. If adequate funds are not available when needed, we may be required to delay, scale back or eliminate some or all of our research and product development and marketing programs. If we are successful in obtaining additional financings, the terms of such financings may have the effect of diluting or adversely affecting the holdings or the rights of the holders of our securities or result in increased interest expense in future periods.

The following table summarizes the notes payable outstanding as of ~~September~~March 3031, ~~2018~~2019.

				~~Ending~~	Ending		~~Non related party~~	Non related party						~~Related party~~	Related party
Origination	Maturity	Interest		~~principal~~	principal					~~Long~~	Long						~~Long~~	Long
date	date	rate		~~September 30, 2018~~	March 31, 2019		~~Current~~	Current		~~term~~	term			~~Current~~	Current		~~term~~	term
2/29/2016	4/1/2019	12%		$	400,000		$	-0-		$	-0-			$	400,000		$	-0-
6/30/2016	4/1/2020		10%		$	420,000		$	-0-		$	420,000			$	-0-		$	-0-
6/30/2016	4/1/2020	~~10%~~	12%		~~420,000~~	137,500		~~-0-~~	-0-		~~420,000~~	137,500			~~-0-~~	-0-		~~-0-~~	-0-
6/30/2016	4/1/2020	12%			282,500			-0-			282,500				-0-			-0-
Discount on notes payable									-0-			(98,548	)			-0-			-0-
Discount on notes payable								-0-			(186,268	)			(46,946	)		-0-
Total					$	557,500		$	-0-		$	458,952			$	-0-		$	-0-
Total				$	1,102,500		$	-0-		$	516,232			$	353,054		$	-0-

The following table summarizes the notes payable outstanding as of December 31, ~~2017~~2018.

				~~Ending~~	Ending		~~Non related party~~	Non related party						~~Related party~~	Related party
Origination	Maturity	Interest		~~principal~~	principal					~~Long~~	Long						~~Long~~	Long
date	date	rate		~~December 31, 2017~~	December 31, 2018		~~Current~~	Current		~~term~~	term			~~Current~~	Current		~~term~~	term
2/29/2016	4/1/2019	12%		$	400,000		$	-0-		$	-0-			$	-0-		$	400,000
6/30/2016	4/1/2020		10%		$	420,000		$	-0-		$	420,000			$	-0-		$	-0-
6/30/2016	4/1/2020	~~10%~~	12%		~~420,000~~	137,500		~~-0-~~	-0-		~~420,000~~	137,500			~~-0-~~	-0-		~~-0-~~	-0-
6/30/2016	4/1/2020	12%			282,500			-0-			282,500				-0-			-0-
Discount on notes payable									-0-			(123,184	)			-0-			-0-
Discount on notes payable								-0-			(279,402	)			-0-			(117,365	)
Total					$	557,500		$	-0-		$	434,316			$	-0-		$	-0-
Total				$	1,102,500		$	-0-		$	423,098			$	-0-		$	282,635

On February 29, 2016, the Company issued a promissory note in the principal amount of $450,000 and warrants to purchase 1,800,000 shares of common stock of the Company at an exercise price of $0.25 per share with an expiration date of April 1, 2019 to our then Chief Executive Officer and Director, Cornelis F. Wit (“Mr. Wit”), in exchange for accrued interest in the amount of $450,000. The note carries an interest rate of 12% per annum and has a maturity date of April 1, 2019. On December 5, 2016, Mr. Wit sold 1,000,000 of the warrants to an employee of the Company. On August 31, 2017, the Company repaid $50,000 of the outstanding principal to Mr. Wit. On December 27, 2018, the Company and Mr. Wit cancelled the remaining outstanding $400,000 in principal in exchange for the exercise price of $400,000 for 1,600,000 warrants of the 2,000,000 warrants with an exercise price of $0.25 per share that he exercised on that date.

1716

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~SEPTEMBER~~MARCH 3031, ~~2018~~2019 AND ~~SEPTEMBER~~MARCH 3031, ~~2017~~2018

(unaudited)

The issuance caused us to calculate and record a derivative liability for the warrant liability. The warrants were valued using the Black Scholes option pricing model. A value of $325,689 was calculated and allocated to the warrants and recorded as a liability to the issuance of the note payable. As a result of the liability we recorded a discount to the note payable. The carrying amount of the note at the time of issuance was therefore $124,311. The warrant liability (discount) will be amortized over the 37 month duration of the note payable. The Company will continue to perform a fair value calculation quarterly on the warrant liability and accordingly the warrant liability is increased or decreased based on the fair value calculation. The resulting increase or decrease is reflected in operations as an unrealized gain or loss on changes in derivative liabilities.

On June 30, 2016, the Company issued promissory notes in the principal amount of $372,500 and warrants to purchase 1,490,000 shares of common stock of the Company at an exercise price of $0.25 per share with an expiration date of April 1, 2020 to two investors in exchange for existing promissory notes in the same amount. The notes carry an interest rate of 12% per annum and have a maturity date of April 1, 2020. On August 31, 2017, athe ~~promissory~~Company ~~note~~repaid ~~for~~ $90,000 ~~was~~to one of the lenders. On December 31, 2018, the Company repaid in$145,000 ~~full~~to one of the lenders.

The issuance caused us to calculate and record a derivative liability for the warrant liability. The warrants were valued using the Black Scholes option pricing model. A value of $246,921 was calculated and allocated to the warrants and recorded as a liability to the issuance of the note payable. As a result of the liability we recorded a discount to the note payable. The carrying amount of the note at the time of issuance was therefore $125,579. The warrant liability (discount) will be amortized over the 45 month duration of the note payables. The Company will continue to perform a fair value calculation quarterly on the warrant liability and accordingly the warrant liability is increased or decreased based on the fair value calculation. The resulting increase or decrease is reflected in operations as an unrealized gain or loss on changes in derivative liabilities.

On June 30, 2016, the Company issued promissory notes in the principal amount of $420,000 and warrants to purchase 1,680,000 shares of common stock of the Company at an exercise price of $0.25 per share with an expiration date of April 1, 2020 to two investors, in exchange for existing promissory notes in the same amount. The notes carry an interest rate of 10% per annum and have a maturity date of April 1, 2020.

The issuance caused us to calculate and record a derivative liability for the warrant liability. The warrants were valued using the Black Scholes option pricing model. A value of $278,408 was calculated and allocated to the warrants and recorded as a liability to the issuance of the note payable. As a result of the liability we recorded a discount to the note payable. The carrying amount of the note at the time of issuance was therefore $141,592. The warrant liability (discount) will be amortized over the 45 month duration of the note payables. The Company will continue to perform a fair value calculation quarterly on the warrant liability and accordingly the warrant liability is increased or decreased based on the fair value calculation. The resulting increase or decrease is reflected in operations as an unrealized gain or loss on changes in derivative liabilities.

NOTE 8:

CONVERTIBLE NOTES PAYABLE

The following table summarizes the convertible debt outstanding as of ~~September~~March 3031, ~~2018~~2019.

~~Carrying amount~~

Carrying amount

Date of

Maturity

Interest

~~Principal at~~

Principal at

~~Short term~~

Short term

~~Long term~~

Long term

issuance

date

rate

~~September 30, 2018~~

March 31, 2019

~~Related~~

~~Non related~~

Non related

~~Related~~

~~Non related~~

Non related

8/29/2008

4/1/2020

~~10%~~

10%

~~1,770,000~~$

1,770,000

~~-0-~~$

-0-

~~-0-~~$

-0-

~~1,770,000~~$

1,770,000

~~-0-~~$

-0-

12/16/2008

4/1/2020

~~12%~~

12%

~~4,000,000~~

4,000,000

~~-0-~~

-0-

~~-0-~~

-0-

~~4,000,000~~

4,000,000

~~-0-~~

-0-

12/16/2008

4/1/2021

~~12%~~

12%

~~200,000~~

200,000

~~-0-~~

-0-

~~-0-~~

-0-

~~-0-~~

-0-

~~200,000~~

200,000

Total

~~5,970,000~~$

5,970,000

~~-0-~~$

-0-

~~-0-~~$

-0-

~~5,770,000~~$

5,770,000

~~200,000~~$

200,000

18The following table summarizes the convertible debt outstanding as of December 31, 2018.

						Carrying amount
Date of	Maturity	Interest		Principal at		Short term				Long term
issuance	date	rate		December 31, 2018		Related		Non related		Related		Non related
8/29/2008	4/1/2020		10%	$	1,770,000	$	-0-	$	-0-	$	1,770,000	$	-0-
12/16/2008	4/1/2020		12%		4,000,000		-0-		-0-		4,000,000		-0-
12/16/2008	4/1/2021		12%		200,000		-0-		-0-		-0-		200,000
Total				$	5,970,000	$	-0-	$	-0-	$	5,770,000	$	200,000

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~SEPTEMBER~~MARCH 3031, ~~2018~~2019 AND ~~SEPTEMBER~~MARCH 3031, ~~2017~~2018

(unaudited)

The following table summarizes the convertible debt outstanding as of December 31, 2017.

					Carrying amount
Date of	Maturity	Interest	Principal at		Short term				Long term
issuance	date	rate	December 31, 2017		Related		Non related		Related		Non related
8/1/1999	6/30/2004	10%	$	50,000	$	-0-	$	50,000	$	-0-	$	-0-
8/29/2008	4/1/2019	10%		150,000		-0-		-0-		-0-		150,000
8/29/2008	4/1/2020	10%		1,770,000		-0-		-0-		1,770,000		-0-
12/16/2008	4/1/2020	12%		4,000,000		-0-		-0-		4,000,000		-0-
12/16/2008	4/1/2021	12%		200,000		-0-		-0-		-0-		200,000
Total			$	6,170,000	$	-0-	$	50,000	$	5,770,000	$	350,000

10% Convertible Notes

During 1999, the Company issued 10% Convertible Notes payable in the amount of $862,500 pursuant to a Confidential Private Placement Memorandum. There were costs of $119,625 associated with this offering. The net proceeds to the Company were $742,875. The notes bear interest at 10% annually, payable semi-annually. The notes were convertible after maturity, which was June 30, 2004, into shares of common stock of the Company at $1.25 per share. On September 30, 2018, the final $50,000 note was repaid in full along with the accrued interest of $96,949. As of ~~September~~March 3031, ~~2018~~2019, $862,500 of the Convertible Notes had been repaid in cash or converted into 1,495,179 shares of common stock of the Company leaving an outstanding principal balance of $-0-.

Secured Convertible Debentures

On September 30, 2009, the Company sold an aggregate of $1,400,000 principal amount 12% Secured Convertible Debentures (the “Debentures”) and common stock purchase warrants (the “Warrants”) to purchase an aggregate of 5,600,000 shares of our common stock exercisable at a price of $0.25 per share for four years subsequent to the closing of the transaction to four accredited investors including our then Chief Executive Officer and Director, Cornelis F. Wit (“Mr. Wit”). The Company received net proceeds of $1,400,000. The Debentures, which bear interest at 12% per annum, matured on March 30, 2011. The Debentures are convertible at any time at the option of the holder into shares of our common stock based upon a conversion rate of $0.25 per share.

On March 30, 2011, the Company repaid $200,000 of the outstanding principal amounts owed and extended $1,200,000 of the Debentures until April 1, 2013, including $1,100,000 in Debentures held by Mr. Wit. The Company also extended the expiration date of the warrants associated with the Debentures.

On February 22, 2013, the Company and two holders extended $1,200,000 of the Debentures until January 1, 2016, including $1,100,000 in Debentures held by Mr. Wit. Mr. Wit also waived all his rights to the security interest under his $1,100,000 of Debentures. The expiration date of the warrants associated with the Debentures was also extended to January 1, 2016.

On January 31, 2015, the Company and Mr. Wit extended the maturity date of $1,100,000 of the Debentures to April 1, 2017. The expiration date of the warrants associated with the Debentures was also extended to April 1, 2017. On November 19, 2015, Mr. Wit converted $475,000 of the Debentures into 1,900,000 shares of our common stock. On November 19, 2015, the Company and Mr. Wit agreed to cancel the 1,900,000 warrants related to the $475,000 of Debentures and $475,000 of unrelated promissory notes in exchange for 1,900,000 shares of our common stock. On November 23, 2015, Mr. Wit sold the remaining $625,000 of Debentures and the related warrants to two unrelated non-affiliate stockholders.

On April 1, 2015, the Company and the holder extended the maturity date of $100,000 of Debentures to April 1, 2018. The expiration date of the warrants associated with the debentures was also extended to April 1, 2018. On June 30, 2017 the Company repaid the $100,000 of Debentures.

On June 30, 2016, the Company and two holders extended the maturity date of $625,000 of Debentures to April 1, 2020. The expiration date of the warrants associated with the debentures was also extended to April 1, 2020. In August 2017 the Company repaid the $625,000 of Debentures in full.

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2018 AND SEPTEMBER 30, 2017

(unaudited)

Convertible Debentures

August 2008

On August 29, 2008, the Company sold $2,270,000 of convertible debentures and warrants to purchase an aggregate of 4,540,000 shares of our common stock to four accredited investors including our then Chief Executive Officer and Director, Cornelis F. Wit (“Mr. Wit”) and one of our then Directors. The convertible debentures, which bear interest at 10% per annum, were due on August 29, 2010. The convertible debentures are convertible at any time at the option of the holder into shares of our common stock based upon a conversion rate of $0.50 per share.

On September 30, 2009, the Company and two Affiliates of the Company extended $1,920,000 of the convertible debentures until August 29, 2013 in accordance with the terms of a Secured Convertible Debenture issued on that date. The expiration date of the warrants associated with the debentures was also extended to August 29, 2013.

On February 22, 2013, the Company and Mr. Wit extended the maturity date of $1,770,000 of the convertible debentures to January 1, 2016. The expiration date of the warrants associated with the debentures was also extended to January 1, 2016.

On February 22, 2013, the Company and Mr. van Kesteren extended the maturity date of $150,000 of the convertible debentures due to our former Director, Guus van Kesteren (“Mr. van Kesteren”) to January 1, 2015. The expiration date of the warrants associated with the debentures was also extended to January 1, 2015.

On April 21, 2014, the Company and Mr. van Kesteren extended the maturity date of his $150,000 of convertible debentures to April 1, 2016. The expiration date of the warrants associated with the debentures was also extended to April 1, 2016. On July 31, 2014 Mr. van Kesteren’s term on the Board of Directors ended. Effective on the same date, his convertible note in the amount of $150,000 was reclassified from Related Party to Non-Related Party.

On January 31, 2015, the Company and Mr. Wit extended the maturity date of the $1,770,000 of convertible debentures to April 1, 2017. The expiration date of the warrants associated with the debentures was also extended to April 1, 2017.

On June 30, 2015, the Company and Mr. van Kesteren extended the maturity date of $150,000 of convertible debentures to April 1, 2017. The expiration date of the warrants associated with the debentures was also extended to April 1, 2017.

On June 30, 2016, the Company and Mr. Wit extended the maturity date of the $1,770,000 of convertible debentures to April 1, 2020. The expiration date of the warrants associated with the debentures was also extended to April 1, 2020.

On June 30, 2016, the Company and Mr. van Kesteren extended the maturity date of $150,000 of convertible debentures to April 1, 2018. The expiration date of the warrants associated with the debentures was also extended to April 1, 2018.

On June 30, 2017, the Company and Mr. van Kesteren extended the maturity date of $150,000 of convertible debentures to April 1, 2019. The expiration date of the warrants associated with the debentures was also extended to April 1, 2019. The $150,000 of convertible debentures was repaid in full on June 30, 2018.

~~December 2008~~18

On December 16, 2008, the Company sold $5,075,000 of convertible debentures and warrants to purchase an aggregate of 10,150,000 shares of common stock to eleven accredited investors, including our then Chief Executive Officer and Director, Cornelis F. Wit (“Mr. Wit”), our then Chief Operating Officer and President, Stephen E. Johnson (“Mr. Johnson”), our then Chief Technology Officer, Randall G. Smith (“Mr. Smith”), our then Chief Financial Officer, Ronald T. Linares and four of our then Directors. The convertible debentures, which bear interest at 12% per annum, were due on December 16, 2010. The convertible debentures are convertible at any time at the option of the holder into shares of our common stock based upon a conversion rate of $0.50 per share.

On September 30, 2009, the Company and eight Affiliates of the Company extended $4,980,000 of the convertible debentures until December 16, 2013 in accordance with the terms of a Secured Convertible Debenture issued on that date. The expiration date of the warrants associated with the convertible debentures was also extended to December 16, 2013.

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~SEPTEMBER~~MARCH 3031, ~~2018~~2019 AND ~~SEPTEMBER~~MARCH 3031, ~~2017~~2018

(unaudited)

December 2008

On February 22, 2013, the Company and the holders agreed to extend the maturity date of $4,505,000 of the convertible debentures including $4,475,000 due to Mr. Wit, $25,000 due to Mr. Johnson and $5,000 due to Mr. Smith, to January 1, 2016. The expiration date of the warrants associated with the debentures was also extended to January 1, 2016.

On February 27, 2013, the Company and our former director Mr. Veatch extended the maturity date of $15,000 of the convertible debentures to January 1, 2016. The expiration date of the warrants associated with the debentures was also extended to January 1, 2016.

On March 6, 2013, the Company and the holder extended the maturity date of $200,000 of convertible debentures to January 1, 2014. The expiration date of the warrants associated with the debentures was also extended to January 1, 2014.

On March 12, 2013, the Company and the holder agreed to extend the maturity date of $100,000 of convertible debentures to January 1, 2015. The expiration date of the warrants associated with the debentures was also extended to January 1, 2015.

In December 2013, the Company and two holders agreed to extend the maturity date of $360,000 of the convertible debentures, including $160,000 due to our then director, Guus van Kesteren (“Mr. van Kesteren”), to January 1, 2016. The expiration date of the warrants associated with the debentures was also extended to January 1, 2016. On July 31, 2014 Mr. van Kesteren’s term on the Board of Directors ended. Effective on the same date, his convertible note in the amount of $160,000 was reclassified from Related Party to Non-Related Party.

On April 28, 2014, the Company and the holder extended the maturity date of $100,000 of convertible debentures to April 1, 2016. The expiration date of the warrants associated with the debentures was also extended to April 1, 2016.

On January 31, 2015, the Company and Mr. Wit extended the maturity date of $4,475,000 of convertible debentures to April 1, 2017. The expiration date of the warrants associated with the debentures was also extended to April 1, 2017. On November 19, 2015, the Company and Mr. Wit agreed to cancel $420,000 of the debentures and 1,680,000 of unrelated warrants in exchange for 1,680,000 shares of our common stock.

On April 27, 2015, the Company and the holder extended the maturity date of $200,000 of convertible debentures to April 1, 2018. The expiration date of the warrants associated with the debentures was also extended to April 1, 2018.

On April 30, 2015, the Company and Mr. Johnson extended the maturity date of $25,000 of convertible debentures to April 1, 2018. The expiration date of the warrants associated with the debentures was also extended to April 1, 2018. The convertible debentures were repaid in full on December 14, 2016.

On May 1, 2015, the Company and Mr. van Kesteren extended the maturity date of $160,000 of the convertible debentures to April 1, 2017. The expiration date of the warrants associated with the debentures was also extended to April 1, 2017.

On May 1, 2015, the Company repaid $5,000 of the convertible debentures to Mr. Smith.

On May 7, 2015, the Company and Mr. Veatch, extended the maturity date of $15,000 of the convertible debentures to April 1, 2018. The expiration date of the warrants associated with the debentures was also extended to April 1, 2018. The $15,000 of convertible debentures were repaid in full on December 14, 2016.

On June 30, 2015, the Company and the holder extended the maturity date of $100,000 of convertible debentures to April 1, 2017. The expiration date of the warrants associated with the debentures was also extended to April 1, 2017.

21On June 30, 2016, the Company and Mr. Wit extended the maturity date of $4,055,000 of convertible debentures to April 1, 2020. The expiration date of the warrants associated with the debentures was also extended to April 1, 2020. On August 31, 2017, the Company repaid $55,000 of the convertible debentures to Mr. Wit.

On June 30, 2016, the Company and Mr. van Kesteren extended the maturity date of $160,000 of the convertible debentures to April 1, 2018. The expiration date of the warrants associated with the debentures was also extended to April 1, 2018. The $160,000 of convertible debentures was repaid in full on December 14, 2016.

On June 30, 2016, the Company and the holder extended the maturity date of $100,000 of convertible debentures to April 1, 2020. The expiration date of the warrants associated with the debentures was also extended to April 1, 2020. On August 31, 2017, the Company repaid $100,000 of convertible debentures to the holder.

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~SEPTEMBER~~MARCH 3031, ~~2018~~2019 AND ~~SEPTEMBER~~MARCH 3031, ~~2017~~2018

(unaudited)

On June 30, 2016, the Company and Mr. Wit extended the maturity date of $4,055,000 of convertible debentures to April 1, 2020. The expiration date of the warrants associated with the debentures was also extended to April 1, 2020. On August 31, 2017, the Company repaid $55,000 of the convertible debentures to Mr. Wit.

On June 30, 2017, the Company and the holder extended the maturity date of $200,000 of the convertible debentures to April 1, 2021. The expiration date of the warrants associated with the debentures was also extended to April 1, 2021.

The principal payments required at maturity under the Company’s outstanding convertible debt at ~~September~~March 3031, ~~2018~~2019 are as follows:

Year	Amount
2018	$	-0-
2019	$	-0-
2019		-0-
2020		5,770,000
2021		200,000
Total	$	5,970,000

NOTE 9:

FAIR VALUE MEASUREMENT

The Company measures the fair value of its assets and liabilities under the guidance of ASC 820, Fair Value Measurements and Disclosures (“ASC 820”), which defines fair value, establishes a framework for measuring fair value in accordance with ~~generally accepted accounting principles~~ GAAP and expands disclosures about fair value measurements. ASC 820 does not require any new fair value measurements, but its provisions apply to all other accounting pronouncements that require or permit fair value measurement.

ASC 820 clarifies that fair value is an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants based on the highest and best use of the asset or liability. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. ASC 820 requires the Company to use valuation techniques to measure fair value that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized as follows:

●

Level 1: Observable inputs such as quoted prices for identical assets or liabilities in active markets;

●

Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly such as quoted prices for similar assets or liabilities or market-corroborated inputs; and

●

Level 3: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions about how market participants would price the assets or liabilities.

The valuation techniques that may be used to measure fair value are as follows:

Market approach - Uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities

Income approach - Uses valuation techniques to convert future amounts to a single present amount based on current market expectations about those future amounts, including present value techniques, option-pricing models and excess earnings methods

Cost approach - Based on the amount that currently would be required to replace the service capacity of an asset (replacement cost)

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2018 AND SEPTEMBER 30, 2017

(unaudited)

The Company also adopted the provisions of ASC 825, Financial Instruments (“ASC 825”). ASC 825 allows companies to choose to measure eligible assets and liabilities at fair value with changes in value recognized in earnings. Fair value treatment may be elected either upon initial recognition of an eligible asset or liability or, for an existing asset or liability, if an event triggers a new basis of accounting. The Company did not elect to re-measure any of its existing financial assets or liabilities under the provisions of this Statement.

The Company’s financial assets or liabilities subject to ASC 820 as of ~~September~~March 3031, ~~2018~~2019 include the conversion feature and warrant liability associated with convertible debentures issued during 2008 and 2009 and the warrants issued during ~~2011 and~~ 2016 that are associated with notes payable. The conversion feature and warrants were deemed to be derivatives (the “Derivative Instruments”) since a fixed conversion price cannot be determined for either of the Derivative Instruments due to anti-dilution provisions embedded in the offering documents for the convertible debentures. The derivative instruments were not issued for risk management purposes and as such are not designated as hedging instruments under the provisions of ASC 815, Disclosures about Derivative Instruments and Hedging Activities. See Note 8 – Convertible Notes Payable.

Following is a description of the valuation methodologies used to determine the fair value of the Company’s financial liabilities including the general classification of such instruments pursuant to the valuation hierarchy.

~~A summary, as of September 30, 2018, of the fair value of liabilities measured at fair value on a recurring basis follows:~~20

	Fair value at		Quoted prices in active markets for identical assets/ liabilities		Significant other observable inputs		Significant unobservable inputs
Derivatives: (1) (2)	September 30, 2018		(Level 1)		(Level 2)		(Level 3)
Conversion feature liability	$	1,840,512	$	-0-	$	-0-	$	1,840,512
Warrant liability		4,436,207		-0-		-0-		4,436,207
Total of derivative liabilities	$	6,276,719	$	-0-	$	-0-	$	6,276,719

(1) The fair value of the derivative instruments was estimated using the Income Approach and the Black Scholes option pricing model with the following assumptions for the nine month period ended September 30, 2018.

(2) The fair value at the measurement date is equal to the carrying value on the balance sheet.

Significant valuation assumptions for derivative instruments at September 30, 2018
Risk free interest rate	2.45%	to	2.45%
Dividend yield		0.00%
Expected volatility	85.7%	to	105.8%
Expected life (range in years)
Conversion feature liability	1.50	to	2.50
Warrant liability	0.25	to	2.50

A summary, as of December 31, 2017, of the fair value of liabilities measured at fair value on a recurring basis follows:

	Fair value at		Quoted prices in active markets for identical assets/ liabilities		Significant other observable inputs		Significant unobservable inputs
Derivatives: (1) (2)	December 31, 2017		(Level 1)		(Level 2)		(Level 3)
Conversion feature liability	$	1,685,947	$	-0-	$	-0-	$	1,685,947
Warrant liability		3,440,799		-0-		-0-		3,440,799
Total of derivative liabilities	$	5,126,746	$	-0-	$	-0-	$	5,126,746

(1) The fair value of the derivative instruments was estimated using the Income Approach and the Black Scholes option pricing model with the following assumptions for the year ended December 31, 2017.

(2) The fair value at the measurement date is equal to the carrying value on the balance sheet.

Significant valuation assumptions for derivative instruments at December 31, 2017
Risk free interest rate	1.56%	to	1.81%
Dividend yield		0.00%
Expected volatility	87.0%	to	118.4%
Expected life (range in years)
Conversion feature liability	1.25	to	3.25
Warrant liability	0.25	to	3.25

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~SEPTEMBER~~MARCH 3031, ~~2018~~2019 AND ~~SEPTEMBER~~MARCH 3031, ~~2017~~2018

(unaudited)

A summary, as of ~~September~~March 3031, ~~2018~~2019, of the fair value of ~~assets~~liabilities measured at fair value on a ~~non-~~recurring basis follows:

	Carrying amount		Carrying amount		Quoted prices in active markets for identical assets/ liabilities		Significant other observable inputs		Significant unobservable inputs
	Fair value at		Quoted prices in active markets for identical assets/ liabilities		Significant other observable inputs		Significant unobservable inputs
Acquired assets (1)	December 31, 2017		September 30, 2018		(Level 1)		(Level 2)		(Level 3)
Derivatives: (1) (2)	March 31, 2019		(Level 1)		(Level 2)		(Level 3)
Promasys B.V. customer list (2) (3)	$	85,786	$	-0-	$	-0-	$	-0-	$	136,253
Conversion feature liability	$	907,498	$	-0-	$	-0-	$	907,498
Promasys B.V. software code (2)		12,139		1,214		-0-		-0-		72,943
Warrant liability		1,604,616		-0-		-0-		1,604,616
Acuity software code (4)		-0-		818,536		-0-		-0-		1,052,403
Total of derivative liabilities	$	2,512,114	$	-0-	$	-0-	$	2,512,114
Total	$	97,925	$	819,750	$	-0-	$	-0-	$	1,261,599

(1) The fair value of the ~~acquired~~derivative ~~assets~~instruments was estimated using the Income Approach and the Black Scholes option pricing model with athe ~~discounted~~following ~~cash~~assumptions ~~flow~~for ~~valuation~~the ~~methodology~~period ~~applied~~ended March 31, 2019. (2) The fair value at the measurement date is equal to the carrying value on the balance sheet.

(2) The acquired Promasys B.V. software code and customer list are not measured on a recurring basis since their initial fair value has been deemed to have a finite life and is being amortized periodically. Instead, the Company performs an impairment analysis on a quarterly basis in order to determine whether the carrying value of the assets reflects the fair value of the assets in a market based transaction.

	Significant valuation assumptions for derivative instruments at March 31, 2019
Risk free interest rate	2.55%	to	2.55%
Dividend yield		0.00%
Expected volatility	88.4%	to	95.4%
Expected life (range in years)
Conversion feature liability	1.01	to	2.01
Warrant liability	0.00	to	2.01

~~(3) During~~A ~~the~~summary, ~~second~~as ~~quarter~~ of ~~2018~~December we31, ~~recognized~~2018, ~~an impairment loss~~ of ~~$79,634 on~~ the ~~Promasys~~fair ~~B.V.~~value ~~Customer~~of ~~List~~liabilities ~~after~~measured ~~performing~~at a fair value ~~analysis~~ on ~~the asset utilizing~~ a ~~discounted~~recurring ~~cash~~basis ~~flow model. The impairment charge is separately presented on the Statement of Operations.~~follows:

(4) The acquired Acuity software code is not measured on a recurring basis since the initial fair value has been deemed to have a finite life and is being amortized periodically. Instead, the Company performs an impairment analysis on a quarterly basis in order to determine whether the carrying value of the assets reflects the fair value of the assets in a market based transaction.

	Fair value at		Quoted prices in active markets for identical assets/ liabilities		Significant other observable inputs		Significant unobservable inputs
Derivatives: (1) (2)	December 31, 2018		(Level 1)		(Level 2)		(Level 3)
Conversion feature liability	$	706,339	$	-0-	$	-0-	$	706,339
Warrant liability		1,288,899		-0-		-0-		1,288,899
Total of derivative liabilities	$	1,995,238	$	-0-	$	-0-	$	1,995,238

A(1) ~~summary,~~The asfair value of the derivative instruments was estimated using the Income Approach and the Black Scholes option pricing model with the following assumptions for the year ended December 31, ~~2017,~~2018. of(2) ~~the~~The fair value ofat ~~assets~~the ~~measured~~measurement atdate ~~fair~~is equal to the carrying value on athe ~~non-recurring~~balance ~~basis follows:~~sheet.

	Carrying amount			Carrying amount		Quoted prices in active markets for identical assets/ liabilities		Significant other observable inputs		Significant unobservable inputs
	Significant valuation assumptions for derivative instruments at December 31, 2018
Acquired assets (1)	December 30, 2016			December 31, 2017		(Level 1)		(Level 2)		(Level 3)
Risk free interest rate	2.70%	to	2.70%
Promasys B.V. customer list (2)	$	82,173		$	85,786	$	-0-	$	-0-	$	136,253
Dividend yield		0.00%
Promasys B.V. software code (2)		26,707			12,139		-0-		-0-		72,943
Expected volatility	92.2%	to	97.0%
Total	$	108,880		$	97,925	$	-0-	$	-0-	$	209,196
Expected life (range in years)
Conversion feature liability	1.25	to	2.25
Warrant liability	0.00	to	2.25

~~(1) The fair value of the acquired assets was estimated using the Income Approach with a discounted cash flow valuation methodology applied.~~21

(2) The acquired Promasys B.V. software code and customer list are not measured on a recurring basis since their initial fair value has been deemed to have a finite life and is being amortized periodically. Instead the Company performs an impairment analysis on a quarterly basis in order to determine whether the carrying value of the assets reflects the fair value of the assets in a market based transaction.

Other identifiable intangible assets, which are subject to amortization, are being amortized using the straight-line method over their estimated useful lives ranging from 3 to 15 years. The Impairment or Disposal of Long-Lived Asset subsection of ASC 360, Property, Plant and Equipment requires us to test the recoverability of long-lived assets, including identifiable intangible assets with definite lives, whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. In testing for potential impairment, if the carrying value of the asset group exceeds the expected undiscounted cash flows, we must then determine the amount by which the fair value of those assets exceeds the carrying value and determine the amount of impairment, if any.

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~SEPTEMBER~~MARCH 3031, ~~2018~~2019 AND ~~SEPTEMBER~~MARCH 3031, ~~2017~~2018

(unaudited)

~~The~~A ~~table~~summary, ~~below~~as ~~presents~~of ~~the~~March ~~unrealized~~31, ~~gains/(losses)~~2019, ~~for~~of the ~~nine~~fair ~~month~~value ~~periods~~of ~~ended~~assets ~~September~~measured ~~30,~~at ~~2018~~fair ~~and~~value ~~September~~on ~~30,~~a ~~2017.~~non-recurring basis follows:

	Other income/(expense)
	Carrying amount			Carrying amount		Quoted prices in active markets for identical assets/ liabilities		Significant other observable inputs		Significant unobservable inputs
	For the nine months ended
Acquired assets (1)	December 31, 2018			March 31, 2019		(Level 1)		(Level 2)		(Level 3)
	September 30, 2018			September 30, 2017
Promasys B.V. customer list (2) (3)	$	-0-		$	-0-	$	-0-	$	-0-	$	136,253
The net amount of gains/(losses) for the period included in earnings attributable to the unrealized and realized gains/(losses) from changes in derivative liabilities at the reporting date	$	(1,160,473	)	$	723,532
Promasys B.V. software code (2)		-0-			-0-		-0-		-0-		72,943
Total unrealized and realized gains/(losses) included in earnings	$	(1,160,473	)	$	723,532
Acuity software code (4)	$	730,835			643,135		-0-		-0-		1,052,403
Total	$	730,835		$	643,135	$	-0-	$	-0-	$	1,261,599

(1) The ~~tables~~fair ~~below~~value ~~set~~of ~~forth~~the acquired assets was estimated using the Income Approach with a ~~summary~~discounted ofcash ~~changes~~flow invaluation methodology applied. (2) The acquired Promasys B.V. software code and customer list are not measured on a recurring basis since their initial fair value ofhas been deemed to have a finite life and is being amortized periodically. Instead, the Company’s ~~Level~~performs 3an ~~financial~~impairment ~~liabilities~~analysis aton a quarterly basis in order to determine whether the carrying value of the assets reflects the fair value ~~for~~of the ~~nine~~assets ~~month~~in ~~period~~a ~~ended~~market ~~September~~based ~~30,~~transaction. ~~2018~~(3) ~~and~~During the ~~year~~second ~~ended~~quarter ~~December~~of 312018 we recognized an impairment loss of $79,634 ~~2017~~on the Promasys B.V. Customer List after performing a fair value analysis on the asset utilizing a discounted cash flow model. The ~~tables~~impairment ~~reflect~~charge ~~changes~~is ~~for~~separately ~~all~~presented ~~financial~~on ~~liabilities~~the atStatement of Operations. (4) The acquired Acuity software code is not measured on a recurring basis since the initial fair value ~~categorized~~has asbeen ~~Level~~deemed 3to ashave ofa ~~September~~finite ~~30,~~life ~~2018~~ and ~~December~~is 31being amortized periodically. Instead, ~~2017~~the Company performs an impairment analysis on a quarterly basis in order to determine whether the carrying value of the assets reflects the fair value of the assets in a market based transaction.

~~The~~A ~~table~~summary, ~~below~~as ~~presents~~of ~~the~~December ~~Level~~31, 32018, ~~financial~~of ~~liabilities~~the at fair value ~~for~~of ~~the~~assets ~~nine~~measured ~~month~~at ~~period~~fair ~~ended~~value ~~September~~on ~~30,~~a ~~2018.~~non-recurring basis follows:

	Level 3 financial liabilities at fair value
	Carrying amount			Carrying amount		Quoted prices in active markets for identical assets/ liabilities			Significant other observable inputs		Significant unobservable inputs
									Net		Reclassification
Acquired assets (1)	December 31, 2017			December 31, 2018		(Level 1)			(Level 2)		(Level 3)
									purchases,		of conversion
Promasys B.V. customer list (2) (3)	$	85,786		$	-0-	$	-0-		$	-0-	$	136,253
	Balance,								issuances		feature liability		Balance,
Promasys B.V. software code (2)		12,139			-0-		-0-			-0-		72,943
	beginning			Net realized		Net unrealized			and		associated with		end
Acuity software code (4)		-0-			730,835		-0-			-0-		1,052,403
Derivatives:	of year			gains/(losses)		gains/(losses)			settlements		convertible debt		of period
Total	$	97,925		$	730,835	$	-0-		$	-0-	$	1,261,599
Conversion feature liability	$	(1,685,947	)	$	-0-	$	(165,065	)	$	-0-	$	10,500	$	(1,840,512	)
Warrant liability		(3,440,799	)		-0-		(995,408	)		-0-		-0-		(4,436,207	)
Total of derivative liabilities	$	(5,126,746	)	$	-0-	$	(1,160,473	)	$	-0-	$	10,500	$	(6,276,719	)

(1) The ~~table~~fair ~~below~~value ~~presents~~of the ~~Level~~acquired assets was estimated using the Income Approach with a discounted cash flow valuation methodology applied. (2) The acquired Promasys B.V. software code and customer list are not measured on a recurring basis since their initial fair value has been deemed to have a finite life and is being amortized periodically. Instead, the Company performs an impairment analysis on a quarterly basis in order to determine whether the carrying value of the assets reflects the fair value of the assets in a market based transaction. (3) ~~financial~~During ~~liabilities~~the atsecond quarter of 2018 we recognized an impairment loss of $79,634 on the Promasys B.V. Customer List after performing a fair value ~~for~~analysis on the ~~year~~asset ~~ended~~utilizing ~~December~~a 31discounted cash flow model. The impairment charge is separately presented on the Statement of Operations. (4) The acquired Acuity software code is not measured on a recurring basis since the initial fair value has been deemed to have a finite life and is being amortized periodically. Instead, ~~2017~~the Company performs an impairment analysis on a quarterly basis in order to determine whether the carrying value of the assets reflects the fair value of the assets in a market based transaction.

	Level 3 financial liabilities at fair value
								Net		Reclassification
								purchases,		of conversion
	Balance,							issuances		feature liability		Balance,
	beginning			Net realized		Net unrealized		and		associated with		end
Derivatives:	of year			gains/(losses)		gains/(losses)		settlements		convertible debt		of year
Conversion feature liability	$	(2,325,730	)	$	48,375	$	188,841	$	-0-	$	402,567	$	(1,685,947	)
Warrant liability		(3,999,362	)		-0-		558,563		-0-		-0-		(3,440,799	)
Total of derivative liabilities	$	(6,325,092	)	$	48,375	$	747,404	$	-0-	$	402,567	$	(5,126,746	)

Other identifiable intangible assets, which are subject to amortization, are being amortized using the straight-line method over their estimated useful lives ranging from 3 to 15 years. The Impairment or Disposal of Long-Lived Asset subsection of ASC 360, Property, Plant and Equipment requires us to test the recoverability of long-lived assets, including identifiable intangible assets with definite lives, whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. In testing for potential impairment, if the carrying value of the asset group exceeds the expected undiscounted cash flows, we must then determine the amount by which the fair value of those assets exceeds the carrying value and determine the amount of impairment, if any.

~~NOTE~~The ~~10:~~table ~~COMMITMENTS~~below ~~AND~~presents ~~CONTINGENCIES~~the unrealized gains/(losses) for the three month periods ended March 31, 2019 and March 31, 2018.

The Company currently leases office space under operating leases for most of its office locations and has operating leases related to server and network co-location and disaster recovery for its operations. The minimum future lease payments required under the Company’s operating leases at September 30, 2018 are as follows:

	Other income/(expense)
	For the three months ended
	March 31, 2019			March 31, 2018
The net amount of gains/(losses) for the period included in earnings attributable to the unrealized and realized gains/(losses) from changes in derivative liabilities at the reporting date	$	(583,657	)	$	28,416

Total unrealized and realized gains/(losses) included in earnings	$	(583,657	)	$	28,416

Year	Payments
2018	$	226,880
2019		654,275
2020		413,574
2021		337,397
2022		337,480
Thereafter		75,052
Total	$	2,044,658

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~SEPTEMBER~~MARCH 3031, ~~2018~~2019 AND ~~SEPTEMBER~~MARCH 3031, ~~2017~~2018

(unaudited)

InThe ~~addition~~tables tobelow ~~annual~~set ~~base~~forth ~~rental~~a ~~payments,~~summary ~~the~~of ~~Company~~changes ~~pays~~in ~~for~~fair ~~the~~value ~~operating~~of ~~expenses~~the ~~associated~~Company’s ~~with~~Level ~~its~~3 ~~leased~~financial ~~office~~liabilities ~~space~~at ~~and~~fair isvalue ~~responsible~~ for ~~any~~the ~~escalation~~three inmonth ~~operating~~period ~~expenses~~ended asMarch ~~determined~~31, in2019 and the ~~leases.~~year ~~Rent~~ended ~~expense~~December ~~was $930~~31,~~972~~ ~~and~~2018. ~~$841,718~~The tables reflect changes for ~~the~~all ~~nine~~financial ~~month~~liabilities ~~periods~~at ~~ended~~fair ~~September~~value 30categorized as Level 3 as of March 31, ~~2018~~2019 and ~~September~~December 3031, ~~2017, respectively~~2018.

The ~~Company’s~~table ~~Fort~~below ~~Lauderdale,~~presents ~~Florida~~the ~~corporate~~Level ~~office~~3 ~~lease~~financial ~~expires~~liabilities inat ~~February~~fair ~~2023.~~value ~~The~~for ~~Company’s~~the ~~lease~~three onmonth ~~its~~period ~~New~~ended ~~Jersey field office expires in~~ March ~~2021. The Company currently operates its wholly-owned subsidiary~~31, OmniComm Ltd., in the United Kingdom under the terms of a lease that expires in September 2020. The Company currently operates its wholly-owned subsidiary, OmniComm Europe, GmbH, in Germany under the terms of a lease that expires in July 2019. The Company currently operates its wholly-owned subsidiary, OmniComm Systems B.V, in the Netherlands under the terms of a lease that expires in October 2018. Our offices in Barcelona, Spain, Tokyo, Japan and Bengaluru, India are administered under service agreements that include the use of office space and other services.

The Company currently leases computer hardware for its operations under leases classified as capital leases. The leased equipment is amortized on a straight line basis over five years. The minimum future lease payments required under the Company’s capital leases at September 30, 2018 are as follows:

	Level 3 financial liabilities at fair value
									Net		Reclassification
									purchases,		of conversion
	Balance,								issuances		feature liability		Balance,
	beginning			Net realized		Net unrealized			and		associated with		end
Derivatives:	of period			gains/(losses)		gains/(losses)			settlements		convertible debt		of period
Conversion feature liability	$	(706,339	)	$	-0-	$	(201,159	)	$	-0-	$	-0-	$	(907,498	)
Warrant liability		(1,288,899	)		-0-		(382,498	)		66,781		-0-		(1,604,616	)
Total of derivative liabilities	$	(1,995,238	)	$	-0-	$	(583,657	)	$	66,781	$	-0-	$	(2,512,114	)

Year	Payments
2018	$	32,958
2019		131,832
2020		131,832
2021		52,779
Total minimum capital lease payments		349,401
Less: Amount representing interest		(28,797	)
Present value of minimum capital lease payments	$	320,604

The table below presents the Level 3 financial liabilities at fair value for the year ended December 31, 2018.

LEGAL PROCEEDINGS

	Level 3 financial liabilities at fair value
								Net		Reclassification
								purchases,		of conversion
	Balance,							issuances		feature liability		Balance,
	beginning			Net realized		Net unrealized		and		associated with		end
Derivatives:	of year			gains/(losses)		gains/(losses)		settlements		convertible debt		of year
Conversion feature liability	$	(1,685,947	)	$	-0-	$	969,108	$	-0-	$	10,500	$	(706,339	)
Warrant liability		(3,440,799	)		-0-		2,142,652		9,248		-0-		(1,288,899	)
Total of derivative liabilities	$	(5,126,746	)	$	-0-	$	3,111,760	$	9,248	$	10,500	$	(1,995,238	)

~~From~~NOTE ~~time~~10: to time the Company may be involved in litigation relating to claims arising out of our operations in the normal course of business. As of September 30, 2018, there were no pending legal proceedings to which the Company or its subsidiaries are a party or to which any of its property is subject that could reasonably be expected to have a material effect on the results of our operations.LEASES

~~PATENT~~We ~~LITIGATION~~adopted ~~SETTLEMENT~~ASU 2016-02, Leases ("Topic 842"), as of January 1, 2019, using the modified retrospective transition approach. The financial results reported in periods prior to 2019 are unchanged. In addition, we elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed us to carry forward the historical lease classification and use hindsight to determine the lease term.

~~Effective April~~Adoption 9,of ~~2009, we entered into a Settlement and License Agreement with DataSci, LLC (“DataSci”). DataSci granted us a worldwide, non-exclusive non-transferable right and license under~~ the ~~Licensed~~new ~~Patent~~standard ~~and~~resulted ~~the~~in ~~right~~additional tooperating ~~sublicense~~lease ~~TrialMaster~~liabilities ~~on a Technology Transfer~~ and ~~Technology~~lease ~~Transition~~assets ~~basis. Under the terms~~ of ~~the Settlement and License Agreement, as amended, we are obligated to pay royalties quarterly for sales of Licensed Products, as defined therein, from January~~ $1, ~~2009 until the termination of the Settlement and License Agreement on December 31~~729, ~~2017 equal to two percent (2%) of OmniComm’s annual Gross Revenues or~~630, alternatively, the annual minimum royalty payment(s), whichever is greater. In addition to the payment of royalties, the Settlement and Licensing Agreement imposes certain obligations on us including commercialization, certain sublicensing, other payments, insurance and confidentiality. In addition and as ~~a license fee for past use~~ of ~~the~~January ~~Licensed Patent which may have occurred prior to the effective date of the Settlement and Licensing Agreement, we issued a warrant to DataSci to purchase~~ 1,~~000,000~~ ~~shares of our common stock at an exercise price of $~~2019.01 ~~per share.~~ The ~~Settlement~~standard ~~and~~did ~~Licensing~~not ~~Agreement~~materially ~~provides~~impact ~~that~~our ~~upon~~consolidated ~~the~~net ~~expiration~~income ~~date of the warrant, at DataSci’s sole discretion, DataSci shall exercise its option under the warrant~~ or licensee shall pay DataSci $300,000. The warrant was exercisable commencing on the second anniversary of the Settlement and Licensing Agreement, April 2, 2011, through the expiration date of the warrant on December 31, 2017. On December 31, 2017, DataSci exercised 50% of the warrant for 500,000 common shares and requested cash ~~payment~~flow ~~on 50% of the warrant~~classification. ~~As a result of the exercise, DataSci received 500,000 restricted common shares and a net cash payment of $145,000.~~

OnOperating ~~June~~right ~~23,~~of ~~2009,~~use weasset ~~entered~~and ~~into~~operating anlease ~~agreement~~liability toare ~~acquire~~recognized at the ~~EDC~~lease ~~assets~~commencement ofdate. ~~eResearch~~Operating ~~Technology.~~lease ~~Concurrent~~liability ~~with~~represents the ~~consummation~~present value of ~~that~~lease ~~transaction~~payments wenot ~~entered~~yet ~~into~~paid. ~~the~~Operating ~~First~~right ~~Amendment~~of touse ~~Settlement~~asset ~~and~~represent ~~Licensing~~our ~~Agreement~~right ~~with DataSci, (i)~~ to ~~include~~use ~~the~~an ~~eResearch~~underlying ~~Technology~~asset ~~EDC~~and ~~assets~~are ~~acquired~~based upon ~~within~~ the ~~definition~~operating oflease ~~Licensed~~liability ~~Products,~~adjusted ~~and~~for asprepayments ~~such~~or ~~subject~~accrued tolease ~~the royalty payment(s)~~payments, ~~under~~initial ~~and~~direct incosts, ~~accordance~~lease ~~with the Settlement and Licensing Agreement~~incentives, and ~~(ii)~~impairment ~~provide a release by DataSci~~ of ~~any~~operating ~~and~~lease ~~all~~assets. ~~claims~~The ofCompany ~~infringement~~used ofour ~~the~~incremental ~~Licensed~~borrowing ~~Patent~~rate into ~~connection~~determine ~~with~~ the ~~eResearch~~present ~~Technology~~value ~~EDC assets acquired which may have occurred prior to the effective date~~ of ~~the~~lease ~~First~~payments ~~Amendment~~not toyet ~~Settlement and Licensing Agreement for an aggregate amount of $300,000~~paid.

26 If we enter into leases that contain multiple components, we identify separate lease components based on whether or not the right to use the underlying assets is distinct and either highly dependent or highly interrelated with other rights in the contract. We also evaluate whether there are any non-lease components in the arrangement. If separate lease and non-lease components are identified, we allocate the consideration in the contract to the lease and non-lease components at the lease inception.

We evaluate arrangements at inception to determine if lease components are included. An arrangement includes a lease component if it identifies an asset and we have control over the asset. For new leases beginning January 1, 2019 or later, we have elected to separate lease components from the non-lease components, included in an arrangement, when measuring the leased asset and leased liability.

Lease assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. Leases with an initial term of 12 months or less are not recorded on the balance sheet. We recognize lease expense on a straight-line basis over the lease term. The discount rate selected is our incremental borrowing rate.

Some of our leases include one or more options to extend the lease term. Certain leases also include options to terminate early. Optional periods may be included in the lease term and measured as part of the lease asset and lease liability if we are reasonably certain to exercise our right to use the leased asset during the optional periods. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~SEPTEMBER~~MARCH 3031, ~~2018~~2019 AND ~~SEPTEMBER~~MARCH 3031, ~~2017~~2018

(unaudited)

NoThe ~~further~~Company ~~payments~~currently leases office space under operating leases for most of its office locations and has operating leases related to server and network co-location and disaster recovery for its operations. The Company’s Fort Lauderdale, Florida corporate office lease expires in February 2023. The Company’s lease on its New Jersey field office expires in March 2021. The Company currently operates its wholly-owned subsidiary, OmniComm Ltd., in the United Kingdom under the terms of a lease that expires in September 2020. The Company currently operates its wholly-owned subsidiary, OmniComm Europe, GmbH, in Germany under the terms of a lease that expires in July 2020. The Company currently operates its wholly-owned subsidiary, OmniComm eClinical Solutions Pvt. Ltd., in India under the terms of a lease that expires in May 2023. The Company currently operates its wholly-owned subsidiary, OmniComm Systems B.V, in the Netherlands under the terms of an agreement that expires in October 2019. Our offices in Barcelona, Spain and Tokyo, Japan are ~~due~~administered under service agreements that include the ~~Settlement~~use of office space and ~~Licensing~~other ~~Agreement~~services.

~~During~~Supplemental ~~the nine~~balance ~~month~~sheet ~~period~~information ~~ended~~related ~~September 30, 2017 the Company recorded a charge~~ to ~~earnings~~leases ofwas ~~($111,979),~~as which amount represented (i) the amount of additional license expense incurred above the stipulated minimum in the DataSci Settlement and License Agreement during the nine month period ended September 30, 2017 and (ii) the accretion of the difference between the total stipulated annual minimum royalty payments and the recorded present value accrual of the annual minimum royalty payments.follows:

Operating Leases	Classification	March 31, 2019
Right-of-use assets	Operating lease assets	$	1,569,465

Current lease liability	Current operating lease liability		598,108
Non-current lease liability	Long term operating lease liability		971,357
Total lease liabilities		$	1,569,465

Our weighted average lease terms and discount rates are as follows:

	March 31, 2019
Weighted-average remaining lease term (in years)
Operating leases		3.30
Finance leases		2.12

Weighted-average discount rate
Operating leases		4.50%
Finance leases		6.94%

The components of lease cost were as follows:

	For the three months ended March 31, 2019
Operating lease cost	$	167,888
Variable lease cost (1)		140,910
Total lease cost	$	308,798
(1) Variable lease cost primarily relates to common area maintenance, property taxes and insurance on leased real estate

Supplemental disclosures of cash flow information related to leases were as follows:

	For the three months ended March 31, 2019
Cash paid for operating lease cost	$	167,942

Operating lease assets obtained in exchange for operating lease liabilities	$	1,729,630

The minimum future lease payments required under the Company’s operating leases at March 31, 2019 are as follows:

Year	Payments
2019	$	468,042
2020		476,293
2021		340,478
2022		340,746
Thereafter		76,446
Total undiscounted lease payments		1,702,005
Less: amount representing interest		(132,540	)
Present value of lease payments	$	1,569,465

As previously disclosed in our 2018 Annual Report on Form 10-K and under the previous lease accounting, minimum future lease payments were as follows as of December 31, 2018:

Year	Payments
2019	$	655,901
2020		414,973
2021		340,029
2022		340,270
Thereafter		76,243
Total	$	1,827,416

In addition to annual base rental payments, the Company pays for the operating expenses associated with its leased office space and is responsible for any escalation in operating expenses as determined in the leases. Rent expense was $311,799 and $289,334 for the three month periods ended March 31, 2019 and March 31, 2018, respectively.

The Company currently leases computer hardware for its operations under leases classified as finance leases. The leased equipment is amortized on a straight line basis over five years. Our finance lease costs for the three month period ending March 31, 2019 was $32,683. The minimum future lease payments required under the Company’s finance leases at March 31, 2019 are as follows:

Year	Payments
2019	$	97,552
2020		130,069
2021		51,898
Total minimum finance lease payments		279,519
Less: amount representing interest		(19,034	)
Present value of minimum finance lease payments	$	260,485

NOTE 11:

COMMITMENTS AND CONTINGENCIES

LEGAL PROCEEDINGS

From time to time the Company may be involved in litigation relating to claims arising out of our operations in the normal course of business. As of March 31, 2019, there were no pending legal proceedings to which the Company or its subsidiaries are a party or to which any of its property is subject that could reasonably be expected to have a material effect on the results of our operations.

EMPLOYMENT AGREEMENTS

We have employment agreements in place with the following members of our executive management team:

Cornelis F. Wit, Executive Chairman

Randall G. Smith, Executive Vice Chairman

Stephen E. Johnson, Chief Executive Officer and President

Thomas E. Vickers, Chief Financial Officer

The employment agreements provide, among other things, for participation in employee benefits available to employees and executives. Each of the agreements will renew for successive one-year terms unless the agreement is expressly terminated by either the employee or the Company prior to the end of the then current term as provided for in the employment agreement. Under the terms of the agreement, we may terminate the employee’s employment upon 30 or 60 days notice of a material breach and the employee may terminate the agreement under the same terms and conditions. The employment agreements contain non-disclosure provisions, as well as non-compete clauses. The agreements for Mr. Smith, Mr. Johnson and Mr. Vickers contain severance provisions which entitles the employee to severance pay equal to one (1) year's salary and benefits in the event of (i) the employee's termination by the Company for any reason other than for cause, as described in the employment agreement, or (ii) termination by the employee pursuant to a material breach of the agreement by the Company or for good reason in connection with a change of control, or (iii) non-renewal of the employment agreement by the Company.

~~NOTE 11: RELATED PARTY TRANSACTIONS~~25

AsTable of September 30, 2018, we have an aggregate of $5,770,000 of convertible debentures and $400,000 of promissory notes outstanding to our Executive Chairman and Chairman of the Board, Cornelis F. Wit (“Mr. Wit”) and have issued certain warrants to Mr. Wit, as follows:Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2019 AND MARCH 31, 2018

(unaudited)

NOTE 12:

RELATED PARTY TRANSACTIONS

As of March 31, 2019, we have an aggregate of $5,770,000 of convertible debentures outstanding to our Executive Chairman and Executive Chairman of the Board, Cornelis F. Wit (“Mr. Wit”) and have issued certain warrants to Mr. Wit, as follows:

●

In June 2008, Mr. Wit invested $510,000 in convertible notes. On August 29, 2008, Mr. Wit converted the $510,000 and invested an additional $1,260,000 in a private placement of convertible debentures and warrants to purchase 3,540,000 shares of our common stock. The convertible debentures, which bear interest at 10% per annum, were due on August 29, 2010. The convertible debentures are convertible at any time at the option of the holder into shares of our common stock based upon a conversion rate of $0.50 per share. On September 30, 2009, the Company and Mr. Wit extended the $1,770,000 of convertible debentures until August 29, 2013 in accordance with the terms of a Secured Convertible Debenture issued on that date. The expiration date of the warrants associated with the debentures was also extended to August 29, 2013.On February 22, 2013, the Company and Mr. Wit extended the maturity date of the $1,770,000 of convertible debentures to January 1, 2016. The expiration date of the warrants associated with the debentures was also extended to January 1, 2016. On January 31, 2015, the Company and Mr. Wit extended the maturity date of the $1,770,000 of convertible debentures to April 1, 2017. The expiration date of the warrants associated with the debentures was also extended to April 1, 2017. On June 30, 2016, the Company and Mr. Wit extended the maturity date of the $1,770,000 of convertible debentures to April 1, 2020. The expiration date of the warrants associated with the debentures was also extended to April 1, 2020.

●

In February 2008, Mr. Wit invested $150,000 in promissory notes and from September 2008 to December 2008, Mr. Wit invested $4,200,000 in convertible notes. On December 16, 2008, Mr. Wit converted the $4,350,000 into a private placement of convertible debentures and warrants to purchase 8,700,000 shares of our common stock. The convertible debentures, which bear interest at 12% per annum, were due on December 16, 2010. The convertible debentures are convertible at any time at the option of the holder into shares of our common stock based upon a conversion rate of $0.50 per share. On September 30, 2009, the Company and Mr. Wit extended the $4,350,000 of convertible debentures until December 16, 2013 in accordance with the terms of a Secured Convertible Debenture issued on that date. The expiration date of the warrants associated with the debentures was also extended to December 16, 2013. In a private transaction on October 16, 2012, Mr. Wit purchased $125,000 of the December 2008 convertible debentures and the related 250,000 warrants from Mr. Ronald Linares, the Company’s former Chief Financial Officer. On February 22, 2013, the Company and Mr. Wit extended the maturity date of the $4,475,000 of convertible debentures to January 1, 2016. The expiration date of the warrants associated with the debentures was also extended to January 1, 2016. On January 31, 2015, the Company and Mr. Wit extended the maturity date of the $4,475,000 of convertible debentures to April 1, 2017. The expiration date of the warrants associated with the debentures was also extended to April 1, 2017. On November 19, 2015, the Company and Mr. Wit agreed to cancel $420,000 of the debentures and 1,680,000 of unrelated warrants in exchange for 1,680,000 shares of our common stock. On June 30, 2016, the Company and Mr. Wit extended the maturity date of the $4,055,000 of convertible debentures to April 1, 2020. The expiration date of the warrants associated with the debentures was also extended to April 1, 2020. On August 31, 2017, the Company repaid $55,000 to Mr. Wit.

● On February 29, 2016, the Company issued a promissory note in the principal amount of $450,000 and warrants to purchase 1,800,000 shares of common stock of the Company at an exercise price of $0.25 per share with an expiration date of April 1, 2019 to Mr. Wit in exchange for accrued interest in the amount of $450,000. The note carries an interest rate of 12% per annum and has a maturity date of April 1, 2019. On Aug 31, 2017, the Company repaid $50,000 to Mr. Wit. On December 27, 2018, the Company and Mr. Wit cancelled the remaining outstanding $400,000 in principal in exchange for the exercise price of $400,000 for 1,600,000 warrants of the 2,000,000 warrants with an exercise price of $0.25 per share that he exercised on that date.

27On March 18, 2013, the Company entered into a $2,000,000 revolving Line of Credit (“Line of Credit”) with The Northern Trust Company guaranteed by our then Chief Executive Officer and Director, Cornelis F. Wit. Mr. Wit receives 2.0% interest (approximately $9,500 per month) from the Company on the assets pledged for the Line of Credit. On December 18, 2013, the Company renewed the Line of Credit and increased the available balance to $4,000,000. On February 3, 2015, the Company renewed the Line of Credit and increased the available balance to $5,000,000. On April 7, 2017, the Company renewed the Line of Credit. The Line of Credit currently matures on April 7, 2020 and carries a variable interest rate based on the prime rate. At March 31, 2019, $2,500,000 was outstanding on the Line of Credit at an interest rate of 4.50%.

For the three month period ended March 31, 2019 we incurred $190,109 in interest expense payable to related parties and $225,418 for the three month period ended March 31, 2018.

Table of Contents

OnOMNICOMM ~~March 18~~SYSTEMS, ~~2013, the Company entered into a $2,000,000 revolving Line of Credit (“Line of Credit”) with The Northern Trust Company guaranteed by our then Chief Executive Officer and Director, Cornelis F~~INC. Wit. Mr. Wit receives 2.0% interest (approximately $9,500 per month) from the Company on the assets pledged for the Line of Credit. On December 18, 2013, the Company renewed the Line of Credit and increased the available balance to $4,000,000. On February 3, 2015, the Company renewed the Line of Credit and increased the available balance to $5,000,000. On April 7, 2017, the Company renewed the Line of Credit. The Line of Credit currently matures on April 7, 2020 and carries a variable interest rate based on the prime rate. At September 30, 2018, $3,200,000 was outstanding on the Line of Credit at an interest rate of 4.25%.

~~For~~NOTES ~~the~~TO ~~nine~~THE ~~month~~UNAUDITED ~~period~~CONDENSED ~~ended~~CONSOLIDATED ~~September~~FINANCIAL ~~30, 2018 we incurred $682,986 in interest expense payable to related parties and $717,782 for the nine month period ended September 30, 2017.~~STATEMENTS

~~NOTE~~MARCH ~~12:~~31, ~~STOCKHOLDERS’~~2019 ~~(DEFICIT)~~AND MARCH 31, 2018

Our authorized capital stock consists of 500,000,000 shares of common stock, $.001 par value per share and 10,000,000 shares of preferred stock, par value $.001 per share, of which 5,000,000 shares have been designated as 5% Series A Preferred Stock, 230,000 shares have been designated as Series B Preferred Stock, 747,500 shares have been designated as Series C Preferred Stock and 250,000 shares have been designated as Series D Preferred Stock.(unaudited)

AsNOTE of13: ~~September~~STOCKHOLDERS’ ~~30, 2018 we had the following outstanding securities:~~(DEFICIT)

○Our ~~152~~authorized capital stock consists of 500,~~309~~000,~~472~~000 shares of common stock, ~~issued~~$0.001 par value per share and ~~outstanding;~~10,000,000 shares of preferred stock, par value $0.001 per share, of which 5,000,000 shares have been designated as 5% Series A Preferred Stock, 230,000 shares have been designated as Series B Preferred Stock, 747,500 shares have been designated as Series C Preferred Stock and 250,000 shares have been designated as Series D Preferred Stock.

○As ~~26,020,000~~of ~~warrants~~March ~~issued~~31, ~~and~~2019 ~~outstanding~~we tohad ~~purchase~~the ~~shares~~following ofoutstanding ~~our common stock;~~securities:

○ 2158,~~670~~278,~~000~~341 ~~options issued and outstanding to purchase~~ shares of ~~our~~ common stock issued and outstanding;

○

19,020,000 warrants issued and outstanding to purchase shares of our common stock;

○

2,420,000 options issued and outstanding to purchase shares of our common stock;

○

250,000 shares of our Series D Preferred Stock issued and outstanding; and

○ $5,970,000 principal amount of Convertible Debentures and $5557,~~973~~838 of accrued interest convertible into 11,940,000 and ~~111~~115,~~945~~677 shares of common stock, respectively.

Common Stock

Holders of common stock are entitled to one vote for each share on all matters submitted to a stockholder vote. Holders of our voting securities do not have cumulative voting rights. Holders of common stock are entitled to share in all dividends that the Board of Directors, in its discretion, declares from legally available funds. In the event of our liquidation, dissolution or winding up each outstanding share of common stock entitles its holder to participate in all assets that remain after payment of liabilities and after providing for each class of stock, if any, having preference over the common stock.

Holders of common stock have no conversion, preemptive or other subscription rights, and there are no redemption provisions for the common stock. The rights of the holders of common stock are subject to any rights that may be fixed for holders of preferred stock, when and if any preferred stock is outstanding. All outstanding shares of common stock are duly authorized, validly issued, fully paid and non-assessable.

On January 1, 2019 the Company issued 1,800,000 shares of common stock to Randall G. Smith, our Executive Vice Chairman, upon the exercise of 1,800,000 warrants with an exercise price of $0.25 per share for an aggregate purchase price of $450,000.

On March 14, 2019, the Company entered into restricted stock award agreements (“RSAs”) with its Chief Executive Officer, Chief Financial Officer, Chief Operating Officer and Chief Technology Officer intended to provide incentive to the executives to ensure certain economic performance of the Company. Under the terms of the RSAs, each executive was awarded 225,000 performance related restricted shares of the Company's common stock subject to forfeiture restrictions based on certain milestones having been met for the year ended December 31, 2019 as follows: a) 75,000 performance related shares are subject to individual performance, b) 75,000 performance related shares shall be forfeited if the Company's 2019 revenue does not equal or exceed $32.5 million and the Company’s 2019 Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA") does not equal or exceed $6.5 million, and c) 75,000 performance related shares shall be forfeited if the Company's 2019 revenue does not equal or exceed $33.9 million and the Company’s 2019 EBITDA does not equal or exceed $6.8 million. The restrictions on 1/3 of the awarded performance shares will lapse on the 1st of April in 2020, 2021 and 2022 provided the individual remains an employee of the Company. The restricted shares granted under the RSAs were valued as of the grant date at $0.28 per share.

On March 21, 2019 the Company issued 209,694 shares of Common stock to an employee upon the cashless exercise of 1,000,000 warrants with an exercise price of $0.25 per share.

Preferred Stock

Our Board of Directors, without further stockholder approval, may issue preferred stock in one or more series from time to time and fix or alter the designations, relative rights, priorities, preferences, qualifications, limitations and restrictions of the shares of each series. In addition, the Board of Directors may fix and determine all privileges and rights of the authorized preferred stock series including:

○

dividend and liquidation preferences;

○

voting rights;

○

conversion privileges; and

○

redemption terms.

Our Board of Directors may authorize the issuance of preferred stock which ranks senior to our common stock for the payment of dividends and the distribution of assets on liquidation. In addition, our Board of Directors can fix limitations and restrictions, if any, upon the payment of dividends on our common stock to be effective while any shares of preferred stock are outstanding.

28The following table presents the cumulative arrearage of undeclared dividends by class of preferred stock as of March 31, 2019 and March 31, 2018, respectively, and the per share amount by class of preferred stock.

	Cumulative arrearage as of				Cumulative arrearage per share as of
	March 31,				March 31,
Series of preferred stock	2019		2018		2019		2018
Series B	$	609,887	$	609,887	$	3.05	$	3.05
Series C		1,472,093		1,472,093	$	4.37	$	4.37
Total preferred stock arrearage	$	2,081,980	$	2,081,980

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~SEPTEMBER~~MARCH 3031, ~~2018~~2019 AND ~~SEPTEMBER~~MARCH 3031, ~~2017~~2018

(unaudited)

The following table presents the cumulative arrearage of undeclared dividends by class of preferred stock as of September 30, 2018 and September 30, 2017, respectively, and the per share amount by class of preferred stock.

	Cumulative arrearage as of				Cumulative arrearage per share as of
	September 30,				September 30,
Series of preferred stock	2018		2017		2018		2017
Series B	$	609,887	$	609,887	$	3.05	$	3.05
Series C		1,472,093		1,472,093	$	4.37	$	4.37
Total preferred stock arrearage	$	2,081,980	$	2,081,980

Warrants Issued in Capital Transactions

The following tables summarize all outstanding warrants for the ~~nine~~three month period ended ~~September~~March 3031, ~~2018~~2019 and the year ended December 31, ~~2017~~2018, and the related changes during these periods.

September 30, 2018

March 31, 2019

Warrants outstanding

~~Warrants exercisable~~

Warrants exercisable

~~Weighted average~~

Weighted average

~~Weighted average~~

Weighted average

~~Weighted average~~

Weighted average

Range of exercise price

Number outstanding

~~remaining contractual life~~

remaining contractual life

~~exercise price~~

exercise price

~~Number exercisable~~

Number exercisable

~~exercise price~~

exercise price

$0.25

–

$0.60

~~26,020,000~~

19,020,000

~~1.15~~

0.97

~~0.42~~

0.48

~~26,020,000~~

$19,020,000

~~0.42~~

0.48

December 31, 2017

December 31, 2018

Warrants outstanding

~~Warrants exercisable~~

Warrants exercisable

~~Weighted average~~

Weighted average

~~Weighted average~~

Weighted average

~~Weighted average~~

Weighted average

Range of exercise price

Number outstanding

~~remaining contractual life~~

remaining contractual life

~~exercise price~~

exercise price

~~Number exercisable~~

Number exercisable

~~exercise price~~

exercise price

$0.25

–

$0.60

~~27,020,000~~

22,020,000

~~1.84~~

1.06

~~0.42~~

0.45

~~27,020,000~~

$22,020,000

~~0.42~~

0.45

Warrants
Balance at December 31, 2016	27,860,000
Issued	-0-
Exercised	-0-
Expired/forfeited	(840,000	)
Balance at December 31, 2017	27,020,000
Issued	-0-
Exercised	~~-0-~~(4,000,000	)
Expired/forfeited	(1,000,000	)
Balance at September 30, 2018	26,020,000
Balance at December 31, 2018	22,020,000
Warrants exercisable at September 30, 2018	26,020,000
Issued	-0-
Weighted average fair value of warrants granted during 2018	n/a
Exercised	(2,800,000	)
Expired/forfeited	(200,000	)
Balance at March 31, 2019	19,020,000
Warrants exercisable at March 31, 2019	19,020,000
Weighted average fair value of warrants granted during 2019	n/a

Other Comprehensive Income/(Loss)

Due to the availability of net operating losses and related deferred tax valuations, there is no tax effect associated with any component of other comprehensive income/(loss). The following table lists the beginning balance, activity and ending balance of the components of accumulated other comprehensive income/(loss).

	Foreign currency translation			Accumulated other comprehensive income/(loss)
Balance at December 31, 2016	$	(410,505	)	$	(410,505	)
Balance at December 31, 2017	$	(397,237	)	$	(397,237	)
2017 Activity		13,268			13,268
2018 Activity		(39,268	)		(39,268	)
Balance at December 31, 2017		(397,237	)		(397,237	)
Balance at December 31, 2018		(436,505	)		(436,505	)
2018 Activity		(34,424	)		(34,424	)
2019 Activity		(5,430	)		(5,430	)
Balance at September 30, 2018	$	(431,661	)	$	(431,661	)
Balance at March 31, 2019	$	(441,935	)	$	(441,935	)

29NOTE 14: EQUITY INCENTIVE PLANS

Stock Option Plans

Description of 2016 Equity Incentive Plan

In 2016, the Company’s Board of Directors and stockholders approved the OmniComm Systems, Inc. 2016 Equity Incentive Plan (the “2016 Plan”). The 2016 Plan provides for granting Incentive Stock Options, Nonqualified Stock Options, Stock Appreciation Rights, Restricted Stock Awards, Phantom Stock Unit Awards and Performance Share Units. The 2016 Plan initially provides for the issuance of up to 10,000,000 shares of our common stock for issuance upon awards granted under the 2016 Plan. In addition, the number of shares of common stock available for issuance under the 2016 Plan automatically increases on January 1st of each year for a period of nine (9) years commencing on January 1, 2017 and ending on (and including) January 1, 2025, in an amount equal to five percent (5%) of the total number of shares authorized under the 2016 Plan. As of March 31, 2019 11,576,250 shares of our common stock were authorized for issuance under the 2016 Plan. Unless earlier terminated by the Board, the 2016 Plan shall terminate on June 29, 2026.

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~SEPTEMBER~~MARCH 3031, ~~2018~~2019 AND ~~SEPTEMBER~~MARCH 3031, ~~2017~~2018

(unaudited)

NOTE 13: EQUITY INCENTIVE PLANS

Stock Option Plans

Description of 2016 Equity Incentive Plan

In 2016, the Company’s Board of Directors and stockholders approved the OmniComm Systems, Inc. 2016 Equity Incentive Plan (the “2016 Plan”). The 2016 Plan provides for granting Incentive Stock Options, Nonqualified Stock Options, Stock Appreciation Rights, Restricted Stock Awards, Phantom Stock Unit Awards and Performance Share Units. The 2016 Plan initially provides for the issuance of up to 10,000,000 shares of our common stock for issuance upon awards granted under the 2016 Plan. In addition, the number of shares of common stock available for issuance under the 2016 Plan automatically increases on January 1st of each year for a period of nine (9) years commencing on January 1, 2017 and ending on (and including) January 1, 2025, in an amount equal to five percent (5%) of the total number of shares authorized under the 2016 Plan. As of September 30, 2018 11,025,000 shares of our common stock were authorized for issuance under the 2016 Plan. Unless earlier terminated by the Board, the 2016 Plan shall terminate on June 29, 2026.

The maximum term for any option grant under the 2016 Plan is ten years from the date of the grant; however, options granted under the 2016 Plan will generally expire five years from the date of grant. Options granted to employees generally vest either upon grant or in two installments. The first vesting, which is equal to 50% of the granted stock options, usually occurs upon completion of one full year of employment from the date of grant and the second vesting usually occurs on the second anniversary of the date of grant. The vesting period typically begins on the date of hire for new employees and on the date of grant for existing employees. The restrictions on restricted shares granted to employees generally lapse in three equal annual installments on the anniversary of the date of grant. Any unvested stock options or restricted shares with restrictions that have not lapsed that are granted under the 2016 Plan are forfeited and expire upon termination of employment.

On September 6, 2018, the Company entered into restricted stock agreements (“RSAs”) with its Chief Executive Officer, Chief Financial Officer, Chief Operating Officer and Chief Technology Officer intended to provide incentive to the executives to ensure certain economic performance of the Company. The shares issuable under the RSAs were valued as of the grant date at $0.33 per share. The RSAs provided for the issuance of up to 225,000 performance related shares of the Company's common stock to each of the executives provided certain milestones were met as follows: a) 75,000 performance related shares are subject to individual performance. ; b) If the Company's 2018 Revenue equals or exceeds $30 million and the Company’s 2018 EBITDA equals or exceeds $6 million, the Company would award 75,000 shares of common stock; and c) If the Company's 2018 Revenue equals or exceeds $32 million and the Company’s 2018 EBITDA equals or exceeds $7 million, the Company would award an additional 75,000 shares of common stock. The restrictions on 1/3 of the awarded performance shares will lapse on the first, second and third anniversaries of the 2018 Annual Stockholder Meeting, which was held on June 7, 2018. AsEffective ofDecember ~~November 12~~31, 2018 the Company had not achieved the milestones relating to Revenue and EBITDA and therefore each of the Officers forfeited 150,000 of the 225,000 restricted shares that had been issued to each of them.

On September 6, 2018, the Company entered into restricted stock agreements (“RSAs”) with its Board of Directors intended to provide incentive to ensure certain economic performance of the Company. The shares issuable under the RSAs were valued as of the grant date at $0.33 per share. The RSAs provided for the issuance of a total of 200,000 restricted shares with the restrictions lapsing on the day prior to the the 2019 Annual Stockholder Meeting to each director. The RSAs include 75,000 performance related shares of the Company's common stock that are subject to the Company's 2018 Revenue equaling or exceeding $30 million and the Company’s 2018 EBITDA equaling or exceeding $6 million. Effective AsDecember ~~of November 12~~31, 2018 the Company had not achieved the milestones relating to Revenue and EBITDA and therefore each of the directors forfeited 75,000 of the 200,000 restricted shares that had been issued to each of them.

~~The~~On ~~total~~March ~~combined~~14, 2019, the Company entered into restricted stock ~~compensation~~award ~~expense~~agreements ~~recognized~~(“RSAs”) with its Chief Executive Officer, inChief Financial Officer, Chief Operating Officer and Chief Technology Officer intended to provide incentive to the ~~statement~~executives to ensure certain economic performance of ~~operations~~the Company. Under the terms of the RSAs, ~~during~~each executive was awarded 225,000 performance related restricted shares of the ~~quarter~~Company's common stock subject to forfeiture restrictions based on certain milestones having been met for the year ended ~~September~~December 3031, ~~2018~~2019 ~~was~~as follows: a) 75,000 performance related shares are subject to individual performance, b) 75,000 performance related shares shall be forfeited if the Company's 2019 revenue does not equal or exceed $4132.5 million and the Company’s 2019 EBITDA does not equal or exceed $6.5 million,~~735~~ and c) 75,000 performance related shares shall be forfeited if the Company's 2019 revenue does not equal or exceed $33.9 million and the Company’s 2019 EBITDA does not equal or exceed $6.8 million. The restrictions on 1/3 of the awarded performance shares will lapse on the 1st of April in 2020, 2021 and 2022 provided the individual remains an employee of the Company. The restricted shares granted under the RSAs were valued as of the grant date at $0.28 per share.

AsThe oftotal ~~September~~combined ~~30, 2018, there were 2,495,000 options and 1,900,000~~ restricted stock ~~shares~~compensation ~~that~~expense ~~have~~recognized, ~~been~~in ~~granted under~~ the ~~2016~~statement ~~Plan.~~of Atoperations, ~~September~~during ~~30,~~the ~~2018,~~quarter ~~there~~ended ~~were~~March 631,~~630,000~~ ~~shares~~2019 ~~available~~was ~~for grant as options or other forms of share-based compensation under the 2016 Plan~~$77,610.

As of March 31, 2019, there were 2,245,000 outstanding stock options, 100,000 exercised stock options and 1,825,000 restricted stock shares that have been granted under the 2016 Plan. At March 31, 2019, there were 7,406,250 shares available for grant as options or other forms of share-based compensation under the 2016 Plan.

Description of 2009 Equity Incentive Plan

In 2009, the Company’s Board of Directors and stockholders approved the OmniComm Systems, Inc. 2009 Equity Incentive Plan (the “2009 Plan”). On June 16, 2016, the 2009 Plan terminated upon the approval of the 2016 Plan. The 2009 Plan provided for granting Incentive Stock Options, Nonqualified Stock Options, Stock Appreciation Rights, Restricted Stock Awards, Phantom Stock Unit Awards and Performance Share Units. Pursuant to the 2009 Plan, 7,500,000 shares of the Company’s common stock were authorized for issuance.

The maximum term for any option grant under the 2009 Plan was ten years from the date of the grant; however, options granted under the 2009 Plan generally expired five years from the date of grant. Options granted to employees generally vested either upon grant or in two installments. The first vesting, which was equal to 50% of the granted stock options, usually occurred upon completion of one full year of employment from the date of grant and the second vesting usually occurred on the second anniversary of the date of grant. The vesting period typically began on the date of hire for new employees and on the date of grant for existing employees. The restrictions on restricted shares granted to employees generally lapsed in three equal annual installments on the anniversary of the date of grant. Any unvested stock options or restricted shares with restrictions that had not lapsed that were granted under the 2009 Plan were forfeited and expired upon termination of employment.

As of ~~September~~March 3031, ~~2018~~2019, there were ~~275~~175,000 outstanding options and 3,876,662 restricted stock shares that have been granted under the 2009 Plan. At ~~September~~March 3031, ~~2018~~2019, there were -0- shares available for grant as options or other forms of share-based compensation under the 2009 Plan.

3029

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~SEPTEMBER~~MARCH 3031, ~~2018~~2019 AND ~~SEPTEMBER~~MARCH 3031, ~~2017~~2018

(unaudited)

The following table summarizes the stock option activity for the Company’s equity incentive plans:

	Number of options			Weighted average exercise price (per share)		Weighted average remaining contractual term (in years)		~~Aggregate intrinsic value~~	Aggregate intrinsic value
Outstanding at December 31, 2016		1,225,000		$	0.17	2.62		$	83,425
Outstanding at December 31, 2017		5,275,000		$	0.26		4.09		$	130,475
Granted		4570,~~650,~~000			0.2628
Exercised		(300,000	)		0.1321
Forfeited/cancelled/expired		(~~300~~2,975,000	)		0.1425
Outstanding at December 31, 2017		5,275,000			0.26	4.09		$	130,475
Outstanding at December 31, 2018		2,570,000			0.28		3.47		$	16,675
Granted		~~570,000~~-0-			-0~~.28~~-
Exercised		~~(200,000~~-0-	)		-0~~.22~~-
Forfeited/cancelled/expired		(2150,~~975,~~000	)		0.25
Outstanding at September 30, 2018		2,670,000		$	0.27	3.58		$	396,500
Outstanding at March 31, 2019		2,420,000		$	0.28		3.20		$	109,000
Vested and exercisable at September 30, 2018		800,000		$	0.22	2.57		$	158,425
Vested and exercisable at March 31, 2019		1,547,500		$	0.26		2.96		$	94,275

The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the Company’s closing stock price at quarter-end and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on ~~September~~March 3031, ~~2018~~2019.

The total number of shares vesting and the fair value of shares vesting for the ~~nine~~three month periods ended ~~September~~March 3031, ~~2018~~2019 and ~~September~~March 3031, ~~2017~~2018, respectively, was:

Fair value of options vesting for the period ended	Number of options vested		Fair value of options vested
September 30, 2018		625,000	$	125,190
March 31, 2019		660,000	$	136,775
September 30, 2017		62,500	$	12,742
March 31, 2018		500,000	$	99,121

Cash received for stock option exercises for the ~~nine~~three month periods ended ~~September~~March 3031, ~~2018~~2019 and ~~September~~March 3031, ~~2017~~2018 was $~~45,000~~ -0- and $35-0-,~~250,~~ respectively. Due to the Company’s net loss position, no income tax benefit has been realized during the ~~nine~~three month periods ended ~~September~~March 3031, ~~2018~~2019 and ~~September~~March 3031, ~~2017~~2018.

The following table summarizes information concerning options outstanding at ~~September~~March 3031, ~~2018~~2019:

Awards breakdown by price range at September 30, 2018
Awards breakdown by price range at March 31, 2019
			~~Outstanding~~	Outstanding								~~Vested~~	Vested
Strike price range ($)			~~Outstanding stock options~~	Outstanding stock options		~~Weighted average remaining contractual life~~	Weighted average remaining contractual life		~~Weighted average outstanding strike price~~	Weighted average outstanding strike price		~~Vested stock options~~	Vested stock options		~~Weighted average remaining vested contractual life~~	Weighted average remaining vested contractual life		~~Weighted average vested strike price~~	Weighted average vested strike price
0.00	to	0.20		~~250,000~~	150,000		~~0.74~~	0.68	$	~~0.17~~$	0.17		~~250,000~~	150,000		~~0.74~~	0.68	$	~~0.17~~$	0.17
0.21	to	0.30		~~1,695,000~~	1,545,000		~~3.79~~	3.28		~~0.26~~	0.26		~~550,000~~	1,210,000		~~3.40~~	3.15		~~0.25~~	0.26
0.31	to	0.50		~~725,000~~	725,000		~~4.07~~	3.57		~~0.34~~	0.34		~~-0-~~	187,500		~~0.00~~	3.57		~~0.00~~	0.34
0.00	to	0.50		~~2,670,000~~	2,420,000		~~3.58~~	3.20	$	~~0.27~~$	0.28		~~800,000~~	1,547,500		~~2.57~~	2.96	$	~~0.22~~$	0.26

3130

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~SEPTEMBER~~MARCH 3031, ~~2018~~2019 AND ~~SEPTEMBER~~MARCH 3031, ~~2017~~2018

(unaudited)

The following table summarizes information concerning options outstanding at December 31, ~~2017~~2018:

Awards breakdown by price range at December 31, 2017
Awards breakdown by price range at December 31, 2018
			~~Outstanding~~	Outstanding								~~Vested~~	Vested
Strike price range ($)			~~Outstanding stock options~~	Outstanding stock options		~~Weighted average remaining contractual life~~	Weighted average remaining contractual life		~~Weighted average outstanding strike price~~	Weighted average outstanding strike price		~~Vested stock options~~	Vested stock options		~~Weighted average remaining vested contractual life~~	Weighted average remaining vested contractual life		~~Weighted average vested strike price~~	Weighted average vested strike price
0.00	to	0.20		~~300,000~~	150,000		~~1.93~~	0.93	$	~~0.18~~$	0.17		~~250,000~~	150,000		~~1.48~~	0.93	$	~~0.17~~$	0.17
0.21	to	0.30		~~4,250,000~~	1,695,000		~~4.12~~	3.54		~~0.25~~	0.26		~~150,000~~	550,000		~~1.30~~	3.15		~~0.22~~	0.25
0.31	to	0.50		~~725,000~~	725,000		~~4.82~~	3.82		~~0.34~~	0.34		~~-0-~~	187,500		~~0.00~~	3.82		~~0.00~~	0.34
0.00	to	0.50		~~5,275,000~~	2,570,000		~~4.09~~	3.47	$	~~0.26~~$	0.28		~~400,000~~	887,500		~~1.42~~	2.92	$	~~0.19~~$	0.25

The weighted average fair value (per share) of options granted during the ~~nine~~three month period ended ~~September~~March 3031, ~~2018~~2019 was $0.2300 as no options were granted during the period and $0.1923 during the ~~nine~~three month period ended ~~September~~March 3031, ~~2017~~2018. The Black Scholes option-pricing model was utilized to calculate these values.

Basis for Fair Value Estimate of Share-Based Payments

Based on analysis of its historical volatility, the Company expects that the future volatility of its share price is likely to be similar to the historical volatility the Company experienced since the Company’s commercialization activities were initiated during the second half of 2000. The Company used a volatility calculation utilizing the Company’s own historical volatility to estimate its future volatility for purposes of valuing the share-based payments that have been granted. Actual volatility, and future changes in estimated volatility, may differ substantially from the Company’s current estimates.

The Company utilizes the historical data available regarding employee and director exercise activity to calculate an expected life of the options. The table below presents the weighted average expected life in years of options granted under the Plan as described above. The risk-free rate of the stock options is based on the U.S. Treasury yield curve in effect at the time of grant, which corresponds with the expected term of the option granted.

Below are the assumptions for the fair value of share-based payments for the ~~nine~~three month period ended ~~September~~March 3031, ~~2018~~2019 and the year ended December 31, ~~2017~~2018.

	Stock option assumptions for the period ended
Stock option assumptions	~~September~~March 3031, ~~2018~~2019		~~December 31, 2017~~	December 31, 2018
Risk-free interest rate	~~2.71%~~	2.48%	~~1.81%~~		2.91%
Expected dividend yield	~~0.0%~~	0.0%	~~0.0%~~		0.0%
Expected volatility	~~110.3%~~	102.6%	~~127.1%~~		111.0%
Expected life of options (in years)	5	5	5		5

The following table summarizes weighted average grant date fair value activity for the Company’s incentive stock plans:

	Weighted average grant date fair value
	for the period ended September 30,
	for the period ended March 31,
	2018		2017
	2019		2018
Stock options granted during the period	$	-0~~.23~~-	$	0.1923
Stock options vested during the period	$	0.2021	$	0.20
Stock options forfeited during the period	$	0.1921	$	0.1319

3231

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~SEPTEMBER~~MARCH 3031, ~~2018~~2019 AND ~~SEPTEMBER~~MARCH 3031, ~~2017~~2018

(unaudited)

A summary of the status of the Company’s non-vested shares underlying stock options as of ~~September~~March 3031, ~~2018~~2019 and changes during the ~~nine~~three month period ended ~~September~~March 3031, ~~2018~~2019 is as follows:

	Shares underlying stock options		Weighted average grant date fair value
Nonvested shares at January 1, 2018		4,875,000	$	0.21
Nonvested shares at January 1, 2019		1,682,500	$	0.24
Nonvested shares at September 30, 2018		1,870,000	$	0.24
Nonvested shares at March 31, 2019		872,500	$	0.27

As of ~~September~~March 3031, ~~2018~~2019, $~~309~~195,~~142~~598 of total unrecognized compensation cost related to unvested stock options is expected to be recognized over a weighted-average period of 1.9 years.

NOTE 1415: SUBSEQUENT EVENTS

Subsequent to ~~September~~March 3031, ~~2018~~2019 the Company repaid $~~900~~1,400,000 on its revolving Line of Credit.

Subsequent to ~~September~~March 3031, ~~2018,~~2019 an ~~John Fontenault, our Chief Operating Officer,~~ employee exercised options that had been granted to him in 2014. As a result 3450,~~175~~000 common shares were issued to ~~him~~the employee.

Subsequent to ~~September 30~~March 31, ~~2018~~2019 Cornelis F. Wit, the Company's ~~extended~~Executive ~~the~~Chairman, ~~lease~~exercised ~~for the~~800,000 ~~office~~warrants inwith an exercise price of $0.25 per share, as a ~~Leiden~~result 800,000 ~~the~~shares ~~Netherlands~~were ~~until~~issued ~~October~~to ~~2019~~Mr. Wit.

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

General

The following information should be read in conjunction with the information contained in our unaudited condensed consolidated financial statements and notes thereto appearing elsewhere herein and other information set forth in this report.

Forward-Looking Statements

Statements contained in this Form 10-Q that are not historical fact are "forward-looking statements". These statements can often be identified by the use of forward-looking terminology such as "estimate", "project", "believe", "expect", "may", "will", "should", "intends", or "anticipates" or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. We wish to caution the reader that these forward-looking statements, contained in this Form 10-Q regarding matters that are not historical facts, are only predictions and are based on information available at the time and/or management’s good faith belief with respect to future events. No assurance can be given that plans for the future will be consummated or that the future results indicated, whether expressed or implied, will be achieved. While sometimes presented with numerical specificity, these plans and projections and other forward-looking statements are based upon a variety of assumptions, which we consider reasonable, but which nevertheless may not be realized. Because of the number and range of the assumptions underlying our projections and forward-looking statements, many of which are subject to significant uncertainties and contingencies that are beyond our reasonable control, some of the assumptions inevitably will not materialize, and unanticipated events and circumstances may occur subsequent to the date of this Form 10-Q. Therefore, our actual experience and results achieved during the period covered by any particular projections or forward-looking statements may differ substantially from those projected. Consequently, the inclusion of projections and other forward-looking statements should not be regarded as a representation by us or any other person that these plans will be consummated or that estimates and projections will be realized, and actual results may vary materially. There can be no assurance that any of these expectations will be realized or that any of the forward-looking statements contained herein will prove to be accurate. Forward-looking statements speak only as of the date the statement was made. The Company does not undertake any obligation to update or revise any forward-looking statement made by it or on its behalf, whether as a result of new information, future events or otherwise.

Overview

We are a healthcare technology company that provides web based electronic data capture (“EDC”) and eClinical solutions and related value-added services to pharmaceutical and biotech companies, clinical research organizations (“CROs”) and other clinical trial sponsors worldwide. Our proprietary software applications: TrialMaster^®; TrialOne^®; eClinical Suite; Promasys^®; IRTMaster; AutoEncoder and Acuity (the “EDC Software”), allow clinical trial sponsors and investigative sites to securely collect, validate, transmit and analyze clinical trial data electronically (“eClinical”).

In 2019, the primary focus of our strategy includes:

	●	Increasing our penetration of the Phase I trial market with our dedicated Phase I solution, TrialOne
	●	Stimulating demand by providing clinical trial sponsors with high value eClinical applications and services including our new AutoEncoder, coding solution as well as Acuity our new data analytics solution
	●	Expanding our penetration of the large pharmaceutical sponsor market
	●	Broadening our suite of services and software applications on an organic research and product development basis and on a selective basis via the acquisition or licensing of complementary solutions
	●	Expanding our business development efforts in Europe and East Asia to capitalize on our operational and clinical capabilities vis-à-vis our competition in those geographic markets

Our operating focus is first, to increase our sales and marketing capabilities and penetration rate and secondly, to continue developing and improving our software solutions and services to ensure our services and products remain an attractive, high-value EDC choice. Our ability to compete within the EDC and eClinical industries is predicated on our ability to continue enhancing and broadening the scope of solutions we offer. Our research and product development efforts are focused on developing new, complementary software solutions, as well as enhancing our existing software solutions through the addition of increased functionality. We spent $1,089,081, which represents 19% of revenue, and $922,304, which represents 13% of revenue, on research and product development activities during the three months ended March 31, 2019 and March 31, 2018, respectively. The majority of these expenses represent salaries and related benefits to our developers which include the costs associated with the continued development of our EDC Software applications to meet current customer requirements and with our efforts at enhancing our suite of products by incorporating new features and services we believe will improve the products and consequently improve our market position. Our research and product development team is comprised of software programmers, engineers and related support personnel.

Table of Contents

~~ITEM~~Our 2clients are able to partially or completely license our EDC solutions. ~~MANAGEMENT’S~~The ~~DISCUSSION~~licensing ~~AND~~business ~~ANALYSIS~~model OFprovides ~~FINANCIAL~~our ~~CONDITION~~clients ~~AND~~with ~~RESULTS~~a OFmore ~~OPERATIONS~~cost effective means of deploying our EDC solutions on a large-scale basis. Our licensed products, falling under the auspices of either a Tech Transition (partial transfer with some services performed by OmniComm) or Tech Transfer, allows us to broaden our potential client base, provides us with a high-margin revenue source and affords us the ability to improve our competitive position within the EDC industry.

~~General~~We feel that the momentum established from new client acquisitions in 2018 and the first three months of 2019 coupled with our ability to retain clients for repeat engagements provide a good operating base from which to build during the remainder of 2019. We expect to continue increasing the level of resources deployed in our sales and marketing efforts through the addition of sales personnel and by increasing our marketing efforts. We feel that a combination of our existing infrastructure, broadened array of eClinical products and services and increased success in new client acquisition, coupled with our ability to retain our existing clients will allow us to compete effectively within the EDC market.

The ~~following~~three ~~information~~months ~~should~~ended beMarch ~~read~~31, in2019 ~~conjunction~~compared ~~with~~to the ~~information~~three ~~contained~~months inended ~~our~~March ~~unaudited~~31, ~~condensed consolidated financial statements and notes thereto appearing elsewhere herein and other information set forth in this report.~~2018

~~Forward-Looking~~RESULTS ~~Statements~~OF OPERATIONS

~~Statements~~A ~~contained~~summarized inversion ~~this Form 10-Q that are not historical fact are "forward-looking statements". These statements can often be identified by the use~~ of ~~forward-looking~~our ~~terminology~~results such as "estimate", "project", "believe", "expect", "may", "will", "should", "intends", or "anticipates" or the negative thereof or other variations thereon or comparable terminology, or by discussions of ~~strategy~~operations that involve risks and uncertainties. We wish to caution the reader that these forward-looking statements, contained in this Form 10-Q regarding matters that are not historical facts, are only predictions and are based on information available at the time and/or management’s good faith belief with respect to future events. No assurance can be given that plans for the ~~future~~three ~~will~~months beended ~~consummated~~March ~~or that the future results indicated~~31, ~~whether~~2019 ~~expressed or implied, will be achieved. While sometimes presented with numerical specificity, these plans~~ and ~~projections~~March ~~and other forward-looking statements are based upon a variety of assumptions~~31, ~~which~~2018 weis ~~consider~~included ~~reasonable,~~in ~~but which nevertheless may not be realized. Because of~~ the ~~number~~table and range of the assumptions underlying our projections and forward-looking statements, many of which are subject to significant uncertainties and contingencies that are beyond our reasonable control, some of the assumptions inevitably will not materialize, and unanticipated events and circumstances may occur subsequent to the date of this Form 10-Qbelow. Therefore, our actual experience and results achieved during the period covered by any particular projections or forward-looking statements may differ substantially from those projected. Consequently, the inclusion of projections and other forward-looking statements should not be regarded as a representation by us or any other person that these plans will be consummated or that estimates and projections will be realized, and actual results may vary materially. There can be no assurance that any of these expectations will be realized or that any of the forward-looking statements contained herein will prove to be accurate. Forward-looking statements speak only as of the date the statement was made. The Company does not undertake any obligation to update or revise any forward-looking statement made by it or on its behalf, whether as a result of new information, future events or otherwise.

Overview

Summarized Statement of Operations
For the three months ended
March 31,
				% of						% of						%
	2019			Revenues			2018			Revenues			Change			Change
Total revenues	$	5,715,819					$	7,190,472					$	(1,474,653	)		-20.5	%

Cost of goods sold		1,123,900			19.7	%		1,211,501			16.8	%		(87,601	)		-7.2	%

Gross margin		4,591,919			80.3	%		5,978,971			83.2	%		(1,387,052	)		-23.2	%

Salaries, benefits and related taxes		3,662,432			64.1	%		3,659,340			51.0	%		3,092			0.1	%
Rent		311,799			5.5	%		289,334			4.0	%		22,465			7.8	%
Consulting services		50,827			0.9	%		125,536			1.7	%		(74,709	)		-59.5	%
Legal and professional fees		131,763			2.3	%		221,252			3.1	%		(89,489	)		-40.4	%
Other expenses		392,343			6.9	%		368,617			5.1	%		23,726			6.4	%
Selling, general and administrative		440,533			7.7	%		409,756			5.7	%		30,777			7.5	%
Total operating expenses		4,989,697			87.4	%		5,073,835			70.6	%		(84,138	)		-1.7	%

Operating income/(loss)		(397,778	)		-7.0	%		905,136			12.6	%		(1,302,914	)		-143.9	%

Interest expense		(269,379	)		-4.7	%		(316,361	)		-4.4	%		46,982			14.9	%
Interest income		4			0.0	%		5			0.0	%		(1	)		-20.0	%
Change in derivatives		(583,657	)		-10.2	%		28,416			0.4	%		(612,073	)		-2,154.0	%
Transaction gain/(loss)		(15,726	)		-0.3	%		(22,678	)		-0.3	%		6,952			30.7	%

Income/(loss) before income taxes and dividends		(1,266,536	)		-22.2	%		594,518			8.3	%		(1,861,054	)		-313.0	%
Income tax (expense)		11			0.0	%		(1,035	)		0.0	%		1,046			101.1	%
Net income/(loss) attributable to common stockholders	$	(1,266,525	)		-22.2	%	$	593,483			8.3	%	$	(1,860,008	)		-313.4	%

WeThe ~~are~~table abelow ~~healthcare technology company that~~ provides ~~web~~a ~~based~~comparison ~~electronic~~of ~~data~~our ~~capture~~recognized ~~(“EDC”)~~revenues ~~solutions~~for ~~and~~the ~~related~~three ~~value-added~~months ~~services~~ended toMarch ~~pharmaceutical and biotech companies~~31, ~~clinical~~2019 ~~research organizations (“CROs”)~~ and ~~other~~March ~~clinical trial sponsors worldwide. Our proprietary software applications: TrialMaster®; TrialOne®; eClinical Suite; Promasys®~~31, IRTMaster, AutoEncoder and Acuity Analytics (the “EDC Software”), allow clinical trial sponsors and investigative sites to securely collect, validate, transmit and analyze clinical trial data electronically (“eClinical”)2018.

In 2018, the primary focus of our strategy includes:

	For the three months ended
Revenue activity	March 31, 2019				March 31, 2018				$ Change			% Change
Set-up fees	$	811,354	14.2	%	$	1,208,554	16.8	%	$	(397,200	)		-32.9	%
Change orders		218,622	3.8	%		420,080	5.8	%		(201,458	)		-48.0	%
Maintenance		1,413,243	24.7	%		1,370,091	19.1	%		43,152			3.1	%
Software licenses		2,300,130	40.2	%		3,269,400	45.5	%		(969,270	)		-29.6	%
Professional services		603,731	10.6	%		431,083	6.0	%		172,648			40.0	%
Hosting		368,739	6.5	%		491,264	6.8	%		(122,525	)		-24.9	%
Total	$	5,715,819	100.0	%	$	7,190,472	100.0	%	$	(1,474,653	)		-20.5	%

~~● Increasing our penetration of the Phase I trial market with our dedicated Phase I solution, TrialOne~~34

●Table ~~Stimulating~~of demand by providing clinical trial sponsors with high value eClinical applications and services including our new AutoEncoder, coding solution as well as Acuity Analytics our new data analytics solutionContents

●Overall ~~Expanding~~revenue ~~our~~decreased ~~penetration~~by of$1,474,653 or 20.5% for the ~~large~~three ~~pharmaceutical~~months ~~sponsor~~ended ~~market~~March 31, 2019 compared with revenue for the three months ended March 31, 2018. This decrease is primarily the result of decreases in software licenses and set-up fees.

●We ~~Broadening~~recorded ~~our~~revenue ~~suite~~ of ~~services~~$3,946,133 including ~~and~~$1,337,323 from software ~~applications~~licensing, $765,397 from onset-up anfees ~~organic~~and ~~research~~$845,729 from ~~and~~maintenance ~~product~~revenues ~~development~~associated ~~basis~~with TrialMaster during the three months ended March 31, 2019 compared with revenue of $4,853,099 that included $1,564,561 from software licensing, $1,208,554 in set-up fees and on$875,080 ain ~~selective~~maintenance ~~basis~~revenues ~~via~~during the ~~acquisition~~three ormonths ~~licensing~~ended ofMarch ~~complementary~~31, ~~solutions~~2018.

●We ~~Expanding~~recorded ~~our~~$223,365 in ~~business~~revenues ~~development~~associated ~~efforts~~with inclients ~~Europe~~using ~~and~~the ~~East~~eClinical ~~Asia~~Suite toduring ~~capitalize~~the onthree ~~our~~months ~~operational~~ended ~~and~~March ~~clinical~~31, ~~capabilities~~2019 ~~vis-à-vis~~compared ~~our~~with ~~competition~~revenue inof $354,924 for ~~those~~the ~~geographic~~three ~~markets~~months ended March 31, 2018. eClinical Suite revenues are primarily comprised of license subscriptions and revenues associated with maintenance services.

~~Our~~We ~~operating focus is first~~recorded $179,607 in torevenues ~~increase~~in ~~our~~maintenance ~~sales~~ and ~~marketing capabilities and penetration rate and secondly~~$12, ~~to continue developing and improving our software solutions and services to ensure our services and products remain an attractive, high-value EDC choice.~~300 ~~Our~~from ~~ability~~hosting toactivities ~~compete~~associated ~~within~~with the ~~EDC and~~ eClinical ~~industries~~Suite isduring ~~predicated on our ability to continue enhancing and broadening~~ the ~~scope~~three ofmonths ~~solutions~~ended weMarch ~~offer. Our research and product development efforts are focused on developing new~~31, ~~complementary~~2019 ~~software~~compared ~~solutions,~~with asrevenue ~~well as enhancing our existing software solutions through the addition~~ of ~~increased functionality. We spent~~ $2279,~~469,280~~040 from maintenance and $215,~~230,565~~500 onfrom ~~research~~hosting ~~and product development~~ activities ~~during~~for the ~~nine~~three months ended ~~September~~March 3031, 2018. ~~and~~OmniComm ~~September~~announced ~~30,~~that ~~2017,~~it ~~respectively.~~would ~~The~~decommission ~~majority~~its ofeClinical ~~these~~Suite ~~expenses~~hosting ~~represent~~platform ~~salaries~~effective ~~and~~April ~~related~~30, ~~benefits~~2019, toas ~~our~~many ~~developers~~of ~~which include~~ the ~~costs~~eClinical ~~associated~~Suite ~~with~~clients ~~the~~utilizing ~~continued~~these ~~development~~hosting ofservices ~~our~~have ~~EDC~~transitioned ~~Software applications~~ to ~~meet~~TrialMaster, ~~current~~the ~~customer~~eClinical ~~requirements~~Suite ~~and~~studies ~~with~~have ~~our~~been ~~efforts~~completed ator ~~enhancing~~the ~~our~~studies ~~suite~~have oftransitioned ~~products~~to byanother ~~incorporating~~hosting ~~new~~platform. ~~features~~Currently ~~and~~there ~~services~~is weone ~~believe~~remaining ~~will~~client ~~improve~~utilizing the ~~products~~hosting ~~and~~platform ~~consequently improve our market position. Our research~~ and ~~product~~we ~~development~~are ~~team~~finalizing isthe ~~comprised~~transition ofplan ~~software~~with ~~programmers,~~the ~~engineers and related support personnel~~client.

34We recorded revenue of $1,190,088 including $834,577 from software licensing and $276,920 for maintenance for clients utilizing our TrialOne EDC software for the three months ended March 31, 2019 compared with revenue of $1,824,492 including $1,622,926 from software licensing and $162,341 for maintenance for the three months ended March 31, 2018. TrialOne revenues are primarily comprised of license subscriptions, professional services and maintenance services.

~~Table~~We recorded revenue of ~~Contents~~$162,448 for the three months ended March 31, 2019 including $33,508 from software licensing and $43,924 from maintenance associated with clients utilizing the Promasys EDC solution as compared to revenue of $147,958 for the three months ended March 31, 2018 including $11,529 from software licensing and $53,630 from maintenance.

~~Our~~We ~~clients~~recorded ~~are~~revenue ~~able to partially or completely license our EDC solutions. The licensing business model provides our clients with a more cost effective means~~ of ~~deploying~~$193,785 from our ~~EDC~~other ~~solutions on a large-scale basis. Our licensed~~ products, ~~falling~~for ~~under~~ the ~~auspices~~three ofmonths ~~either~~ended aMarch ~~Tech Transition (partial transfer with some services performed by OmniComm) or Tech Transfer~~31, ~~allows~~2019 uscompared to ~~broaden~~revenue ~~our~~of ~~potential client base~~$10,000 for ~~provides~~our usother ~~with~~products afor ~~high-margin revenue source and affords us~~ the ~~ability~~three tomonths ~~improve~~ended ~~our~~March ~~competitive~~31, ~~position within the EDC industry~~2018.

WeOur ~~feel~~TrialMaster ~~that~~EDC ~~the~~application ~~momentum~~has ~~established~~historically ~~from~~primarily ~~new~~been ~~client~~sold ~~acquisitions~~on inan ~~2017~~application ~~and~~service ~~the~~provider ~~first~~(“ASP”) ~~nine~~basis ~~months~~that ofprovides ~~2018~~EDC ~~coupled~~and ~~with our~~other ~~ability~~services tosuch ~~retain~~as ~~clients~~an ~~for~~enterprise ~~repeat~~management ~~engagements~~suite ~~provide~~which aassists ~~good~~our ~~operating~~clients ~~base~~in ~~from~~the ~~which~~pharmaceutical, tobiotechnology ~~build~~and ~~during~~medical device industries in accelerating the ~~remainder~~completion of ~~2018~~clinical trials. We ~~expect~~During to2009 ~~continue~~we ~~increasing~~completed the ~~level~~acquisition of ~~resources~~the ~~deployed~~eResearch EDC Assets and TrialOne, in ~~our~~2013 ~~sales~~we acquired Promasys and ~~marketing~~in ~~efforts~~2018 ~~through~~we acquired Acuity (collectively the ~~addition~~“Acquired ofSoftware”). These ~~sales~~software ~~personnel~~applications ~~and~~have byhistorically ~~increasing~~been ~~our~~sold ~~marketing~~on ~~efforts.~~a Welicensed ~~feel~~or ~~that~~technology atransfer ~~combination~~basis. As ofwe have continued developing our ~~existing~~software ~~infrastructure,~~applications ~~broadened~~and ~~array~~our ofclient ~~eClinical~~relationships ~~products~~mature, ~~and~~an ~~services~~increasing ~~and~~potion of our ~~increased~~clients ~~success~~are deploying inTrialMaster ~~new~~on ~~client~~a ~~acquisition~~licensed, ~~coupled~~rather ~~with~~than ~~our~~ASP ~~ability~~hosted tobasis. ~~retain~~We ~~our~~expect ~~existing~~the ~~clients~~Acquired ~~will~~Software ~~allow~~applications usto continue to ~~compete~~be ~~effectively~~sold ~~within~~primarily ~~the~~on ~~EDC~~a ~~market~~licensed basis.

~~The~~TrialMaster ~~nine~~contracts ~~months~~for ~~ended~~ASP ~~September~~services ~~30,~~provide ~~2018~~for ~~compared~~pricing that is based on both the size and duration of the clinical trial. Size parameters include the number of case report forms used to collect data and the ~~nine~~number ~~months~~of ~~ended~~sites ~~September~~utilizing 30TrialMaster. The client will pay a trial setup fee at the beginning of a project based on the previously mentioned factors and then pay an on-going maintenance fee for the duration of the clinical trial that provides software, ~~2017~~network and site support during the trial.

~~RESULTS~~Generally, OFASP ~~OPERATIONS~~contracts will range in duration from one month to several years. ASP setup fees are generally recognized in accordance with Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") 606 (“ASC 606"). ASC 606, which requires that the revenues be recognized when or as performance obligations are satisfied. ASP maintenance fee revenues are earned and recognized monthly. Costs associated with contract revenues are recognized as incurred.

ALicense ~~summarized~~contracts ~~version~~are oftypically ~~our~~sold ~~results~~on ofa ~~operations~~subscription basis that takes into account system usage both on a data volume and system user basis. Pricing includes additional charges for ~~the~~consulting ~~nine~~services ~~months~~associated ~~ended~~with ~~September~~the 30installation, ~~2018~~validation, training and ~~September~~deployment ~~30,~~of ~~2017~~our isEDC ~~included~~and ineClinical software and solutions. Licensed contracts of the ~~table~~eClinical ~~below~~Suite have historically been sold both on a term and on a perpetual license basis with hosting and maintenance charges being paid quarterly. The Company expects most licenses it sells of its software products to be sold under three to five year term licenses.

~~Summarized~~Our ~~Statement~~top five customers accounted for approximately 28% of ~~Operations~~our ~~For~~revenues during the ~~nine~~three ~~months~~month period ended ~~September~~March 3031, 2019 and approximately 35% of our revenues during the three month period ended March 31, 2018. One customer accounted for approximately 7% of our revenues during the three month period ended March 31, 2019. One customer accounted for approximately 11% of our revenues during the three month period ended March 31, 2018. The loss of any of these contracts or these customers in the future could adversely affect our results of operations.

				% of				% of	$			%
	2018			Revenues	2017			Revenues	Change			Change
Total revenues	$	20,332,949			$	20,175,800			$	157,149			0.8	%
Cost of goods sold		3,608,991		17.7%		4,123,165		20.4%		(514,174	)		-12.5	%
Gross margin		16,723,958		82.3%		16,052,635		79.6%		671,323			4.2	%
Salaries, benefits and related taxes		10,695,132		52.6%		9,906,293		49.1%		788,839			8.0	%
Rent		930,972		4.6%		841,718		4.2%		89,254			10.6	%
Consulting services		219,856		1.1%		185,222		0.9%		34,634			18.7	%
Legal and professional fees		381,648		1.9%		367,403		1.8%		14,245			3.9	%
Other expenses		1,358,830		6.7%		1,102,051		5.5%		256,779			23.3	%
Selling, general and administrative		1,297,008		6.4%		937,313		4.6%		359,695			38.4	%
Total operating expenses		14,883,446		73.3%		13,340,000		66.1%		1,543,446			11.6	%
Operating income/(loss)		1,840,512		9.1%		2,712,635		13.4%		(872,123	)		-32.2	%
Interest expense		(966,393	)	-4.8%		(1,060,022	)	-5.3%		93,629			8.8	%
Interest income		16		0.0%		589		0.0%		(573	)		-97.3	%
Change in derivatives		(1,160,473	)	-5.7%		723,532		3.6%		(1,884,005	)		-260.4	%
Transaction gain/(loss)		(97,984	)	-0.5%		19,006		0.1%		(116,990	)		-615.5	%
Income/(loss) before income taxes and dividends		(384,322	)	-1.9%		2,395,740		11.9%		(2,780,062	)		-116.0	%
Income tax (expense)		(155,106	)	-0.8%		(1,194	)	0.0%		(153,912	)		-12890.5	%
Net income/(loss) attributable to common stockholders	$	(539,428	)	-2.7%	$	2,394,546		11.9%	$	(2,933,974	)		-122.5	%

We currently have business operations in Southampton, England; Leiden, the Netherlands; Bonn, Germany; Barcelona, Spain; Tokyo, Japan; and Bengaluru, India, and our international customers, who are principally located in Europe and East Asia, accounted for approximately 32% of our total revenues for the three month period ended March 31, 2019 and approximately 30% of our total revenues for the three month period ended March 31, 2018.

35One customer accounted for approximately 10% of our accounts receivables as of March 31, 2019. One customer accounted for approximately 20% and another customer accounted for approximately 10% of our accounts receivable as of December 31, 2018.

~~Table~~Cost of ~~Contents~~goods sold decreased approximately 7% or $87,601 from $1,211,501 for the three months ended March 31, 2018 as compared to $1,123,900 for the three months ended March 31, 2019. Cost of goods sold were approximately 20% of revenues for the three months ended March 31, 2019 compared to approximately 17% for the three months ended March 31, 2018. Cost of goods sold relates primarily to (i) salaries and related benefits associated with the programmers, developers and systems analysts producing clinical trials on behalf of our clients and (ii) the costs associated with pass-through revenues (reimbursable revenues). Cost of goods sold decreased during the three months ended March 31, 2019 primarily due to a decrease in the costs associated with producing clinical trials on behalf of our clients. The pass-through revenue and expense primarily relate to specific work being performed for a few clients. At this time we do not expect the volume of the pass-through revenue and expense to grow significantly and therefore we do not expect any significant degradation of our gross margin.

~~The table below provides a comparison of our recognized revenues for the nine months ended September 30, 2018 and September 30, 2017.~~35

	For the nine months ended
Revenue activity	September 30, 2018			September 30, 2017			$ Change			% Change
Set-up fees	$	2,683,182	13.2%	$	3,948,687	19.6%	$	(1,265,505	)		-32.0	%
Change orders		1,090,333	5.4%		1,054,288	5.2%		36,045			3.4	%
Maintenance		4,163,138	20.4%		3,749,897	18.6%		413,241			11.0	%
Software licenses		8,423,355	41.4%		7,951,228	39.4%		472,127			5.9	%
Professional services		2,617,149	12.9%		2,526,379	12.5%		90,770			3.6	%
Hosting		1,355,792	6.7%		945,321	4.7%		410,471			43.4	%
Total	$	20,332,949	100.0%	$	20,175,800	100.0%	$	157,149			0.8	%

Table of Contents

Overall, ~~revenue~~total ~~increased~~operating byexpenses ~~$157,149 or~~decreased ~~0.8~~approximately 2% for the ~~nine~~three months ended ~~September~~March 3031, ~~2018~~2019 compared ~~with~~to ~~revenue for~~ the ~~nine~~three months ended ~~September~~March 3031, ~~2017~~2018. ~~This~~The ~~increase~~decrease in operating expenses is primarily the result of ~~increases~~a decrease in ~~software~~legal ~~licenses~~and professional fees, ~~maintenance~~ consulting services and ~~hosting~~travel expenses partially offset by aincreases ~~decrease~~ in ~~set-up~~depreciation, ~~fees~~amortization and selling, general and administrative expenses.

WeSalaries ~~recorded~~and ~~revenue~~related ofexpenses ~~$13,401,543 including~~were ~~$4,000,779 from~~our ~~software~~biggest ~~licensing, $2,678,656 from~~operating ~~set-up~~expense ~~fees~~at ~~and~~73% ~~$2,784,867 from~~of ~~maintenance~~total ~~revenues~~operating ~~associated~~expenses ~~with~~for ~~TrialMaster during~~ the ~~nine~~three months ended ~~September~~March 3031, ~~2018~~2019 compared ~~with~~to ~~revenue~~72% of ~~$15~~total operating expenses for the three months ended March 31,~~184,340~~ 2018. ~~that~~Salaries ~~included~~and ~~$4,838,537~~related ~~from~~expenses ~~software~~increased ~~licensing,~~by ~~$3,948,687~~approximately in0% ~~set-up~~for ~~fees~~the ~~and~~three $2months ended March 31,~~557,261 in~~ ~~maintenance~~2019 ~~revenues~~compared ~~during~~to the ~~nine~~three months ended ~~September~~March 3031, ~~2017~~2018. The table below provides a summary of the significant components of salaries and related expenses by primary cost category.

We recorded $823,082 in revenues associated with clients using the eClinical Suite during the nine months ended September 30, 2018 compared with revenue of $1,329,257 for the nine months ended September 30, 2017. eClinical Suite revenues are primarily comprised of license subscriptions and revenues associated with maintenance services.

	For the three months ended
Expense category	March 31, 2019		March 31, 2018		$ Change			% Change
OmniComm corporate operations	$	2,592,374	$	2,623,054	$	(30,680	)		-1.2	%
New Jersey operations office		302,513		296,874		5,639			1.9	%
OmniComm Europe, GmbH		100,239		168,124		(67,885	)		-40.4	%
OmniComm Ltd.		321,905		330,566		(8,661	)		-2.6	%
OmniComm Spain S.L.		92,653		99,991		(7,338	)		-7.3	%
OmniComm Systems B.V.		1,933		84,205		(82,272	)		-97.7	%
OmniComm eClinical Solutions Pvt. Ltd.		120,278		-0-		120,278			n/a
Employee stock compensation		130,537		56,526		74,011			130.9	%
Total salaries and related expenses	$	3,662,432	$	3,659,340	$	3,092			0.1	%

WeAs ~~recorded $643,424 in~~of ~~revenues~~March in31, ~~maintenance~~2019, ~~and~~we ~~$47,700~~employed 175 ~~from~~employees ~~hosting~~and ~~activities~~consultants ~~associated~~Company-wide ~~with~~as ~~the~~follows: ~~eClinical~~69 out ~~Suite~~of ~~during~~our ~~the~~headquarters ~~nine~~in ~~months~~Fort ~~ended~~Lauderdale, ~~September 30~~Florida, ~~2018~~8 out ~~compared~~of ~~with~~a ~~revenue~~regional ofoperating ~~$682,135~~office ~~from~~in ~~maintenance~~Somerset, ~~and~~New ~~$188~~Jersey,~~367~~ 27 ~~from~~in ~~hosting~~remote ~~activities~~locations ~~for~~throughout the ~~nine~~United ~~months~~States. ~~ended~~Our ~~September~~wholly-owned 30subsidiary, ~~2017. Generally~~OmniComm Europe, ~~these~~GmbH, ~~revenues~~employs ~~are~~17 in ~~paid~~Bonn, ~~quarterly~~Germany. Our ~~and~~wholly-owned ~~are~~subsidiary, ~~connected~~OmniComm toLtd., ~~hosting~~employs ~~and~~16 in ~~client~~Southampton, ~~support~~England. ~~for~~Our ~~clients~~wholly-owned ~~licensing~~subsidiary, ~~the~~OmniComm ~~eClinical~~Spain, ~~Suite~~S. On ~~April~~L. 30employs 3 in Barcelona, ~~2019~~Spain. Our wholly-owned subsidiary, OmniComm ~~will~~Systems ~~decommission~~B.V. ~~its~~employs ~~eClinical~~2 in ~~Suite~~the ~~hosting~~Netherlands ~~platform~~and as2 in ~~the~~Japan. ~~eClinical~~Our ~~Suite~~wholly-owned ~~clients~~subsidiary, ~~utilizing~~OmniComm ~~these~~eClinical ~~hosting~~Solutions ~~services~~Pvt. ~~have~~Ltd., ~~transitioned~~formed toin ~~TrialMaster~~July 2018, employs 31 in the ~~eClinical~~Bengaluru, ~~Suite~~India. ~~studies~~We ~~have~~believe ~~been~~that ~~completed~~relations orwith ~~the~~our ~~studies~~employees ~~have~~are ~~transitioned~~good. None toof ~~another~~our ~~hosting~~employees ~~platform~~are represented by a collective bargaining agreement.

WeDuring ~~recorded~~the ~~revenue~~three ofmonths $5ended March 31,~~402,178~~ ~~including~~2019 $4and the three months ended March 31,~~053,847 from~~ ~~software~~2018 ~~licensing~~we ~~and~~incurred $~~593~~130,~~868~~537 ~~for maintenance for~~and ~~clients~~$56,526, ~~utilizing~~respectively, ~~our~~in ~~TrialOne~~salary ~~EDC~~expense ~~software~~in ~~for~~connection ~~the~~with ~~nine~~ASC ~~months~~718, ~~ended~~Compensation ~~September~~– 30Stock Compensation, ~~2018~~(“ASC ~~compared~~718”) ~~with~~which ~~revenue~~establishes ofstandards ~~$3,286,129 including~~for ~~$2,573,361~~ transactions in which an entity exchanges its equity instruments services from ~~software~~employees. ~~licensing~~This ~~and~~standard ~~$313,551~~requires ~~for maintenance for~~companies ~~the~~to ~~nine~~measure ~~months~~the ~~ended~~cost ~~September~~of ~~30,~~employee ~~2017.~~services ~~TrialOne~~received ~~revenues~~in ~~are~~exchange ~~primarily~~for ~~comprised~~an award of ~~license~~equity ~~subscriptions,~~instruments ~~professional~~based ~~services~~on ~~and~~the ~~maintenance~~grant-date ~~services~~fair value of the award.

WeRent ~~recorded~~and ~~revenue~~related ofexpenses increased ~~$450~~by approximately 8% during the three months ended March 31,~~506~~ ~~for~~2019 compared to the ~~nine~~three months ended ~~September~~March 3031, 2018. The ~~including~~table ~~$67,491~~below details the significant portions of our rent expense. ~~from~~Our ~~software~~primary ~~licensing~~data ~~and~~site ~~$140~~is located at a co-location facility in Cincinnati,~~979 from~~ ~~maintenance~~Ohio ~~associated~~and ~~with~~we ~~clients~~will continue utilizing this facility for the ~~Promasys~~foreseeable ~~EDC~~future ~~solution~~since asit ~~compared~~is designed to ~~revenue~~ensure of100% ~~$376~~production system up-time and to provide system redundancy. We also utilize co-location and disaster recovery space in the Fort Lauderdale,~~074~~ Florida area. This facility provides us with disaster recovery and business continuity services for our operations. In 2018 we added a new co-location facility in Frankfurt, Germany. We currently lease office space in Bonn, Germany for our European subsidiary, OmniComm Europe, GmbH under a lease that expires in July 2020. We currently lease office space for a regional operating office in New Jersey under a lease that expires in March 2021. Our OmniComm Ltd. subsidiary leases office space in Southampton, UK under a lease that expires in September 2020. Our OmniComm eClinical Solutions Pvt. Ltd. subsidiary leases office space in Bengaluru, India under the terms of a lease that expires in May 2023. The Company currently operates its office space for our OmniComm Systems B.V, in the ~~nine~~Netherlands ~~months~~under ~~ended~~the ~~September~~terms 30of an agreement that expires in October 2019. Our Fort Lauderdale corporate office lease expires in February 2023. Our offices in Barcelona, ~~2017~~Spain ~~including~~and ~~$90~~Tokyo,~~274~~ Japan ~~from~~are ~~software~~administered ~~licensing~~under service agreements that include the use of office space and other services. The table below provides the significant components of our rent related expenses by location or subsidiary. Included in rent during the three months ended March 31, 2019 was a decrease in expense of $~~196~~54 in non-cash,~~950~~ ~~from~~straight ~~maintenance~~line rent recorded to give effect to contractual, inflation-based rent increases in our leases compared to a decrease in expense of $561 for the three months ended March 31, 2018.

Our TrialMaster EDC application has historically been primarily sold on an application service provider (“ASP”) basis that provides EDC and other services such as an enterprise management suite which assists our clients in the pharmaceutical, biotechnology and medical device industries in accelerating the completion of clinical trials. During 2009 we completed the acquisition of the eResearch EDC Assets and TrialOne, in 2013 we acquired Promasys and in 2018 we acquired Acuity Analytics (collectively the “Acquired Software”). These software applications have historically been sold on a licensed or technology transfer basis. As we continue developing our software applications and our client relationships mature, we expect some of our clients to deploy TrialMaster on a licensed, rather than ASP hosted basis. We expect the Acquired Software applications to continue to be sold primarily on a licensed basis.

	For the three months ended
Expense category	March 31, 2019			March 31, 2018			$ Change			% Change
Corporate office	$	106,785		$	104,200		$	2,585			2.5	%
Co-location and disaster recovery facilities		126,109			129,785			(3,676	)		-2.8	%
New Jersey operations office		13,148			13,148			-0-			0.0	%
OmniComm Europe, GmbH		18,775			21,524			(2,749	)		-12.8	%
OmniComm Ltd.		18,038			16,325			1,713			10.5	%
OmniComm Spain S.L.		3,001			3,454			(453	)		-13.1	%
OmniComm Systems B.V.		500			1,459			(959	)		-65.7	%
OmniComm eClinical Solutions Pvt. Ltd.		25,497			-0-			25,497			n/a
Straight-line rent expense		(54	)		(561	)		507			90.3	%
Total	$	311,799		$	289,334		$	22,465			7.8	%

TrialMaster contracts for ASP services provide for pricing that is based on both the size and duration of the clinical trial. Size parameters include the number of case report forms used to collect data and the number of sites utilizing TrialMaster. The client will pay a trial setup fee at the beginning of a project based on the previously mentioned factors and then pay an on-going maintenance fee for the duration of the clinical trial that provides software, network and site support during the trial.36

~~Generally,~~Table ~~ASP~~of contracts will range in duration from one month to several years. ASP setup fees are generally recognized in accordance with Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") 606 (“ASC 606"). ASC 606, which requires that the revenues be recognized when or as performance obligations are satisfied. ASP maintenance fee revenues are earned and recognized monthly. Costs associated with contract revenues are recognized as incurred.Contents

36Consulting services expense decreased to $50,827 for the three months ended March 31, 2019 compared with $125,536 for the three months ended March 31, 2018. Consulting services are comprised of fees paid to consultants for help with product development and for services related to our sales and marketing efforts. Expenses for both categories decreased year over year. The table provided below provides the significant components of the expenses incurred related to consulting services.

Table of Contents

	For the three months ended
Expense category	March 31, 2019		March 31, 2018		$ Change			% Change
Sales and marketing	$	8,276	$	13,250	$	(4,974	)		-37.5	%
Product development		42,551		112,286		(69,735	)		-62.1	%
Total	$	50,827	$	125,536	$	(74,709	)		-59.5	%

~~License~~Legal ~~contracts~~and ~~are~~professional ~~typically~~fees ~~sold~~decreased onapproximately a40% ~~subscription~~for ~~basis~~the ~~that~~three ~~takes~~months ~~into~~ended ~~account~~March ~~system~~31, ~~usage~~2019 ~~both~~compared onwith athe ~~data~~three ~~volume~~months ~~and~~ended ~~system~~March ~~user~~31, ~~basis~~2018. ~~Pricing~~ ~~includes~~Professional ~~additional~~fees ~~charges~~include ~~for~~fees ~~consulting~~paid ~~services~~to ~~associated~~our ~~with~~auditors ~~the~~for ~~installation,~~services ~~validation,~~rendered ~~training~~on a quarterly and ~~deployment~~annual ofbasis in connection with our ~~eClinical~~filings ~~software~~with the Securities and ~~solutions. Licensed~~Exchange ~~contracts~~Commission of(“SEC”) ~~the~~and ~~eClinical~~fees ~~Suite~~paid ~~have~~to ~~historically~~our ~~been~~attorneys ~~sold~~in ~~both~~connection onwith arepresentation ~~term~~in matters involving litigation and onacquisitions aor ~~perpetual~~for ~~license~~services ~~basis~~rendered ~~with~~to ~~hosting~~us ~~and~~related ~~maintenance~~to ~~charges~~securities ~~being~~and ~~paid~~SEC ~~quarterly~~related matters. The ~~Company~~table ~~expects~~below ~~most licenses~~compares itthe ~~sells~~significant components of ~~its~~our ~~software~~legal ~~products~~and toprofessional befees ~~sold~~for ~~under~~the three tomonths ~~five~~ended ~~year~~March ~~term~~31, ~~licenses~~2019 and March 31, 2018, respectively.

Our top five customers accounted for approximately 34% of our revenues during the nine month period ended September 30, 2018 and approximately 35% of our revenues during the nine month period ended September 30, 2017. One customer accounted for approximately 12% of our revenues during the nine month period ended September 30, 2018. One customer accounted for approximately 10% of our revenues during the nine month period ended September 30, 2017. The loss of any of these contracts or these customers in the future could adversely affect our results of operations.

	For the three months ended
Expense category	March 31, 2019		March 31, 2018		$ Change			% Change
Financial advisory	$	-0-	$	27,633	$	(27,633	)		-100.0	%
Audit and related		44,253		35,223		9,030			25.6	%
Accounting services		47,261		59,934		(12,673	)		-21.1	%
Legal-employment related		14,646		10,661		3,985			37.4	%
Legal-financial related		16,231		66,976		(50,745	)		-75.8	%
General legal		9,372		20,825		(11,453	)		-55.0	%
Total	$	131,763	$	221,252	$	(89,489	)		-40.4	%

~~Our~~Selling, ~~international~~general ~~customers~~and administrative expenses (“SG&A”) increased by $30,777 or ~~who~~approximately ~~are~~8% ~~principally~~from ~~located~~$409,756 for inthe ~~Europe~~three ~~and~~months ~~East~~ended ~~Asia~~March 31, ~~accounted~~2018 compared to $440,533 for ~~approximately~~the ~~30%~~three ofmonths ended March 31, 2019. SG&A expenses relate primarily to costs incurred in running our ~~total~~offices ~~revenues~~in ~~for~~Fort ~~the~~Lauderdale, ~~nine~~Florida; Somerset, ~~month~~New ~~period~~Jersey; Southampton, ~~ended~~England; Barcelona, ~~September~~Spain; Bonn, 30Germany; Leiden, ~~2018~~the Netherlands; Tokyo, Japan and ~~approximately~~Bengaluru, ~~21%~~India ofon a day-to-day basis and other costs not directly related to other captioned items in our ~~total~~income ~~revenues~~statement. ~~for~~SG&A includes the ~~nine~~cost ~~month~~of ~~period~~office ~~ended~~equipment ~~September~~and 30supplies, ~~2017~~the costs of attending conferences and seminars and other expenses incurred in the normal course of business.

~~One~~During ~~customer~~the ~~accounted~~three ~~for~~months ~~approximately~~ended ~~13%~~March 31, 2019 we recognized a reduction in bad debt expense of ~~our~~$23,353 compared ~~accounts~~to ~~receivables~~a asreduction of ~~September~~bad 30debt expense of $3,387 for the three months ended March 31, 2018. ~~One~~This ~~customer~~change ~~accounted~~was ~~for~~primarily ~~approximately~~the ~~27%~~result of a decrease in aged receivable balances that allowed us to decrease our reserve. During the remainder of 2019 we will continue to carefully and ~~another~~actively ~~customer~~manage ~~accounted~~our ~~for~~potential ~~approximately~~exposure ~~11%~~to ofbad debt by closely monitoring our accounts receivable asand ofproactively ~~September~~taking ~~30,~~the ~~2017~~action necessary to limit our exposure. We have been very successful in managing and collecting our outstanding accounts receivable. We believe that our current allowance for uncollectible accounts accurately reflects any accounts which may prove uncollectible during the remainder of 2019.

~~Cost~~Interest ofexpense ~~goods~~was ~~sold decreased approximately 12% or~~ $~~514~~269,~~174 from $4,123,165~~ 379 for the ~~nine~~three months ended ~~September~~March 3031, ~~2017 as~~2019 compared to $3316,~~608,991~~ 361 for the ~~nine~~three months ended ~~September~~March 3031, 2018., a ~~Cost~~decrease of ~~goods~~$46,982. Interest ~~sold~~incurred ~~were~~to ~~approximately~~related ~~18%~~parties ofwas ~~revenues~~$190,109 during ~~for~~ the ~~nine~~three months ended ~~September~~March 3031, ~~2018~~2019 ~~compared~~and ~~to approximately 20%~~ $225,418 for the ~~nine~~three months ended ~~September~~March 3031, ~~2017~~2018. Included ~~Cost~~in ofinterest ~~goods~~expense ~~sold~~is ~~relates~~the ~~primarily~~accretion toof ~~(i)~~discounts ~~salaries~~recorded ~~and~~ related ~~benefits~~to ~~associated~~financial ~~with~~instrument ~~the~~derivatives ~~programmers,~~that ~~developers~~were ~~and~~deemed ~~systems~~a ~~analysts~~part ~~producing clinical trials on behalf~~ of ~~our clients and (ii)~~ the ~~costs~~financings ~~associated~~we ~~with~~undertook ~~pass-through~~in ~~revenues~~2008 ~~(reimbursable~~and ~~revenues).~~2009 ~~Cost~~and ofrelating ~~goods~~to ~~sold~~warrants ~~decreased~~issued during ~~the~~2011 ~~nine~~and ~~months~~2016. Interest ~~ended~~expense ~~September~~decreased ~~30,~~year ~~2018~~over year primarily due to ~~a decrease in~~ the ~~costs~~repayment ~~associated~~of ~~with~~outstanding ~~pass-through revenues (reimbursable revenues)~~debt. The ~~pass-through~~table ~~revenue~~below ~~and~~provides ~~expense~~detail ~~primarily~~on ~~relate~~the tosignificant ~~specific~~components ~~work~~of ~~being~~interest ~~performed~~expense for ~~a few clients. At this time we do not expect~~ the ~~volume~~three ofmonths ~~the~~ended ~~pass-through~~March ~~revenue~~31, ~~and~~2019 ~~expense to grow significantly~~ and ~~therefore~~March we31, ~~do not expect any significant degradation of our gross margin~~2018.

Overall, total operating expenses increased approximately 12% for the nine months ended September 30, 2018 compared to the nine months ended September 30, 2017. The increase in operating expenses is primarily the result of an increase in salaries, benefits and related taxes as well as an increase in selling, general and administrative expenses.

	For the three months ended
Debt description	March 31, 2019		March 31, 2018		$ Change			% Change
Accretion of discount from derivatives	$	24,637	$	54,518	$	(29,881	)		-54.8	%
August 2008 convertible notes		43,644		47,342		(3,698	)		-7.8	%
December 2008 convertible notes		124,274		124,274		-0-			0.0	%
General interest		48,715		50,282		(1,567	)		-3.1	%
Related party notes payable		28,109		39,945		(11,836	)		-29.6	%
Total	$	269,379	$	316,361	$	(46,982	)		-14.9	%

~~Salaries~~We ~~and~~evaluate ~~related~~the ~~expenses~~cost ~~were~~of ~~our~~capital ~~biggest~~available ~~operating~~to ~~expense~~us atin ~~72%~~combination ofwith ~~total~~our ~~operating~~overall ~~expenses~~capital ~~for~~structure and the ~~nine~~prevailing ~~months~~market ~~ended~~conditions ~~September~~in ~~30,~~deciding ~~2018~~what ~~compared~~financing tobest ~~74%~~fulfills ofour ~~total~~short ~~operating~~and ~~expenses~~long-term ~~for~~capital ~~the~~needs. ~~nine~~Given ~~months~~the ~~ended~~overall ~~September~~economic ~~30,~~climate ~~2017. Salaries~~ and ~~related~~in ~~expenses~~particular ~~increased~~the bydifficulties ~~approximately~~nano-cap 8%companies ~~for~~have ~~the~~experienced ~~nine~~in ~~months~~obtaining ~~ended September 30~~financing, ~~2018~~we ~~compared~~believe to the ~~nine~~structure ~~months~~and ~~ended~~terms ~~September~~of ~~30,~~the ~~2017. The~~transactions ~~table~~we ~~below~~entered ~~provides~~into aduring ~~summary~~2016 ofand ~~the~~2017 ~~significant~~were ~~components~~obtained ofat ~~salaries and~~the ~~related~~best ~~expenses~~terms byavailable ~~primary~~to ~~cost~~the ~~category~~Company.

	For the nine months ended
Expense category	September 30, 2018		September 30, 2017		$ Change			% Change
OmniComm corporate operations	$	7,722,487	$	6,815,015	$	907,472			13.3	%
New Jersey operations office		817,044		814,050		2,994			0.4	%
OmniComm Europe, GmbH		501,030		481,792		19,238			4.0	%
OmniComm Ltd.		895,071		655,418		239,653			36.6	%
OmniComm Spain S.L.		261,984		295,138		(33,154	)		-11.2	%
OmniComm Systems B.V.		269,112		376,950		(107,838	)		-28.6	%
OmniComm eClinical Solutions Pvt. Ltd.		29,041		-0-		29,041			n/a
Employee stock compensation		199,363		467,930		(268,567	)		-57.4	%
Total salaries and related expenses	$	10,695,132	$	9,906,293	$	788,839			8.0	%

37Table of Contents

~~Table~~We record unrealized gains/losses related to changes in our derivative liabilities associated with the issuance of ~~Contents~~convertible debt that occurred during 2008 and 2009 and warrants associated with promissory notes issued in 2011 and 2016. We recorded a net unrealized loss of $583,657 during the three month period ended March 31, 2019 compared with a net unrealized gain of $28,416 during the three month period ended March 31, 2018. The unrealized gains/losses can be attributed to fair value calculations undertaken periodically on the warrant and conversion feature liabilities recorded by us at the time the convertible debt and promissory notes were issued. Accordingly the warrant and conversion feature liabilities are increased or decreased based on the fair value calculations made at each quarterly balance sheet date. These non-cash gains and losses have materially impacted our results of operations during the three month periods ended March 31, 2019 and March 31, 2018 and can be reasonably anticipated to materially affect our net loss or net income in future periods. The fair value calculations are heavily reliant on the value of our common stock and on the calculated volatility of the price of our common stock on the OTCQX Marketplace. Accordingly, significant changes in our stock price will create large unrealized gains and losses on our financial statements. We are, however, unable to estimate the amount of such income/expense in future periods as the income/expense is partly based on the market price of our common stock at the end of a future measurement date. In addition, if we issue securities in the future which are classified as derivatives we will incur expense and income items in future periods. Investors are cautioned to consider the impact of this non-cash accounting treatment on our financial statements.

AsThe ofbelow ~~September~~table ~~30,~~contains ~~2018,~~the wecumulative ~~employed~~arrearage ~~162 employees~~for ~~and~~each ~~consultants~~series ~~Company-wide as follows: 66 out~~ of ~~our~~preferred ~~headquarters~~stock inas ~~Fort Lauderdale, Florida, 8 out~~ of aMarch ~~regional operating office in Somerset~~31, ~~New Jersey, 27 in remote locations throughout the United States and Canada~~2019. Our wholly-owned subsidiary, OmniComm Europe, GmbH, employs 19 in Bonn, Germany. Our wholly-owned subsidiary, OmniComm Ltd., employs 13 in Southampton, England. Our wholly-owned subsidiary, OmniComm Spain, S. L. employs 2 in Barcelona, Spain. Our wholly-owned subsidiary, OmniComm Systems B.V. employs 3 in the Netherlands and 2 in Japan. Our wholly-owned subsidiary, OmniComm eClinical Solutions Pvt. Ltd. employs 22 in the Bengaluru, India. We believe that relations with our employees are good. None of our employees are represented by a collective bargaining agreement.

During the nine months ended September 30, 2018 and the nine months ended September 30, 2017 we incurred $199,363 and $467,930, respectively, in salary expense in connection with ASC 718, Compensation – Stock Compensation, (“ASC 718”) which establishes standards for transactions in which an entity exchanges its equity instruments services from employees. This standard requires companies to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award.

Series of Preferred Stock	Cumulative Arrearage
Series B	$	609,887
Series C		1,472,093
Total preferred stock arrearages	$	2,081,980

~~Rent and related expenses~~LIQUIDITY ~~increased by approximately 11% during the nine months ended September 30, 2018 compared to the nine months ended September 30, 2017.~~AND ~~The table below details the significant portions of our rent expense.~~CAPITAL Our primary data site is located at a co-location facility in Cincinnati, Ohio and we will continue utilizing this facility for the foreseeable future since it is designed to ensure 100% production system up-time and to provide system redundancy. We also utilize co-location and disaster recovery space in the Fort Lauderdale, Florida area. This facility provides us with disaster recovery and business continuity services for our operations. In 2018 we added a new co-location facility in Frankfurt, Germany. We currently lease office space in Bonn, Germany for our European subsidiary, OmniComm Europe, GmbH under a lease that expires in July 2019. We currently lease office space for a regional operating office in New Jersey under a lease that expires in March 2021. Our OmniComm Ltd. subsidiary leases office space in Southampton, UK under a lease that expires in September 2020. Our OmniComm Systems B.V. subsidiary leases office space in Leiden, the Netherlands under a lease that expires in October 2018. Our Fort Lauderdale corporate office lease expires in February 2023. Our offices in Barcelona, Spain, Tokyo, Japan and Bengaluru, India are administered under service agreements that include the use of office space and other services. The table below provides the significant components of our rent related expenses by location or subsidiary. Included in rent during the nine months ended September 30, 2018 was a decrease in expense of $5,592 in non-cash, straight line rent recorded to give effect to contractual, inflation-based rent increases in our leases compared to a decrease in expense of $2,882 for the nine months ended September 30, 2017.RESOURCES

	For the nine months ended
Expense category	September 30, 2018			September 30, 2017			$ Change			% Change
Corporate office	$	343,399		$	310,813		$	32,586			10.5	%
Co-location and disaster recovery facilities		413,134			379,856			33,278			8.8	%
New Jersey operations office		39,444			39,444			-0-			0.0	%
OmniComm Europe, GmbH		66,845			58,254			8,591			14.7	%
OmniComm Ltd.		50,862			43,463			7,399			17.0	%
OmniComm Spain S.L.		8,400			5,958			2,442			41.0	%
OmniComm Systems B.V.		5,547			6,812			(1,265	)		-18.6	%
OmniComm eClinical Solutions Pvt. Ltd.		8,933			-0-			8,933			n/a
Straight-line rent expense		(5,592	)		(2,882	)		(2,710	)		-94.0	%
Total	$	930,972		$	841,718		$	89,254			10.6	%

Liquidity is the ability of a company to generate adequate amounts of cash to meet its operating, investing and financing needs for cash. We have historically experienced negative cash flows and have relied on the proceeds from the sale of debt and equity securities to fund our operations. At March 31, 2019, we had working capital deficit of $4,154,241.

Consulting services expense increased to $219,856 for the nine months ended September 30, 2018 compared with $185,222 for the nine months ended September 30, 2017. Consulting services are comprised of fees paid to consultants for help with product development and for services related to our sales and marketing efforts. Product development consulting expenses increased year over year as we utilized the services of additional consultants during the nine month period ended September 30, 2018. The table provided below ~~provides~~summarizes ~~the~~key ~~significant~~measures ~~components~~ of ~~the~~our ~~expenses~~liquidity ~~incurred~~and ~~related~~capital ~~to consulting services.~~resources:

	For the nine months ended
Liquidity and Capital Resources
Expense category	September 30, 2018			September 30, 2017			$ Change			% Change
Summarized Balance Sheet Disclosure
Sales and marketing	$	45,549		$	56,000		$	(10,451	)		-18.7	%
	March 31, 2019			December 31, 2018			$ Change			% Change
Product development		174,307			129,222			45,085			34.9	%
Cash	$	1,351,916		$	1,440,524		$	(88,608	)		-6.2	%
Total	$	219,856		$	185,222		$	34,634			18.7	%
Accounts receivable, net of allowance for doubtful accounts		3,989,881			6,175,277			(2,185,396	)		-35.4	%
Prepaid expenses		261,741			384,212			(122,471	)		-31.9	%
Other current assets		1,633			5,204			(3,571	)		-68.6	%
Current assets		5,605,171			8,005,217			(2,400,046	)		-30.0	%
Accounts payable and accrued expenses		1,230,092			2,070,158			(840,066	)		-40.6	%
Deferred revenue, current portion		5,302,370			6,457,319			(1,154,949	)		-17.9	%
Finance lease liability		116,728			115,761			967			0.8	%
Conversion feature liability, related parties		862,083			670,634			191,449			28.5	%
Conversion feature liability		45,415			35,705			9,710			27.2	%
Warrant liability, related parties		750,625			601,781			148,844			24.7	%
Warrant liability		853,991			687,118			166,873			24.3	%
Operating lease liability, current portion		598,108			-0-			598,108			n/a
Current liabilities		9,759,412			10,638,476			(879,064	)		-8.3	%
Working capital (deficit)	$	(4,154,241	)	$	(2,633,259	)	$	(1,520,982	)		-57.8	%

Table of Contents

Legal and professional fees increased approximately 4% for the nine months ended September 30, 2018 compared with the nine months ended September 30, 2017. Professional fees include fees paid to our auditors for services rendered on a quarterly and annual basis in connection with our filings with the Securities and Exchange Commission (“SEC”) and fees paid to our attorneys in connection with representation in matters involving litigation and acquisitions or for services rendered to us related to securities and SEC related matters. The table below compares the significant components of our legal and professional fees for the nine months ended September 30, 2018 and September 30, 2017, respectively.

Statement of Cash Flows Disclosure
	For the three months ended
	March 31, 2019			March 31, 2018			$ Change			% Change
Net cash provided by/(used in) operating activities	$	166,011		$	(1,103,006	)	$	1,269,017			-115.1	%
Net cash provided by/(used in) investing activities		(270,711	)		(645,197	)		374,486			58.0	%
Net cash provided by/(used in) financing activities		19,635			1,750,000			(1,730,365	)		98.9	%

Net increase/(decrease) in cash and cash equivalents		(88,608	)		(814	)		(87,794	)		-10,785.5	%

Changes in operating accounts		340,393			(1,917,655	)		2,258,048			117.8	%

Effect of non-cash transactions on cash and cash equivalents	$	1,092,143		$	221,166		$	870,977			393.8	%

	For the nine months ended
Expense category	September 30, 2018		September 30, 2017		$ Change			% Change
Financial advisory	$	27,633	$	52,974	$	(25,341	)		-47.8	%
Audit and related		48,222		39,777		8,445			21.2	%
Accounting services		159,405		178,588		(19,183	)		-10.7	%
Legal-employment related		11,439		21,778		(10,339	)		-47.5	%
Legal-financial related		108,605		67,122		41,483			61.8	%
General legal		26,344		7,164		19,180			267.7	%
Total	$	381,648	$	367,403	$	14,245			3.9	%

Cash and Cash Equivalents

~~Selling,~~Cash ~~general~~ and ~~administrative~~cash ~~expenses~~equivalents ~~(“SG&A”)~~decreased ~~increased~~ by $~~359~~88,~~695~~608 orto ~~approximately 38% from~~ $~~937~~1,~~313~~351,916 at ~~for~~March ~~the nine months ended September 30~~31, ~~2017 compared~~2019 tofrom $1,~~297~~440,~~008~~524 at ~~for~~December ~~the nine months ended September 30~~31, 2018. ~~SG&A~~The ~~expenses~~decrease ~~relate~~is primarily tocomprised ~~costs~~of ~~incurred~~a innet ~~running~~loss ~~our~~of ~~offices~~($1,266,525), changes in ~~Fort~~working ~~Lauderdale,~~capital ~~Florida,~~accounts ~~Somerset~~of $340,393 and ~~New~~an ~~Jersey,~~increase ~~Southampton,~~from ~~England,~~non-cash ~~Barcelona,~~transactions ~~Spain,~~of ~~Bonn~~$1, ~~Germany~~092,143. ~~Leiden,~~During the ~~Netherlands,~~three ~~Tokyo,~~months ~~Japan~~ended ~~and~~March ~~Bengaluru~~31, ~~India~~2019 onwe ahad ~~day-to-day~~investing ~~basis~~activities ~~and~~of ~~other~~($270,711). ~~costs~~We ~~not~~had ~~directly~~financing ~~related~~activities tothat ~~other~~included ~~captioned~~repayments of ~~items in~~ $400,000 to our ~~income~~revolving ~~statement.~~line ~~SG&A~~of ~~includes~~credit, ~~the~~proceeds ~~cost~~ of ~~office~~$450,000 ~~equipment~~from warrant exercises and ~~supplies,~~payment ~~the costs~~ of ~~attending~~$30,365 for ~~conferences~~finance leases ~~and~~during ~~seminars~~the ~~and~~three ~~other~~month ~~expenses~~period ~~incurred~~ended inMarch ~~the~~31, ~~normal course of business~~2019.

~~During~~Capital the nine months ended September 30, 2018 we recognized bad debt expense of $47,931 compared to bad debt expense of $40,369 for the nine months ended September 30, 2017. This change was primarily the result of a increase in aged receivable balances that caused us to increase our reserve. During the remainder of 2018 we will continue to carefully and actively manage our potential exposure to bad debt by closely monitoring our accounts receivable and proactively taking the action necessary to limit our exposure. We have been very successful in managing and collecting our outstanding accounts receivable. We believe that our current allowance for uncollectible accounts accurately reflects any accounts which may prove uncollectible during the remainder of 2018.Expenditures

~~Interest~~Any ~~expense~~amounts ~~was~~expended ~~$966,393~~ for ~~the~~capital ~~nine~~expenditures ~~months~~would ~~ended~~be ~~September 30, 2018 compared to $1,060,022 for~~ the ~~nine~~result ~~months ended September 30, 2017, a decrease~~ of ~~$93,629. Interest~~an ~~incurred~~increase ~~to related parties was $682,986 during the nine months ended September 30, 2018 and $717,782 for the nine months ended September 30, 2017. Included~~ in ~~interest expense is~~ the ~~accretion~~capacity ofneeded ~~discounts recorded related~~ to ~~financial~~adequately ~~instrument~~service ~~derivatives~~any ~~that~~increase ~~were~~in ~~deemed~~our abusiness. ~~part~~To ofdate ~~the financings~~ we ~~undertook~~have inprimarily ~~2008~~paid ~~and~~for ~~2009~~any ~~and~~needed ~~relating~~additions to ~~warrants~~our ~~issued~~capital ~~during~~equipment ~~2011~~infrastructure ~~and~~from ~~2016. Interest~~working ~~expense~~capital ~~decreased~~funds ~~year~~and ~~over~~anticipate ~~year~~this ~~primarily~~being ~~due to~~ the ~~repayment~~case ofin ~~outstanding debt. The table below provides detail on~~ the ~~significant components of interest expense for the nine months ended September 30, 2018 and September 30, 2017~~future.

	For the nine months ended
Debt description	September 30, 2018		September 30, 2017		$ Change			% Change
Accretion of discount from derivatives	$	163,553	$	241,664	$	(78,111	)		-32.3	%
August 2008 convertible notes		139,825		143,605		(3,780	)		-2.6	%
December 2008 convertible notes		376,964		389,347		(12,383	)		-3.2	%
September 2009 secured convertible debentures		-0-		54,962		(54,962	)		-100.0	%
General interest		164,884		105,282		59,602			56.6	%
Related party notes payable		121,167		125,162		(3,995	)		-3.2	%
Total	$	966,393	$	1,060,022	$	(93,629	)		-8.8	%

Presently, we have approximately $500,000 planned for capital expenditures to further develop our infrastructure to allow for growth in our operations during the remainder of 2019. We expect to fund these capital expenditure needs through a combination of vendor-provided financing, the use of operating or finance equipment leases and cash provided from operations.

WeContractual evaluate the cost of capital available to us in combination with our overall capital structure and the prevailing market conditions in deciding what financing best fulfills our short and long-term capital needs. Given the overall economic climate and in particular the difficulties nano-cap companies have experienced in obtaining financing, we believe the structure and terms of the transactions we entered into during 2016 and 2017 were obtained at the best terms available to the Company.Obligations

39The following table sets forth our contractual obligations as of March 31, 2019:

Table of Contents

Contractual obligation			Payments due by period
	Total		Less than 1 year		1-2 Years			2-3 Years			3+ Years
Promissory notes (1)	$	557,500	$	-0-	$	557,500	(2)	$	-0-		$	-0-
Convertible notes (1)		5,970,000		-0-		5,770,000	(3)		200,000	(4)		-0-
Lines of credit (5)		2,500,000		-0-		2,500,000			-0-			-0-
Operating lease obligations (6)		1,824,770		732,268		427,193			331,698			333,611	(7)
Finance lease obligations (8)		260,485		116,729		124,523			19,233			-0-
Total	$	11,112,755	$	848,997	$	9,379,216		$	550,931		$	333,611

We1. ~~record~~Amounts ~~unrealized~~do ~~gains/losses~~not ~~related~~include interest to ~~changes~~be inpaid. ~~our~~2. ~~derivative~~Includes ~~liabilities~~$420,000 ~~associated~~in ~~with~~10% ~~the~~notes ~~issuance~~payable ~~of convertible debt~~ that ~~occurred~~mature ~~during~~in ~~2008~~April ~~and~~2020 ~~2009~~ and ~~warrants~~$137,500 ~~associated~~in ~~with~~12% ~~promissory~~ notes ~~issued~~payable that mature in ~~2011~~April ~~and~~2020. ~~2016~~3. We ~~recorded~~Includes ~~a net unrealized loss of~~ $1,~~160~~770,~~473 during~~000 ~~the~~in ~~nine~~10% ~~month~~convertible ~~period~~notes ~~ended~~that ~~September~~mature ~~30,~~in ~~2018~~April ~~compared~~2020 ~~with~~and ~~a net unrealized gain of~~ $~~723~~4,~~532 during the nine month period ended September 30~~000,000 ~~2017. The~~in ~~unrealized~~12% ~~gains/losses~~convertible ~~can~~notes bethat ~~attributed~~mature toin ~~fair~~April ~~value~~2020. ~~calculations~~4. ~~undertaken~~Includes ~~periodically~~$200,000 onin ~~the~~12% ~~warrant and conversion feature liabilities recorded by us at the time the~~ convertible ~~debt~~notes ~~and~~that ~~promissory~~mature ~~notes~~in ~~were~~April ~~issued~~2021. ~~Accordingly~~ ~~the~~5. ~~warrant~~Includes ~~and~~$2,500,000 ~~conversion~~due ~~feature liabilities are increased or decreased based~~ on the ~~fair~~revolving ~~value~~Line ~~calculations~~of ~~made~~Credit atwith ~~each~~The ~~quarterly~~Northern ~~balance~~Trust ~~sheet~~Company. ~~date~~6. ~~These~~ ~~non-cash~~Includes ~~gains~~office ~~and~~lease ~~losses have~~obligations ~~materially~~for ~~impacted~~ our ~~results~~Corporate ofOffice ~~operations~~in ~~during the nine month periods ended September 30~~Florida, ~~2018 and September 30, 2017 and can be reasonably anticipated to materially affect~~ our ~~net~~regional ~~loss~~operating oroffice ~~net income~~ in ~~future~~New ~~periods.~~Jersey, ~~The fair value calculations are heavily reliant on the value of~~ our ~~common~~co-location ~~stock~~ and ondisaster ~~the~~recovery ~~calculated~~locations ~~volatility~~in ~~of the price of our common stock on the OTCQX Marketplace. Accordingly~~Ohio, ~~significant~~Florida ~~changes in our stock price will create large unrealized gains~~ and ~~losses~~Germany, on our ~~financial~~office ~~statements.~~in ~~We are~~England, ~~however,~~our ~~unable~~office toin ~~estimate~~ the ~~amount~~Netherlands, ofour ~~such~~European ~~income/expense~~headquarters in ~~future~~Germany ~~periods~~and ~~as the income/expense is partly based on the market price of~~ our ~~common~~office ~~stock~~in atIndia. ~~the~~7. ~~end~~Includes ofoffice alease ~~future~~obligations ~~measurement~~through ~~date~~2023. In8. ~~addition,~~Includes iffinance welease ~~issue~~obligations ~~securities~~for inhardware ~~the~~located ~~future which are classified as derivatives we will incur expense and income items~~ in ~~future~~our ~~periods. Investors are cautioned to consider the impact of this non~~co-~~cash~~location ~~accounting~~sites ~~treatment~~in onOhio ~~our~~and ~~financial statements~~Germany.

~~The below table contains the cumulative arrearage for each series of preferred stock as of September 30, 2018.~~39

Series of Preferred Stock	Cumulative Arrearage
Series B	$	609,887
Series C		1,472,093
Total preferred stock arrearages	$	2,081,980

Table of Contents

~~The three months ended September 30, 2018 compared to the three months ended September 30, 2017~~Leases

~~RESULTS~~We had ~~OF OPERATIONS~~operating lease assets and operating lease liabilities of $1,569,465 as of March 31, 2019.

AOff ~~summarized~~Balance ~~version~~Sheet ~~of our results of operations for the three months ended September 30, 2018 and September 30, 2017 is included in the table below.~~Arrangements

~~Summarized~~We ~~Statement~~have ofno ~~Operations~~off-balance ~~For~~sheet ~~the~~arrangements ~~three~~that ~~months~~have ~~ended~~or ~~September~~are 30reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

				% of					% of		$			%
	2018			Revenues		2017			Revenues		Change			Change
Total revenues	$	6,842,824				$	6,715,913				$	126,911			1.9	%
Cost of goods sold		1,297,813			19.0%		1,315,445			19.6%		(17,632	)		-1.3	%
Gross margin		5,545,011			81.0%		5,400,468			80.4%		144,543			2.7	%
Salaries, benefits and related taxes		3,483,627			50.9%		3,393,915			50.5%		89,712			2.6	%
Rent		337,824			4.9%		292,669			4.4%		45,155			15.4	%
Consulting services		55,736			0.8%		64,488			1.0%		(8,752	)		-13.6	%
Legal and professional fees		72,776			1.1%		126,959			1.9%		(54,183	)		-42.7	%
Other expenses		463,176			6.8%		408,520			6.1%		54,656			13.4	%
Selling, general and administrative		383,958			5.6%		277,047			4.1%		106,911			38.6	%
Total operating expenses		4,797,097			70.1%		4,563,598			68.0%		233,499			5.1	%
Operating income/(loss)		747,914			10.9%		836,870			12.5%		(88,956	)		-10.6	%
Interest expense		(325,528	)		-4.8%		(380,073	)		-5.7%		54,545			14.4	%
Interest income		7			0.0%		3			0.0%		4			133.3	%
Change in derivatives		(2,918,886	)		-42.7%		(812,535	)		-12.1%		(2,106,351	)		-259.2	%

Filing Compare · OMNICOMM SYSTEMS INC